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Summary 
The B cell antigen receptor (BCR), composed of surface immunoglobulin 
associated with the Ig-a/Ig-P heterodimer, mediates the antigen-dependent 
activation of B lymphocytes. Transmembrane signalling by the BCR occurs via 
the immunoreceptor tyrosine-based activation motifs (ITAMs) present in the 
cytoplasmic domains of both lg-a and Ig-p. The BCR of the IgM class, comprising 
two µ heavy chains and two light chains (Kor A), plays a critical role not only in 
activation, but also in early development of the B cell. 
In order to discriminate between the functions of the lg-a and Ig-P polypeptides, 
transgenic mice expressing chimeric IgM BCR transgenes were analysed. Surface 
IgM molecules fused directly to the cytoplasmic domains of either lg-a or Ig-P 
were sufficient to signal B cell activation in primary cells and in cell lines in 
response to antigen. In transgenic mice, they could also mediate the antigen-
independent development of mature peripheral B cells and allelic exclusion of 
endogenous immunoglobulin heavy chains. However, when the Ig-P ITAM was 
mutated, signalling was abrogated. Thus, it appears that the individual lg-a or Ig-
p cytoplasmic domains can broadly perform the signalling activities of the intact 
BCR; a function for which an ITAM is essential. 
The transcriptional activity of the lg K light chain enhancers was characterised in 
transgenic mice bearing different transgenes containing either the K intron 
enhancer (Ei) or the K 3' enhancer (E3'), or both. In spleen, the expression of a 
rearranged K transgene versus endogenous K suggested that E3', in the absence of 
Ei, is not only -sufficient to drive transcription, but also becomes active early 
enough in B cell development to effect allelic exclusion. The activation of E3' at 
this early stage is consistent with the finding that a rearranged µ transgene 
driven by the K enhancers was able to rescue development blocked at the late 
pro-/pre-B cell stage in µMT B cell-deficient mice. Indeed, the expression of a 
human P-globin reporter transgene linked to E3' in different bone marrow 
subsets indicates that E3' does become transcriptionally active in pre-B cells, at a 
stage prior to VK rearrangement. 
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Chapter 1: Introduction 
1.1 B cell antigen receptor structure and function 
1.1.1 Selection theories predicted an antigen receptor on B cells. 
The immune system defends the body from disease and infection. Even before attack 
from bacteria, viruses and other pathogens, it is equipped to recognise and eliminate 
foreign antigens. Our understanding of the response mediated by antibodies 
(composed of immunoglobulin [lg] molecules produced by B lymphocytes) has 
come a long way since the initial discovery of the Antikorper (antibody) in 1890 (von 
Behring and Kitasato, 1890). Immunity to diphtheria and tetanus was shown to be 
due to a large protein in the blood, a discrete entity that carried specificity against 
the toxins. A few years later, Ehrlich, studying the interactions between antigen and 
antibody, developed the side-chain theory and was the first to suggest the existence 
of a cell-surface receptor for toxin (antigen) (Ehrlich, 1897; Ehrlich, 1900). He 
proposed that certain cells having a natural affinity for toxin would bind toxin 
molecules via specific receptors on the surface, assimilate the toxin as a metabolite, 
and regenerate the receptors. Large amounts of toxin would cause the cell to over-
compensate for the loss of the side-chain receptors and to regenerate excess side 
chains that were released into the body as anti-toxins (antibodies). 
From the 1930s, the enormous range in antibody diversity (Landsteiner, 1933) 
favoured an instruction hypothesis where the antibody moulded its polypeptide 
sequence around the antigen template in a complementary conformation (Breinl and 
Haurowitz, 1930; Haurowitz, 1952; Pauling, 1940). However, the theory was later 
dismissed by the central dogma that information flowed in only one direction from 
DNA to RNA to protein (Crick, 1958), and that protein folding is determined by its 
polypeptide sequence, indicating that the specificity of an antibody must be encoded 
by its genes. 
In the suggestion that the immune response was selective (rather than instructive) 
and that the production of pre-exisiting antibodies was enhanced after antigen 
recognition (Jerne, 1955), Ehrlich's original concept was revived in the late 1950s. 
These ideas developed into Burnet's clonal selection theory (Burnet, 1959): from the 
large pool of potential antibody-producing cells (each capable of making a different 
antibody), recognition of the antigenic determinant by a cell would trigger its clonal 
expansion. Daughter cells possessing the same properties for antigen recognition 
would be generated, or the clones would undergo cellular differentiation for 
UNIVfRSITY 
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antibody secretion. 
An important prediction to arise from the work of Ehrlich and Burnet was that a 
receptor must exist on the surface of the cell that would recognise the antigen in a 
similar way to the antibody itself. 
Not long after publication of the clonal selection theory, rabbit lymphocytes were 
shown to proliferate in vitro when stimulated by anti-lg antisera, indicating that a 
form of antibody was present on the B cell surface (Sell and Gell, 1965). 
Confirmation of surface lg on lymphocytes came from direct fluorescent or 
radioactive detection (Pernis et al., 1970; Raff et al., 1970). These results also 
explained the background staining in earlier experiments when indirect 
immunofluorescence was used to detect histocompatibility antigens on living 
lymphocytes (Moller, 1961). Thus it was possible that antibody itself could act as the 
B cell antigen receptor (BCR). However, it was not clear until the development of 
molecular cloning, how the antibodies that were secreted and those that were 
expressed on the surface could share the same specificity for antigen. 
1.1.2 Immunglobulin can be expressed in secretory and membrane forms. 
Antibodies are made up of disulphide-linked lg heavy (H) and light (L) chains 
containing amino-terminal variable (V) regions determining the antigen specificity 
and carboxy-terminal constant (C) regions (Fig. l.lA). The five H chain isotypes (µ, 
8; y, a,£) give rise to different classes (IgM, IgD, IgG, IgA and IgE, respectively) and 
can combine with either of the two L chain isotypes (Kand A) . 
The µ H chain is the first class of BCR expressed during development. Its gene 
encodes two distinct forms which are generated by alternative splicing: a membrane 
form ofµ, as well as that for secretary antibodies (Alt et al., 1980; Early et al., 1980; 
Rogers et al., 1980). Both mRNAs encode the same V region and they differ only in 
their 3' ends at Cµ4. Instead of the secretary tailpiece, the alternative splice of two 3' 
exons (Ml and M2) generates the membrane form containing extracellular spacer~ 
transmembrane and cytoplasmic regions appended to the Cµ4 exon. However, the 
short cytoplasmic tail thus determined only contains three amino acids, calling into 
question how surface IgM could transmit signals. It was suggested that IgM may be 
associated with other proteins in order to mediate the biological activities of the 
BCR. 
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1.1.3 Membrane lg associates with the Ig-a/Ig-p heterodimer as the BCR complex. 
Plasmacytoma cell lines represent the terminal stage of development, when B cells 
have differentiated to secrete large amounts of antibody, and contain predominantly 
secretory transcripts. Transfection of the membrane-only form ofµ resulted in its 
expression, but not its transport to the surface of the plasmacytoma, despite surface 
µ expression in pre-B and B cell lines (Hombach et al., 1988; Sitia et al., 1987). Instead, 
µ was retained in the endoplasmic reticulum and was subsequently degraded. 
However, the isolation of a plasmacytoma variant that did express the transfected µ 
on the cell surface (Hombach et al., 1988) resulted in the discovery that the BCR is in 
fact a complex. 
The BCR complex is composed of membrane lg associated with a disulphide-linked 
heterodimer of lg-a and lg-P (Campbell and Cambier, 1990; Hombach et al., 1990) 
(Fig. l.lA). The genes encoding lg-a and lg-P (mb -1 and B29 respectively) had 
previously been isolated by subtractive hybridisation of B cell-specific mRNAs 
(Hermanson et al., 1988; Sakaguchi et al., 1988). Characterisation of their gene 
expression revealed that although lg-P is expressed throughout B cell development, 
the expression of lg-a is downregulated at the terminal plasma cell stage, consistent 
with the inability of membrane lgM to be transported to the surface in the 
plasmacytoma transfection experiments (Hombach et al., 1988). Membrane µ 
requires the lg-a/lg-P heterodimer to sheath its relatively hydrophilic 
transmembrane region for stable insertion into the membrane, and this non-covalent 
association is affected by mutation of theµ transmembrane region (Williams et al., 
1990). Furthermore, the same lg-a/lg-P heterodimer associates with all five classes 
of membrane lg (although the glycosylation patterns of the H chain isotypes and 
dependence for surface transport differ) and the BCR complex has been 
reconstituted in non-lymphoid cell lines (Venkitaraman et al., 1991). Although it 
remains to be shown, one could speculate that the stoichiometry of the BCR is 
membrane lgM sheathed by two lg-a/lg-p heterodimers, sinceµ offers two identical 
surfaces for interaction with the lg-a/lg-P heterodimer (Reth, 1992) (Fig. l.lA). 
Whilst it is clear that membrane lg is the central component of the BCR and that lg-a 
and lg-P are required for surface transport and biological activity, there have been 
reports of additional BCR constituents, such as the BCR-associated proteins (BAPs) 
that bind to the transmembrane regions of lgM and lgD (Kim et al., 1994; Terashima 
et al., 1994), and p40/42 which associates with the transmembrane or extracellular 
domains of the lg-a/lg-P heterodimer (Lee et al. , 1996). However, their functions are 
as yet unknown. 
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1.1.4 IT AMs are essential for transmembrane signalling by the BCR. 
The lg-a/lg-~ heterodimer not only facilitates surface transport of lgM, but provides 
the BCR with cytoplasmic domains for interacting with signalling molecules. The 
cytoplasmic tails of both lg-a and lg-~ contain sequences bearing homology to 
several other cytoplasmic domains of receptors which are involved in the immune 
response, such as the T cell receptor (TCR) and the Fe receptor for lgE (Fc£R) (Reth, 
1989) (Fig. l.lB) . This conserved sequence has been designated the immunoreceptor 
tyrosine-based activation motif (ITAM) (Cambier, 1995). The ITAMs are essential for 
the initiation of transmembrane signalling by the BCR (Flaswinkel and Reth, 1994; 
Papavasiliou et al., 1995; Sanchez et al., 1993; Taddie et al ., 1994; Williams et al., 1994). 
Triggering of the BCR results in signal transduction via the lg-a/lg-~ heterodimer. 
Protein tyrosine phosphorylations occur (Brunswick et al., 1991; Campbell and 
Sefton, 1990; Gold et al., 1990; Lane et al., 1991), including phosphorylation of the two 
conserved tyrosines in the ITAM for recruitment of SH2 (Src homology 2) domain-
containing molecules (Songyang et al ., 1993) such as protein tyrosine kinases, Syk 
and members of the Src family (Bolen, 1995). Subsequent signalling pathways 
diverge and include the activation of phospholipase C (PLC), Ras, 
phosphatidylinositol 3-kinase (PI3-K), or G proteins, ultimately regulating gene 
expression and determining cellular responses (Cambier et al., 1994). 
1;1.s Are the signalling activities of lg-a and lg-~ similar or different? 
The evidence for the relative roles of lg-a and lg-~ in BCR-mediated signalling are 
unclear . Several groups have attempted to d iscriminate between the activities of the 
individual polypeptides in cell line transfectants expressing chimeric receptors of 
extracellular and transmembrane domains of lgM, CDS or FcyRII fused to either the 
lg-a or the lg-~ cytoplasmic tail. Although some signalling assays suggest that the 
presence of the ITAM renders lg-a and lg-~ functionally redundant, conflicting 
evidence suggests that the polypeptides perform distinct roles in signal 
transd uction. 
Some experiments in cell line transfectants expressing chimeric mouse lgM and 
human CDS receptors suggest that both lg-a and lg-~ can independently mediate 
signalling in several assays. The lg-a and lg-~ cytoplasmic tails were shown to be 
sufficient to induce tyrosine phosphorylation of total cellular proteins or specific 
substrates (Vav, Pl-3K, CD22), inositol phosphate production, calcium flux, and IL-2 
production in 2PK3, A20, LK35.2 and D0-11.10 cell lines (Law et al., 1993; Taddie et 
al., 1994; Williams et al., 1994). 
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Human lgM chimeras in A20 (Sanchez et al., 1993) or mouse CDS chimeras in K46 
(Kim et al., 1993) also exhibit no difference between lg-a and lg-~ in mediating in the 
rise in intracellular calcium concentration in reponse to receptor crosslinking. 
However, the total tyrosine phosphorylation effected by lg-~ is impaired in 
comparison to the lg-a response, both in the kinetics of the response and in the 
range of substrates phosphorylated. Further analysis of the calcium response by 
FcyRII chimeras in single cells suggests that the polypeptides differ, since lg-a 
mediates a full calcium flux, whereas lg-~ exhibits oscillations of the calcium spikes 
(Choquet et al., 1994). The dissection of the lg-a and lg-~ lTAM sequences in single 
cell calcium analysis suggests that the four amino acid sequences that differ between 
the lg-a (DSCM) and lg-~ (QTAT) ITAMs (see Fig. 1.1) can in part account for their 
differential signalling abilities (Cassard et al., 1996). Mutation of the lg-~ QTAT 
sequence to DSCM rescued the calcium response mediated by lg-~. However, the 
dissection is complicated by the apparent negative regulatory role of regions 
flanking the ITAM in lg-~. lg-a and lg-~ have also been proposed to bind different 
downstream effectors (Clark et al., 1992). Indeed, the DSCM sequence of lg-a 
appears to mediate the specific association of signalling molecules such as SHC 
(D'Ambrosio et al., 1996). 
Nevertheless, the discrimination of which cytoplasmic tail binds which effector may 
not be as important as the interplay between all the molecules recruited within the 
context of the intact BCR complex (Luisiri et al., 1996). 
1.1.6 BCR-mediated tyrosine phosphorylation activates multiple effectors. 
BCR crosslinking leads to protein tyrosine phosphorylation of multiple substrates 
including several members of the Src family kinases, Lyn, Fyn, Blk, Lek (Burkhardt 
et al., 1991; Campbell and Sefton, 1992; Clark et al., 1992; Yamanashi et al., 1991). The 
Src kinases can ~ind differentially to the downstream effectors PLCy2, microtubule-
associated protein (MAP) kinase, GTPase-activating protein (GAP), and PI3-K 
(Pleiman et al., 1993). For example, BCR crosslinking results in the association of Lyn 
with the p85 subunit of PI 3-K and activation of both kinases (Yamanashi et al., 1992). 
Recruitment of the Src kinases not only occurs to the activated BCR (Law et al., 1993), 
but signalling molecules can associate with the resting BCR (Clark et al., 1992). Lyn 
and Fyn can associate with both phosphorylated and non-phosphorylated forms of 
lg-a (Pleiman et al., 1994). Association of the Src kinases with the activated BCR 
occurs via binding of their SH2 domains to the phosphorylated lg-a lTAM tyrosines 
essential for Src kinase activation (Flaswinkel and Reth, 1994). Association of the Src 
kinases with the resting BCR may occur via their SH4 domains which mediate 
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association both to the ITAM and with plasma membrane (Timson-Gauen et al., 
1996). The Src kinases may exhibit overlapping or redundant functions, however, 
gene-targetted Lyn-deficient mice exhibit impaired BCR-mediated signalling in the 
generation of peripheral B cells and also in the elimination of autoreactive B cells 
(Nishizumi et al., 1995). 
The Syk protein tyrosine kinase (Taniguchi et al., 1991) plays a crucial role in BCR 
signalling and is tyrosine phosphorylated after crosslinking of membrane lg 
(Hutchcroft et al., 1992; Law et al., 1993; Yamada et al., 1993). The centrality of Syk to 
BCR signalling was revealed by mice rendered Syk-deficient by germline disruption 
(Cheng et al., 1995; Turner et al., 1995). The mice died perinatally due to severe 
haemorrhaging, but irradiated RAG-I - mice reconstituted by Syk-deficient foetal 
liver exhibited a block in B cell development from the pro-B to pre-B cell stage, 
similar to that observed in mice lacking membrane IgM or surrogate light chain 
(Kitamura et al., 1992; Kitamura et al., 1991). These findings indicate that Syk 
expression and function is essential for mediating the activities of the pre-BCR. 
Additionally, although a small number of immature B cells were detected, mature B 
cells were absent, suggesting that Syk is also required for the maintenance of the 
mature B cell pool (Turner et al., 1995). 
Syk bears homology to the TCR-associated ZAP-70 protein tyrosine kinase (Chan et 
al., 1992) and both contain two SH2 domains 1 (Fawson and 
I 
-..... Gish, 1 '92). Indeed, ZAP-70 reconstituted BCR signalling in Syk-deficient B cells 
demons-trating functional redundancy between the kinases (Kong et al., 1995). 
Phosphorylation of both tyrosine residues in the ITAM is essential for high affinity 
binding of Syk and ZAP-70 via their dual SH2 domains (Bu et al., 1995; Hatada et al., 
1995). Syk needs to bind to the doubly-phosphorylated ITAM before it can undergo 
tyrosine phosphorylation and activation (Kurosaki et al., 1995). This can occur by 
autophosphorylation (Rowley et al., 1995), although Syk can also be activated by the 
Src kinases (Kurosaki et al., 1994). 
It is not clear whether Syk or a Src family kinase initiates the tyrosine 
phosphorylation cascade (if that is a distinction that can be made) . Different 
phosphorylated ITAMs vary in their preferences for binding Syk versus Lyn, 
although the lg-a and lg-~ ITAMs bind Lyn in preference to Syk (Johnson et al., 
1995). Experiments using Lyn-deficient and Syk-deficient chicken B cell lymphomas 
(Takata et al., 1994), suggest that Syk and Lyn may effect distinct signalling 
pathways or cooperate. Syk seems to be required for inositol phosphate turnover, 
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whereas Lyn mediates a calcium response independent of inositol phosphate 
generation. 
The low molecular weight GTP-binding protein, Ras, is a key regulator of cellular 
activation and proliferation in a number of cell types (Lowy and Willurnsen, 1993) 
and its activation state seems to be regufated by multiple mechanisms (Boguski and 
McCormick, 1993). Ras was found to co-cap with membrane lg following BCR 
ligation (Graziadei et al., 1990), and is activated in a PKC-independent manner 
(Harwood and Carnbier, 1993). Furthermore, anti-lg treatment of B cells leads to the 
activation of the Ras/Raf-1/MEK/MAP kinase pathway (Tordai et al., 1994). 
The Ras pathway was proposed to be regulated by the product of the vav proto-
oncogene, Vav, which is a target for tyrosine phosphorylation after BCR crosslinking 
(Bustelo and Barbacid, 1992; Bustelo et al., 1992; Margolis et al., 1992). However, it 
was later suggested that Vav does not act as a GTP-exchange protein for Ras, but 
that Vav and Ras could mediate distinct, yet interactive, pathways. (Bustelo et al., 
1994). Nevertheless, the importance of Vav in BCR signalling was revealed in mice 
using the RAG-complementation approach, where embryonic stern cells bearing a 
gerrnline disruption of the vav gene were injected into blastocysts from gene-
targetted RAG-I- blastocysts (Tarakhovsky et al., 1995; Zhang et al., 1995). The B-1 
lineage B cells were absent and the Vav-deficient conventional B cells were unable 
to undergo proliferation in response to anti-lg, although the lipopolysaccharide 
(LPS) and CD40 pathways seemed unaffected. 
The SH2 domain-containing protein, SHC (Pelicci et al.~ 1992) may provide another 
means for Ras activation via the Grb2/Sos complex. BCR ligation results in tyrosine 
phosphorylation of SHC with recruitment of Grb2/Sos and membrane translocation 
of the SHC/Grb2 complex (Lankester et al., 1994; Saxton et al., 1994; Smit et al., 1994). 
SHC not only binds to the phosphorylated lTAMs of both lg-a and lg-~ via its SH2 
domain (Baumann et al., 1994), but also associates with the resting BCR via the four 
amino acid sequence DSCM in the non-phosphorylated lTAM of lg-a (D'Arnbrosio 
et al., 1996). 
Further downstream in BCR cell activation pathways, the Btk protein tyrosine kinase 
(Rawlings et al. , 1993) mediates binding via its pleckstrin homology domain 
(Musacchio et al., 1993) to signalling molecules such as the ~ and y subunits of 
heterotrimeric G proteins (Tsukada et al., 1994), PKC (Yao et al., 1994) and 
phosphatidylinositol-4,5-bisphosphate (Harlan et al., 1994). A mutation in the 
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pleckstrin homology domain of mouse Btk results in the xid (X-linked immune 
deficiency) phenotype (Rawlings et al., 1993). The xid mouse exhibits defective BCR 
signalling: the B-1 cells are absent and the conventional B cells exhibited impaired 
responses to LPS or ligation of IgM or CD40 (Hasbold and Klaus, 1994; Scher, 1982; 
Wicker and Scher, 1986). Since the xid phenotype is more severe than the effect of 
disrupting vav (Tarakhovsky et al., 1995; Zhang et al., 1995), Btk may function 
downstream of Vav and may integrate the different B cell signalling pathways. It 
also may be regulated by the Src kinases (Saouaf et al., 1994) since Fyn and Lyn bind 
to Btk via their SH3 domains (Cheng et al., 1994). 
1.1.7 Other cell surface receptors can modulate BCR signalling. 
The physiological events in B cell development and activation are not mediated by 
the BCR in isolation, but result from a complex interplay of the BCR with other 
receptors that modulate its signals, such as CD19, FcyRIIbl and CD22 (Doody et al., 
1996). 
CD19, a surface glycoprotein expressed in the B lineage from early in development, 
is a target for tyrosine phosphorylation following BCR crosslinking (Fearon and 
Carter, 1995). When co-crosslinked with membrane lg, it acts as a positive regulator 
and lowers the antigen threshold for triggering the BCR (Carter and Fearon, 1992). 
CD19 forms a complex with CD21 (complement receptor 2) and CD81 (TAPA-1) 
(Fearon and Carter, 1995). In viva, coligation of the CD19 and BCR complexes via 
~tigen-complement aggregates could provide a link between the innate response 
and T cell-dependent antibody responses by enhancing the potency of antigen for 
the BCR (Dempsey et al., 1996). Indeed, gene-targetted mice lacking CD19 exhibit 
deficiencies in T cell-dependent responses and germinal centre formation (Engel et 
al., 1995; Rickert et al., 1995). The CD19-deficient mice also lack B-1 cells and this 
phenotype bears similarites to that of Vav-deficient mice (Tarakhovsky et al., 1995; 
Zhang et al., 1995). This is consistent with reports that CD19 activates Vav and MAP-
K (Weng et al., 1994), and that CD19 is necessary for self-renewal of the B-1 
population (Krop et al., 1996). The CD19 complex also associates with PI 3-K, and Src 
kinases Fyn and Lyn (Chalupny et al., 1995; Tuveson et al., 1993; van Noesel et al.,. 
1993). 
FcyRIIbl, which binds to the Fe regions of IgG (Ravetch, 1997), could act as a 
coreceptor with the BCR to mediate feedback of the concentration of serum 
antibodies. Its negative regulatory role in modulating BCR-mediated signals was 
first apparent in observations that anti-IgM-induced activation of B cells was 
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abrogated if intact antibody was used to crosslink the BCR (Phillips and Parker, 
1984). Co-ligation of FcyRIIlb with BCR results in the phosphorylation of a single 
tyrosine in an inhibitory motif contained in the FcyRIIbl cytoplasmic domain. This 
phosphorylated tyrosine residue interacts with and activates the tyrosine 
phosphatase, SHP (PTP-lC) (D'Ambrosio et al., 1995), and is essential for mediating 
the negative signal which inhibits the influx of extracellular calcium across the cell 
membrane (Choquet et al., 1993; Muta et al., 1994). 
The SHP protein tyrosine phosphatase also interacts with CD22 (Campbell and 
Klinman, 1995; Doody et al., 1995), a B cell-specific surface glycoprotein that 
associates with membrane lg with low stoichiometry (Leprince et al., 1993; Peaker 
and Neuberger, 1993). Triggering of the BCR leads to the rapid tyrosine 
phosphorylation of the cytoplasmic domain of CD22 (Schulte et al., 1992); the 
phosphorylated tyrosines recruit SHP (Campbell and Klinman, 1995; Doody et al., 
1995) and the tandem SH2 domains of Syk (Wienands et al., 1995). The association 
with SHP suggests that CD22 is a negative regulator of BCR signalling and is 
consistent with the increase in B cell response resulting from ligating CD22 
separately or preventing its association with the BCR (Doody et al., 1995; Pezzutto et 
al., 1988) . Indeed, B cells from gene-targetted CD22-deficient mice are 
hyperresponsive to BCR-mediated signals, exhibiting not only enhanced B cell 
activation, but also advanced B cell maturation (O'Keefe et al., 1996; Otipoby et al., 
1996; Sato et al., 1996). CD22 is normally expressed at the mature B cell stage 
(Erickson et al., 1996) and may act to increase the antigen threshold for BCR 
~gnalling after the stage when immature B cells are sensitive to self-antigens. 
1.1.8 The BCR mediates antigen presentation to recruit help from T cells. 
The signalling activities of the BCR are often not sufficient for B cell activation in 
response to T cell-dependent antigen, and in order to recruit T cell help (such as 
cytokine secretion), B cells must present antigen (Lanzavecchia, 1985). The BCR 
constitutively internalises bound antigen (Watts and Davidson, 1988) for processing 
and presentation as antigenic peptides complexed with MHC class II molecules 
(Pieters, 1997). The Ig-a/Ig-~ heterodimer confers . efficient antigen presentation 
(Patel and Neuberger, 1993) by driving the intracellular targetting of antigen 
(Aluvihare et al., 1997). The relative contributions of lg-a and lg-~ to the antigen 
presentation process are unclear; whilst chimeras bearing the individual lg-a and lg-
~ cytoplasmic tails have been shown to target antigen to different intracellular 
compartments (Bonnerot et al., 1995), the relevance of these findings to BCR function 
in viva remains to be shown. 
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Efficient antigen presentation by B cells for the stimulation of T cells also requires 
costimulation between the B and T cells, as suggested by the two-signal model of 
lymphocyte activation (Bretscher, 1992; Bretscher and Cohn, 1970; Schwartz, 1990). 
One such interaction results from the upregulation of B7 after BCR ligation and 
signalling. The B7 (CD80 and CD86) family of cell surface costimulatory molecules 
bind CD28 or CTLA4 expressed on the surface of T cells (June et al., 1994), however, 
absence of this costimulatory signal leads to partial activation and anergy (Ho et al., 
1994). CD80 and CD86 are differentially regulated with respect to time and tissue-
specificity, and have also been implicated in regulating the type of T-cell dependent 
response (Freeman et al., 1995; Kuchroo et al ., 1995). 
\ 
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1.2 Immunoglobulin gene expression 
1.2.1 Organisation of immunoglobulin genes 
One limitation of the side chain theory (and later the clonal selection theory) became 
apparent after studies with artificial haptens indicating that the body contains 
antibodies with innumerable specifities and differing affinites (Landsteiner, 1933). 
This enormous diversity could not be explained by a simple model of pre-existing 
antibody side chains. Instead of each antibody being encoded by its own gene, it was 
proposed that immunoglobulin molecules may be generated by the recombination of 
two separate pools of genes: a very large pool for variable (V) regions and another 
for constant (C) regions (Dreyer and Bennett, 1965). The V regions would differ in 
antigen specificity but the functional properties of the antibody would be conferred 
by the C region. The prediction that lymphocyte DNA undergoes somatic 
rearrangement was borne out when 'AL chain DNA was shown to hybridise to one 
fragment of myeloma DNA, but to two fragments from embryonic DNA (Hozumi 
and Tonegawa, 1976). Furthermore, the V regions are encoded by smaller gene 
segments that recombine (Tonegawa, 1983), providing diversity by combinatorial 
joining. 
The mouse IgH locus is made up of exons encoding V and C regions (Fig. 1.2). The V 
region is composed of three families of gene segments, VH, DH and JH; the choice 
within each family increases potential diversity. The C region exons encode for 
diff~rent isotypes of H chain, giving rise to the different classes of antibody. Mature 
B cells can co-express both IgM and IgD classes, which are generated by alternative 
splicing. B cell activation and differentiation can lead to the deletion of upstream CH 
regions by class switching (Shimizu and Honjo, 1984), which is mediated by short 
tandem repeats known as switch recombination sequences (Radbruch et al., 1986). 
Antibody class switching results in the expression of downstream H chain isotypes 
with different effector functions (Morgan and Weigle, 1987) but yet retain the same 
antigen specificity. 
Mice can express either the Kor AL chain isotype, although K predominates and is 
expressed by 95% of B cells (Coleclough et al., 1981). The mouse lgK locus is made up 
of V and C region exons (Fig. 1.2), but it is less complex than the IgH locus. Only two 
families of V gene segments, VK and JK, rearrange to form the V region, and a single 
exon encodes the CK region. 
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1.2.2 Control and tissue-specificity of lg gene expression 
The expression of functionally rearranged lg genes is regulated by the promoter and 
enhancer elements present at the loci (Staudt and Lenardo, 1991) (Fig. 1.2). The 
control elements ensure the cell type- and stage-specificity of expression. Most 
studies of the regulatory sequences have focussed on their transcriptional activities. 
However, the elements also play roles in such processes as demethylation and 
rearrangement of the gene segments. 
All lg promoters share two sequence motifs, a TATA box which is not cell-restricted, 
and an octamer motif (Staudt and Lenardo, 1991). The octamer present in the lg 
promoter directed lymphoid-specific expression, and yet also activated transcription 
in other cell types, acting selectively with different enhancers (Parslow et al., 1987). 
The conflict in specificity may be due to the differential expression and activity of 
the POU-doi\1.ain family of transcription factors (Herr et al., 1988). B cell specificity is 
driven primarily by Oct-2, which is restricted to the B cell lineage, but expressed 
throughout development (Staudt et al., 1986). In contrast, Oct-1 is expressed by most 
cell types (Singh et al., 1986; Sturm et al., 1988). 
Enhancer elements play an important role in directing events at the lg loci. For 
example, two enhancers have been identified for the KL chain, the K intron enhancer 
(Ei) and the K 3' enhancer (E3') (Meyer and Neuberger, 1989; Picard and Schaffner, 
1984). Experiments in LPS-activated pre-B cell lines suggested that Ei is required 
at the pre-B cell stage for transcription (Atchison and Perry, 1987; Fulton and 
Van Ness, 1993; Lenardo et al., 1987). Moreover, Ei plays a role in demethylation of 
the K gene, possibly by directing locus accessibility prior to VK rearrangement 
(Lichtenstein et al., 1994). The activity of Ei is dependent on binding of the 
transcription factor, NFKB (Atchison and Perry, 1987). In contrast, the second, 
stronger tissue-restricted enhancer, located 3' of CK can drive the expression of Kin 
cell lines that lack NFKB and has been shown to be active from the B cell stage 
onw ards in development (Meyer and Neuberger, 1989; Park and Atchison, 1991; 
Pongubala and Atchison, 1991). 
1.2.3 V region rearrangement generates antibody diversity. 
Early in B cell development, V region rearrangement occurs firstly at the IgH locus, 
in an ordered process with Dtt-JH joining followed by Vtt-DJtt (Alt et al. , 1984). VK-
JK rearrangement generally occurs after Vtt, but signals from the pre-BCR are not 
necessary for triggering this process (Ehlich et al. , 1993; Grawunder et al. , 1993). V 
gene segment rearrangement occurs at consensus recombination signal sequences 
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(RSSs) that flank the segment (Schatz et al., 1992; Tonegawa, 1983). RSSs consist of a 
palindromic heptamer element (adjacent to the coding region) separated by a spacer 
region of 12 or 23 non-conserved nucleotides from a conserved nonamer element. 
Efficient joining of gene segments requires the interaction of a 12 bp spacer-
containing RSS with a 23 bp spacer-containing RSS (the 12/23 rule); the presence of 
these two types of'RSS is both necessary and sufficient (Aguilera et al., 1987; Hesse et 
al., 1989). 
The recombination machinery involves the products of the recombination activating 
genes, RAG-1 and RAG-2 (Oettinger et al., 1990; Schatz et al., 1989), and the scid gene 
product, which is a DNA-dependent kinase (Kirchgessner et al., 1995) also 
implicated double-strand break repair (Bosma et al., 1983; Hendrickson et al., 1991). 
Mice defective for these genes lack mature B and T cells due to impaired V 
rearrangement. However, the block in B cell development can be overcome by the 
introduction of functionally rearranged H and L chains (Chang et al., 1995; 
Reichman-Fried et al., 1990; Spanopoulou et al., 1994; Young et al., 1994). The 
expression of the RAG genes is biphasic; this pattern correlates with the two periods 
of V region rearrangement, firstly of the H chain and then of the L chain gene loci 
(Grawunder et al., 1995). 
The imprecise joining of gene segments, as well as the combinatorial mechanism, 
gives rise to diversity of the V regions. In the case of H chain rearrrangements, VH 
regions can undergo the insertion of random "N" nucleotides by TdT (terminal 
deoxynucleotidyl transferase), creating additional diversity at the coding joints (Alt 
and Baltimore, 1982; Landau et al., 1987). However, junctional diversity and N-
region insertion can also give rise to non-functional genes due to out~of-frame 
joining or the introduction of stop codons. 
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1.3 B cell development 
1.3.1 Expression of lg and cell differentiation markers during B cell development 
B cell development in the adult mouse bone marrow has been characterised by 
separating B lineage subpopulations according to the expression of lg and different 
cell surface markers, status of V region rearrangement, and growth requirements. 
The system of dividing developmental stages varies between groups, but perhaps 
the most straightforward nomenclature is that of Hardy et al., 1991, which l have 
adapted with additional data from reviewed in Rolink et al., 1994 and Grawunder et 
al., 1995, and summarised below (Fig. 1.3). 
When a haematopoietic stem cell becomes committed to the B cell lineage, it may be 
identified by surface expression of B220 (CD45R). These pre-pro-B cells (Hardy 
fraction A) also express CD43, c-kit (CD117), but have not started to express any lg. 
At this stage, the cells are dependent only on contact with stromal cells (Nishikawa 
et al., 1988). CD19 is also expressed throughout B cell development, and may be the 
preferred marker for pan-B cell-specificity, since B220 is expressed on a minor 
subpopulation of natural killer cell progenitors that are negative for both heat stable 
antigen (HSA [CD24]) and BP-1, thus falling into fraction A (Rolink et al., 1996). 
Early pro-B cells begin to express HSA and IL-7 receptor (lL-7R), which correlates 
with their requirement for both stromal contact and the presence of lL-7. lL-7R is 
important for growth, but also induces H chain rearrangement (Corcoran et al., 
1996). The pro-B cells start DH-JH rearrangement with the expression of the 
recombinase activating genes RAG-1 and RAG-2, and TdT (which mediates N region 
insertions). At later stages, pro-B cells also begin to express BP-1; the combination of 
CD43, HSA and BP-1 expression has been used to discriminate between the earliest 
stages in B cell development (Hardy fractions A to C). 
Productive VDJH rearrangement leads to cytoplasmicµ expression at the large pre-B 
cell stage, and the cells no longer require stromal contact but still need lL-7. The 
association of functionally-rearrangedµ with the su~rogate light chains, V preB and 
A5, results in surface transport of the pre-BCR complex (with the lg-a/lg-~ 
heterodimer (Brouns et al., 1993; Gong and Nussenzweig, 1996; Matsuo et al., 1993)). 
The pre-BCR signals a clonal expansion phase and the large majority of cells 
beginning to expressµ or pre-BCR are in cell cycle (Karasuyama et al., 1994). As the 
pre-B cells start to express CD25 (TAC, lL-2 receptor a chain) on the surface, they 
also downregulate the expression of RAG-1, RAG-2 and TdT. 
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After the proliferative stage, the cells exit the cell cycle, becoming small pre-B cells. 
They lose expression of CD43 and surrogate light chains, but upregulate RAG-1 and 
RAG-2 expression again for VK-JK and VA-JA rearrangement. The productive 
rearrangement of L chain results in L chain association withµ and expression of the 
mature BCR. The immature B cells displaying surface IgM no longer need the 
recombination machinery and they also downregulate the expression of IL-7R and 
pre-B cell marker BP-1. 
1.3.2 Role of the pre-BCR in developmental checkpoints 
B cell development serves to generate antibodies recognising numerous antigens, 
however, the pre-BCR plays a crucial role even before the cell is exposed to antigen. 
Signals from the pre-BCR mediate several processes, including the indication of 
productive Vtt rearrangement and expansion/ survival of those cells, pro- to pre-B 
transition, allelic exclusion of IgH, and activation of VL rearrangement, all of which 
may constitute distinct checkpoints in development. 
The structure of the pre-BCR is not dissimilar to that of the BCR (Reth, 1992), since 
the Ig-a/Ig-~ heterodimer is required for its surface expression and function (Brouns 
et al., 1993; Gong and Nussenzweig, 1996; Matsuo et al., 1993). µ H chains were 
detected on the surface of B cell progenitors without K or A L chains (Pillai and 
Baltimore, 1988), an observation that could be explained by the presence of two non-
rearranging polypeptides, AS and Vpre-B, with homology to the C and V regions of 
the AL chain, respectively (Kudo and Melchers, 1987; Sakaguchi and Melchers, 1986). 
AS and VpreB act as surrogate light chains in the pre-BCR complex; AS binds 
covalently to µ whilst VpreB associates non-covalently (Karasuyama et al., 1990; 
Tsubata and Reth, 1990). 
Expression of a productively rearrangedµ chain, surrogate light chains and the Ig-
a/Ig-~ heterodimer are essential for the function of the pre-BCR, since gene-
targetted mice that cannot express membrane µ, AS , lg-~ or the cytoplasmic domain 
of lg-a exhibit a block at the pro-B cell stage (Ehlich et al., 1993; Gong and 
Nussenzweig, 1996; Kitamura et al., 1992; Kitamura et al., 1991; Torres et al ., 1996). 
Indeed, the pre-BCR complex seems to mediate its biological activities by 
transmembrane signalling. Although it is presumed to be an antigen-independent 
event, crosslinking µ, AS or lg-a in pre-B cell lines results in downstream tyrosine 
phosphorylation and increases in intracellular calcium concentration (Matsuo et al., 
1993; Misener et al., 1991; Takemori et al., 1990). 
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productive Vtt rearrangement seems to act as a checkpoint whose completion is 
signalled via expression of the pre-BCR on the surface. Mice that are unable to 
rearrange VDJH due to germline disruption of the JH locus (Chen et al., 1993) or the 
RAG-1, RAG-2 or scid genes involved in the recombination machinery (Bosma et al., 
1983; Mombaerts et al., 1992; Shinkai et al., 1992) are blocked at development in pro-B 
cells. However, progression from the pro- to pre-B cell stage is rescued by the 
presence of a rearranged H chain or both Hand L chain transgenes (Chang et al., 
1995; Reichman-Fried et al., 1990; Spanopoulou et al., 1994; Young et al., 1994). 
Most of the pre-B cells that express a productively-rearrangedµ are in the Sor G2 
phase of the cell cycle (Karasuyama et al., 1994), a higher proportion than at any 
other stage in early B cell development, suggesting that the pre-BCR has signalled 
and licensed the functionally Vtt-rearranged pre-B cell to undergo proliferative 
expansion (Rolink et al., 1993). 
Central to the clonal selection theory, is the prevention of expression of more than 
one antibody specificity. The mechanism that ensures monospecificity is known as 
allelic exclusion. Allelic exclusion of the IgH locus requires surface expression of the 
pre-BCR. Mice carrying µ transgenes encoding µ or membrane-only µ inhibited 
endogenous Vtt rearrangements (Manz et al., 1988; Nussenzweig et al., 1987; Rusconi 
and Kohler, 1985; Weaver et al., 1985). However, mice in which one allele ofµ could 
only express the secretary form were not able to exclude the other IgH allele and 
generated B cells expressing both alleles (Kitamura and Rajewsky, 1992). 
Several models have been proposed to account for allelic exclusion. Assuming that 
rearrangement proceeds independently on both IgH alleles, the stochastic model 
suggests that the process is intrinsically error-prone and that there is a low 
probability that two functional Vtt rearrangements would be generated within a 
given time (Cohn and Langman, 1990; Coleclough et al., 1981; Langman and Cohn, 
1987; Walfield ei al., 1981). Alternatively, the expression of both alleles could be toxic 
to the B cells and cause the death of the double expressers (Wabl and Steinberg, 
1982). 
However, more recent evidence favours an ordered model, initally based on studies 
using Abelson-transformed pre-B cell lines (Alt et al., 1981). Rearrangement is 
initiated at the IgH locus and µ chain expression from a productive Vtt 
rearrangement prevents rearrangement of the other allele (Alt et al., 1984). Allelic 
exclusion may be related to the downregulation of RAG-1 and RAG-2 gene 
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expression in pre-B cells, however, this offers only a partial explanation since RAG 
expression is upregulated again for VL rearrangement (Grawunder et al., 1995). 
An additional form of regulation governing productive rearrangement may exist via 
a truncated form of membrane µ, Dµ, which lacks Vtt segments and results from 
DJH rearrangements (Reth and Alt, 1984), The Dµ protein seems to be expressed in a 
similar complex to the pre-BCR (Tsubata et al., 1991), and can also mediate allelic 
exclusion (Gu et al., 1991; Loffert et al., 1996). Dµ provides a possible mechanism for 
counterselecting rearrangement in reading frame (rf) 2, which is underselected in the 
repertoire compared to rfl (Gu et al., 1991; Kaartinen and Makela, 1985). Rf3 often 
contains stop codons which render those rearrangements non-productive. 
lg V region rearrangement in B cells usually begins at the IgH locus and it was 
proposed that the functionally-rearranged µ provided the signal to induce VL 
rearrangement (Iglesias et al., 1991; Reth et al., 1987; Tsubata et al., 1992). However, 
the detection of VK rearrangement in pre-B cell lines (Grawunder et al., 1993; 
Kubagawa et al., 1989; Schlissel and Baltimore, 1989) or pre-BCR-deficient mice 
(Blackwell et al., 1989; Chen et al., 1993; Ehlich et al., 1993), indicated that the IgH and 
IgL loci rearrange independently. B cell development in 11,5-deficient mice was 
rescued by a rearranged K transgene, but not a rearranged K targetted into the 
genomic K locus (Pelanda et al., 1996). However, since the transgene was expressed 
prematurely, it was suggested that the regulation of VK rearrangement operates at 
the level of gene expression. 
VK rearrangement occurred only at a low frequency in the pro-B cells of pre-BCR-
deficient inice (Chen et al., 1993; Ehlich et al., 1993). Although signals from the pre-
BCR are not necessary for the initiation of VL rearrangement, pre-BCR signalling 
may still be required for the upregulation of V L rearrangement activity as suggested 
by Abelson-transformed pre-B cell line experiments (Iglesias et al., 1991; Reth et al., 
1987; Tsubata et al., 1992). 
1.3.3 Selection and maturation of the peripheral B cell pool 
The discrimination between self and non-self endures as one of the major 
immunological questions yet to be understood. However, transplantation 
experiments using dizygotic cows (Owen, 1945) or skin grafts on mice of different 
strains (Billingham et al., 1956) demonstrated that self-recognition and tolerance 
were acquired during the development of lymphocytes, and indicated that the 
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potential antibody-producing B cells must be selected. 
Tolerance induction seems to be correlated with the maturational status of the B cell 
rather than the form of the antigen (Klinman, 1996). Despite the daily generation of 
immature B cells estimated at 10-20 million (Osmond, 1991), few (3%) of these IgM+ 
B cells are selected into the long-lived peripheral B cell pool, in part reflecting 
negative selection processes that protect against autoreactive antibodies. Transgenic 
model systems have suggested that if B cells are strongly crosslinked by self-antigen, 
they may be eliminated in the bone marrow and prevented from migrating into the 
periphery (Chen et al., 1995; Goodnow et al., 1995; Hartley et al., 1991; Nemazee and 
Burki, 1989). Although immature B cells express IgM, they do not seem to respond 
to antigen in the same way as mature B cells; instead of undergoing activation and 
differentiation, apoptosis is induced in immature B cells (Monroe, 1996; Norvell et 
al., 1995; Wechsler and Monroe, 1995; Yellen et al., 1991). Levels of the bcl-2 gene are 
downregulated in immature B cells (Li et al., 1993; Merino et al., 1994), suggesting 
that they are programmed to die unless they receive a signal (possibly mediated by 
the BCR) required for their survival and maturation (Torres et al., 1996). Once 
rescued from apoptosis and selected into the long-lived peripheral B cell pool, levels 
of bcl-2 expression increase again (Merino et al., 1994). 
Tolerance may also be induced when BCRs on immature B cells are inefficiently 
crosslinked by monovalent soluble antigen. B220 and surface IgM expression are 
downregulated, and the B cells are rendered anergic, as revealed by mice expressing 
an anti-HEL transgene (Goodnow et al., 1988). Anergy can occur not only to B cells 
developing in the bone marrow, but also to mature B cells (Goodnow et al., 1989). 
Furthermore, cell transfer experiments showed that these anergic cells are impaired 
when competing with wild type cells for populating the peripheral lymphoid 
organs, or when entering B cell follicles (Cyster et al., 1994). 
In response to autoantigen, immature B cells can undergo receptor editing (Gay et 
al., 1993; Radie et al., 1993; Tiegs et al., 1993). At this stage in development they may 
still be expressing RAG-1 and RAG-2, allowing the1!1 to induce secondary L chain 
rearrangements and alter their antigen specificity (Feddersen and Van Ness, 1985; 
Harada and Yamagishi, 1991; Rolink et al., 1993). However, immature B cells are 
short-lived, with a lifespan of only 3-4 days compared to that of the peripheral B cell 
pool, which may be months (Forster and Rajewsky, 1990; Rajewsky, 1993). If 
immature B cells do not receive a survival signal, they may die from apoptosis. 
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Survival of positive or negative selection events results in the co-expression of both 
IgM and IgD classes by the mature B cell. Maturation of the B cell also leads to the 
expression of other cell surface molecules such as CD22 (Erickson et al., 1996), CD23 
(Fe£ receptor) (Conrad, 1991; Waldschmidt et al., 1991), CD21/35 (complement 
receptors 2 and 1) (Ahearn and Fearon, 1989; Gelfand et al., 1974) and varying levels 
of HSA expression, depending on the differentiation status of the B cell in the follicle 
or in the marginal zone (Allman et al., 1993; Erickson et al., 1996). 
1.3.4 Affinity maturation and memory B cells 
The germinal centre (GC) (Kelsoe, 1996; MacLennan, 1994) is a specialised 
microenvironment formed when B cells are activated by T cell-dependent antigen. 
The B cells migrate into and populate follicles, which also contain antigen-specific T 
cells (Fuller et al., 1993) and follicular dendritic cells (FDCs) (Tew et al., 1990). The 
FDCs retain antigen for long periods, bound to antibodies or in complexes with 
complement factors, and present antigen to drive the GC reaction for affinity 
maturation of serum antibodies. The GC B cells (identified by binding peanut 
agglutinin) within the polarised architecture of the GC (Liu et al., 1991) are divided 
into the dark zone populated by rapidly proliferating centroblasts, and the light 
zone containing non-dividing centrocytes. It is believed that somatic hypermutation 
(Berek et al., 1991; Jacob et al., 1991) (when point mutations are accumulated by the V 
regions) occurs in the centroblasts, whereas the high-affinity mutant centrocytes are 
selected for their ability to bind antigen displayed by the FDC in the light zone. 
GCs are also necessary for memory B cell generation. GC B cells that survive 
repeated rounds of mutation and selection enter the memory B cell compartment 
and dominate later responses (Weiss and Rajewsky, 1990). These selected B cells 
leave the GC and populate the marginal zone (Liu et al., 1988); their migration from 
the GC is suggested from the detection of mutated V regions (Dunn-Walters et al., 
1995). Memory B cells are generally resting and long-lived, and have undergone 
class-switching (Rajewsky, 1996). They can efficiently effect a secondary response to 
antigen, since re-activation induces the upregulation of costimulatory molecules 
more rapidly compared to nai:ve cells, thus mediating more efficient antigen 
presentation (Hayakawa et al., 1987; Liu et al., 1995). 
1.3.5 B-1 cells: a separate lineage from conventional B cells 
B-1 (Ly-1 B) cells (Hayakawa and Hardy, 1988) appear to constitute a separate B cell 
lineage from the conventional (or B-2; Kantor, 1991) B cells that primarily colonise 
the peripheral lymphoid organs. B-1 cells can be distinguished from conventional B 
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• 
cells by expression of the cell surface molecules CDS, Mac-1 (Hardy et al., 1994) and 
CD43 (Wells et al., 1994), and they predominate in the B cell pool found in the 
peritoneum. They are generated early in ontogeny in the foetal liver and are self-
renewing (Hardy et al., 1994; Hayakawa et al., 1986), with a low turnover rate 
(Deenen and Kroese, 1993), unlike conventional bone marrow-derived B cells. 
Despite their relatively small numbers, B~ 1 cells produce at least 50% of serum IgM 
(Herzenberg et al., 1986; Stall et al., 1986). They are considered to be a major source of 
autoantibodies (Hayakawa and Hardy, 1988; Murakami et al., 1992) and undergo 
"natural" antibody production without immunisation or exposure to environmental 
antigen (Bos et al., 1989; Forster and Rajewsky, 1987). 
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1.4 Aims of this study 
The analysis of B cell antigen receptor expression and signalling described in this 
study falls into two sections: 
• The relative roles of lg-a and lg-~ in transmembrane signalling mediated by the 
BCR complex (chapters 3 and 4) 
• The transcriptional activity of the K enhancer regulatory elements during B cell 
development (chapter 5 and 6). 
The cytoplasmic domains of lg-a and lg-~ are essential for the initiation of BCR-
mediated signals. However the literature is unclear as to whether the two 
polypeptides are functionally redundant or if they have distinct roles to perform 
within the context of the intact BCR. To extend on the cell line transfection strategy 
used in experiments by others, I decided to use a transgenic approach to facilitate 
the discrimination of the signalling activities of lg-a and lg-~ in primary cells and 
during B cell development. 
Clearly, the effect of signals from the BCR is dependent on the timing of lg 
expression. In the case of the lg KL chain gene, two enhancer elements, the K intron 
enhancer and the K 3' enhancer, have been identified and are presumed to play 
distinct roles in regulating the expression of K at different stages in B cell 
development. In order to characterise and discriminate the transcriptional activities 
of the two K enhancers throughout differentiation of the B cell lineage in viva, I took 
advantage of transgenic mice already available that expressed transgenes bearing 
either of the K enhancers, or both. 
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Figure 1.1 The B cell antigen receptor complex contains IT AMs 
(A) Schematic diagram of the structure of the B cell antigen receptor. The complex is composed of 
membrane immunglobulin associated with lg-a and lg-13, which contain ITAMs in their 
cytoplasmic domains. lgM, the first class expressed in ontogeny, is depicted, formed byµ heavy 
and K light chain (V, variable region; C, constant region; S-S, disulphide bond). 
(B) Immunoreceptor tyrosine-based activation motif (IT AM). Polypeptide sequences (Reth, 1989; 
Cambier et al., 1994) from multichain immune recognition receptors are aligned with the 
conserved amino acids in bold type. Italics indicate residues proposed to account for differences 
in the signalling activities of lg-a and lg-!3. Sequences are from mouse except where indicated 
and gaps (-) were inserted for optimal alignment. 
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Figure 1.1 The B cell antigen receptor complex contains IT AMs 
(A) Schematic diagram of the structure of the B cell antigen receptor. The complex is composed of 
membrane immunglobulin associated with lg-a and lg-p, which contain ITAMs in their 
cytoplasmic domains. lgM, the first class expressed in ontogeny, is depicted, formed by µ heavy 
and K light chain (V, variable region; C, constant region; S-S, disulphide bond). 
(B) Immunoreceptor tyrosine-based activation motif (IT AM). Polypeptide sequences (Reth, 1989; 
Cambier et al., 1994) from multichain immune recognition receptors are aligned with the 
conserved amino acids in bold type. Italics indicate residues proposed to account for differences 
in the signalling activities of lg-a and lg-p. Sequences are from mouse except where indicated 
and gaps (-) were inserted for optimal alignment. 
Chapter 1: Introduction 34 
Src P P / P 
kinases ::: Syk 
e.g.~; Ip)~ d~ 
=::Y&~ 
'\ ~ ! 
B ?-8 
BCR-mediated tyrosine phosphorylation 
Summary of the interactions of signalling molecules recruited to the activated BCR (described 
in section 1.1.6). SH2 domain-containing proteins bind to the phosphorylated tyrosine residues 
(P) present in the lTAMs of lg-a and lg-~. The arrows represent the subsequent activation of 
donwstream targets by binding and/ or tyrosine phosphorylation by the kinases. 
n 
::," 
Sll 
"d 
.... 
ro 
>-; 
>--' 
...... 
::i 
.... 
>-; 
0 p_. 
i:: 
n 
.... 
..... 
0 
::i 
vJ 
(JI 
lgH 
VH (100-1000) DH (10-20) JH (4) 
n 
5
'~!1-ll-11 
p E S 
IQK 
VK(100s) JK(4) CK(1) 
Cµ Co 
. 
- n 
5
' t{}{}-11 {H}-11 3' 
p E E 
S Cy3 
CH (8) 
S Cy1 S Cy2b S Cy2a S Cc S Ca 
Figure 1.2 Immunoglobulin gene loci 
Schematic representation of the organisation of the mouse 
immunoglobulin heavy chain and K light chain genes. 
Figures in brackets denote the number of gene segments 
available for recombination, and regulatory elements are 
indicated in italics (P, promoter; E, enhancer; S, switch 
region) . 
3' 
9 
PJ 
"Cl 
..... 
(1) 
"'i 
I-' 
~ 
M" 
"'i 
0 
0., 
~ 
M" g· 
~ 
O'I 
<I.) Hardy et al. pre-pro-8 early pro-8 late pro-B pre-8 immature B mature B 
.... 
::J 
co Fraction A Fraction B Fraction C Fraction C' Fraction D Fraction E Fraction F u 
C 
~ { Rolink et al. pro-8 pre-8-1 
- lar~e pre-8-11 - small pre-B-11 immature B mature B ~ Grawunder et al. c-kit+ SL 156 large CD25+ small CD25+ lgM'°lgD lgM+lgD+ 
pre-pro-B , · early pro-8 late pro-8 large pre-8 small pre-8 immature B mature B 
~ ~ ~ ~ 
(/) B220 (CD45R) 
,._ 
~ CD19 
,._ 
~ c-kit (CD117) 
~ CD25 (TAC) 
~ CD43 
::J HSA (CD24) Cl) 
ci3 BP-1 u 
IL-7R 
C 
0 
·en RAG-1 
Cl) 
(l) RAG-2 ,._ 
Cl.. 
---------~ TdT 
<( A-5 z 
~ sterile K 
Figure 1.3 B cell development in mouse bone marrow. 
Summary of stages defined by surface expression of immunoglobulin and cell differentiation markers, and status of V region rearrangement, based 
on Hardy et al. (1991), Rolink et al. (1994) and Grawunder et al. (1995). Large circles depict active cycling cells, whilst small circles depict resting cells (pre-BCR, pre-B cell antigen receptor; SLC, surrogate light chains). IgH and IgL rearrangment status of the cells are denoted by Hand L subscripts 
respectively (GL, germline; V, D and J represent recombination of those gene segments). Bold lines indicate periods of expression of the protein or gene (dotted line denotes detection of RAG-2 protein). 
n 
!:J" 
Pl 
"Cl 
..... 
re 
>-; 
>--' 
5" 
..... 
>-; 
0 p.. 
~ 
n 
..... 
..... § 
(;l 
(JI 
lgH 
VH (100-1000) OH (10-20) JH (4) 
n 
s·4f..;;f-l-;; 
p E S 
IQK 
V.t( (100s) JK(4) CK(1) 
Cµ Co 
. n 
5
' ~11{H}-11 3' 
p E E 
S Cy3 
CH (8) 
S Cy1 S Cy2b S Cy2a S Cc S Ca 
Figure 1.2 Immunoglobulin gene loci 
Schematic representation of the organisation of the mouse 
immunoglobulin heavy chain and K light chain genes. 
Figures in brackets denote the number of gene segments 
available for recombination, and regulatory elements are 
indicated in italics (P, promoter; E, enhancer; S, switch 
region). 
3' 
Q 
Pl 
'"d 
ft 
>-t 
,... 
5" 
.-,. 
>-t 
0 p_. 
C 
n 
.-,. g· 
vJ 
O'I 
~ Hardy et al. pre-pro-B 
1il Fraction A 
c3 
C 
early pro-B 
Fraction B 
~ { Rolink et al. pro-B . pre-8-1 ~ Grawunder et al. c-kit+ -------
Fraction C 
late pro- pre-B immature B 
Fraction C' Fraction D Fraction E 
- lar~e pre-B-11 - small pre-8-11 immature B 
SL 156 large CD25+ small co25+ lg~lgD 
pre-pro-8 early pro-B late pro-B large pre-B small pre-B immature B 
~,~ 
~ 
GL~ ~~ I~ GLL ~ 
~ B220 (CD45R) 
t CD19 
~ c-kit (CD1 1?) g CD25 (TAC) 
t CD43 
::) 
:;; HSA (CD24) 
c'.3 BP-1 
IL-7R 
C 
.Q ~ RAG-1 
Cl) a. RAG-2 · 
~ TdT 
~ A.5 i sterile K 
Figure 1.3 B cell development in mouse bone marrow . 
mature B 
Fraction F 
mature B 
lgM+lgD+ 
mature B 
Summary of stages defined by surface expression of immunoglobulin and cell differentiation markers, and status of V region rearrangement, based 
on Hardy et al. (1991), Rolink et al. (1994) and Grawunder et al. (1995). Large circles depict active cycling cells, whilst small circles depict resting cells (pre-BCR, pre-B cell antigen receptor; SLC, surrogate light chains). IgH and IgL rearrangment status of the cells are denoted by Hand L subscripts 
respectively (GL, germ.line; V, D and J represent recombination of those gene segments). Bold lines indicate periods of expression of the protein or gene (dotted line denotes detection of RAG-2 protein). 
Materials and Methods 
Chapter 2 
37 
Chapter 2: Materials and Methods 
Many of the procedures were followed as described in Sambrook et al., 1989 or 
according to the maufacturer's instructions. 
2.1 Materials 
2.1.1 DNA constructs 
Plasmids driving the expression of the hen egg lysozyme (HEL)-specific receptors 
were based on pSV2gpt and pSVneo (Fig. 3.lA). The K transcription unit 
(Aluvihare et al., 1997), in which the VK segment of the mouse Dl.3 monoclonal 
antibody (Amit et al., 1985; McCafferty et al., 1990) is linked to rat CK, was 
assembled by exchanging the SacI-XhoI P-globin insert of LK-PG (Yelamos et al., 
1995) for an analogous PCR-generated SacI-XhoI fragment containing Dl.3 VK. 
The H chain vectors derive from pSV-Vµl (Neuberger, 1983) (Fig. 5.lA) but with 
the VNP VH segment replaced by a PCR-generated PstI-BstEII Dl.3 VH segment 
(Fig. 3.lA). For the chimeric µ chains, the transmembrane and cytoplasmic 
domains of µ were replaced (using ApaI sites within Cµ4 and gpt selectable 
marker gene of the vector) by fusions of Cµ4 to the cytoplasmic domains of lg-a 
alone (IgM/ a) (Aluvihare et al., 1997) or Ig-P (IgM/P) or mutant Ig-P with the 
ITAM tyrosines substituted by leucine (IgM/pY->L) (Patel and Neuberger, 1993) 
via a hydrophobic transmembrane region (derived from mouse H2-Kh) which 
facilitates surface transport without association of the Ig-a/Ig-P heterodimer 
(Williams et al., 1993; Patel and Neuberger, 1993). 
The VNP Cµ[Ei,E3'JK transgene (provided by G. Williams) (Fig. 5.lA) also derives 
from plasmid pSV-Vµl (Neuberger, 1983) in which the region of DNA located 
between the most 5' and 3' XbaI sites in the JH-Cµ intron was replaced by a 2.1 kb 
section of the mouse JK-CK intron spanning the K intron enhancer /matrix 
attachment region (Ei/MAR) obtained by PCR using oligonucleotides MSN152 
and MSN153. The XbaI-SacI 802 bp fragment containing the K 3' enhancer (E3') 
was then introduced into the unique Xhol site located just 3' of the CµM exons of 
pSV-Vµl. 
Construction of the L K, LK[Ei/MAR] and LK[E3 '] (Fig. 6.1) have been described 
previously (Betz et al., 1994). 
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The f3G[E3'] transgene (provided by G. Williams) (Fig. 6.5A) was assembled by 
inserting a 1 kb XbaI-SacI fragment including the mouse K E3' into a Bluescript 
derivative in which a human P-globin gene had been inserted between the Kpnl 
and XbaI sites. The KpnI-XbaI P-globin fragment w as generated by PCR from 
human genomic DNA using oligonucleotides priming 105 nucleotides 5' of the 
transcription start site (introducing a 5' Kpnl site) and 340 nucleotides 3' of the 
polyadenlyation signal (introducing a 3' Xbal site). The amplified P-globin gene 
(which extends from 5' of the promoter to 3' of the polyadenylation site) was 
assembled from two subfragments; the strategy involved a Spel site in the second 
p-globin intron, 460 nucleotides downstream of the splice donor site. 
2.1.2 Cell lines 
Cell lines were usually cultured in DMEM/10% FCS/50 µM 2-ME and incubated 
at 37°C in 10% C02. 
The A20 transfectants expressing anti-HEL receptors were established after 
plasmids encoding the anti-BEL-specific B chain constructs were linearised with 
Clal and introduced by electroporation into a transfectant of the mouse A20 B cell 
lymphoma expressing the anti-BEL-specific K L chain (provided by V. 
Aluvihare) . After plating out to the density required to isolate single clones, 
stable transfectants were selected in DMEM/10% FCS/50 µM 2-ME containing 1 
mg/ml G418 sulphate and 2 mg/ml mycophenolic acid, and screened by 
immunofluorescent microscopy for the expression of IgM and rat K , 
discriminating the transfected lg from the endogenous IgG2a and mouse K 
expressed by A20. 
The lES.111 helper T cen hybridoma (provided by L. Adorini) recognises BEL 
peptide (amino acids 108-116) in the context of MBC class II I-Ed molecules and is 
induced to secrete IL-2 (Adorini et al. , 1993) . 
2.1.3 Transgenic mice 
Transgenic m ice were established by microinj ection of vector-free DNA 
fragments into the nuclei of (C57BL/6 x CBA /Ca) Fl zygotes (performed by S. 
Davies) and founder animals were bred with Fls, C57BL/6 or crossed with µM T 
B cell-deficient mice (Kitamura et al., 1991) (provided by K. Rajewsky). 
For the anti-B EL-specific receptors, an EcoRI fragment containing the L chain 
transcription unit was coinjected together with either a ClaI-XhoI (wild type IgM) 
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or ClaI-KpnI (chimeric IgM) fragment for the H chain (Fig. 3.lA). For all four 
constructs, multiple founders were identified that carried a H or L chain 
transgene. However, only one founder that had cointegrated both H and L 
transgenes was identified for each chimeric receptor construct; Southern analysis 
revealed that they were present in ten to twenty copies (S. Davies, unpublished 
observations). In the case of wild type BEL-specific IgM, two founders (lines A 
and B) that had cointegrated the H and L transcription units were studied, 
although only line B was bred into a µMT background. Litters were screened by 
PCR for presence of the H chain transgene and for endogenous background 
alleles; the K transgene bearing a rat CK region was detected by ELISA. The 
presence of the IgM transgene in line B was detected using 5' oligonucleotide 
PCRD13 which primed within the Dl.3 Vtt region. The IgM B transgene could 
not, however, be detected using 5' oligonucleotide MSN146 which primed 
upstream of the TATA box, suggesting that integration may have resulted in the 
truncation of the 5' end of the IgM transgene bearing the promoter. 
Although other founders expressing the VNP Cµ[Ei,E3'}1C transgene had been 
generated, experiments were performed only on a line that had integrated a high 
number of copies (S. Davies, unpublished observations). Mice were screened by 
PCR. 
Two founder lines each of the previously described LK, LK[Ei/MAR] and LK[E3'] 
mice (Betz et al., 1994) were analysed; the number of transgene copies is denoted 
by. superscript and the mice were screened by ELISA. However, the LK[E3']5 line 
used in Betz et al. (1994) was lost and LK[E3']6 was used instead, revealing 
conflicting results. Confusion resulting from the difference in notation of the 
founder lines between Meyer et al. (1996), Betz et al. (1994), and the laboratory 
database may be clarified below. 
Notation in Meyer et al. 
and in this study 
LK[Ei/MAR]4 
LK[Ei/MARf 
LK[E3']2 
(LK[E3']5) 
LK[E3']6 
Notation in Betz et al. 
and Betz, PhD thesis 
LK[Ei/MAR] line B 
LK[Ei/MAR] line A 
LK[E3'] line A 
LK[E3'] line B 
Notation in Neuberger 
group database 
DELA 
DEL C(I) 
EXOA 
EXOB 
EXOC 
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For the f3G[E3') transgene, three founder lines were established, and although 
only line A, bearing 10-20 copies was analysed in this study, line B (line C on the 
lab database) bearing 5-10 copies was also used in Meyer et al. (1996). Litters were 
screened by PCR. 
2.1.4 Oligonucleotides for PCR 
For replacement of Eµ by Ei/MAR in VNP Cµ[Ei,E3']K transgene: 
MSN152 GGACTAGTGATAGGAACAGAGCCACT 
MSN153 GCTCTAGACAGAGATTCAGACCAGTTTA 
For screening for anti-HEL Dl.3 V region (0.3 kb): 
PCRD13 CATCACATGCACCGTCTCAGG 
MSN146 CGCGGATCCTTTTAAGGACTCACCTGAGG 
For screening for the presence of a µMT allele (detects within neo, 192 bp): 
TOKN30 CTTCTGAGGGGATCGGCA 
0MN63 CGGCTCGAGGTTCAGAACAGGGTGACGGTGGTGCTGTAGAA 
For screening to discriminate µMT alleles (1.3 kb) from wild type (0.2 kb) 
MSN251 AGGGCACCCCACCCTTATGC 
0MN63 CGGCTCGAGGTTCAGAACAGGGTGACGGTGGTGCTGTAGAA 
For screening to discriminate IgHa (209 bp) from IgHb (231 bp) (detects "(2.a intron): 
MSN235 ATGATCCTCCTAGGATAGATGTCC 
MSN236 GGAGTGGAGCTCTGGTCTAG 
For screening for transgenic Vtt (VNP or Dl.3 [except IgMB]) (0.6 kb): 
MSN145 CCGGGGAATTCTATGTATCCTGCTCATGAAT 
MSN146 CGCGGATCCTTTTAAGGACTCACCTGAGG 
For screening for PG[E3'] transgene (0.7 kb): 
MSN212 CGCGAATTCTATTGCTTACATTTGCTTCTG 
MSN213 CGCGGATCCCATTCTAAACTGTACCCTGT 
For RT-PCR of P-globin transcripts (328 bp product): 
CCTGAGGAGAAGTCTGCC 
AGCACACAGACCAGCACG 
For RT-PCR of HPRT transcripts (461 bp product): 
TGCCGACCCGCAGTCCCAGCGTCG 
GCTGTACTGCTTAACCAGGGAAAG 
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2.1.5 Immunoreagents (listed according to manufacturer) 
Amersham International 
streptavidin-FITC 
Becton Dickinson 
mouse anti-BrdU-FITC (clone: B44) 
GIBCO BRL Life Technologies 
rat anti-mouse B220(CD45R)-PE (clone: RA3-6B2) 
streptavidin-RED670 
Jackson ImmunoResearch Laboratories 
goat anti-mouse IgM F(ab')z (115-006-020) 
goat anti-mouse IgG F(ab')z (115-006-071) 
goat anti-human IgG-FITC (109-095-008) 
streptavidin-PE 
Nordic 
sheep anti-mouse IgD-FITC 
PharMingen 
mouse anti-mouse IgMa-biotin (clone: DS-1) 
rat anti-mouse CD4-PE (clone: RM4-5) 
rat anti-mouse CD8a-FITC (clone: 53-6.7) 
rat anti-mouse CD2l/35(CR2/1) (clone: 7G6) 
rat anti-mouse-CD23-PE (clone: B3B4) 
rat anti-mouse HSA(CD24)-biotin (clone: Ml/69) 
rat anti-mouse CD25-FITC (clone: 7D4) 
rat anti-mouse CD43-biotin ( clone: S7) 
rat anti-mouse CD44-PE (clone: 1M7) 
rat anti-mouse B220(CD45R)-FITC ( clone: RA3-6B2) 
rat anti-mouse B220(CD45R)-PE (clone: RA3-6B2) 
hamster anti-mouse CD69-FITC (clone: Hl.2F3) 
rat anti-mouse Thyl.2(CD90.2)-biotin (clone: 53-2.1) 
Sigma 
mouse anti-mouse Thyl.2(CD90.2)-FITC (clone: TS) 
Southern Biotechnology Associates 
goat anti-mouse IgM (1020-01) 
goat anti-mouse IgM-FITC (1020-02) 
goat anti-mouse IgM-biotin (1020-08) 
rat anti-mouse IgD...,PE (clone: ?) 
goat anti-mouse IgG1-FITC (1070-02) 
goat anti-rat Ig-FITC (3010-02) 
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Non-commercial 
mouse anti-·mouse IgMb-FITC (clone: MB86; Nishikawa et al., 1986) (provided by 
M. Neuberger) 
rat anti-mouse K-biotin (clone: 187.1; Yelton et al., 1981) (provided by R. Pannell) 
mouse anti-rat K-biotin (clone: RG7.1; Springer et al., 1982) (provided by R. 
Pannell) 
mouse anti-rat K (clone: MRC OX12) (provided by R. Pannell) 
mouse anti-rat K-biotin ( clone: MRC OX12) (provided by R. Pannell) 
mouse anti-mouse BP-1-biotin (clone: BP-1; Cooper et al., 1986)) (protein 
provided by G. Williams) 
mouse anti-HEL (clone: HyHELlO; Smith Gill et al., 1984) (protein gift from S. 
Smith-Gill) 
mouse anti-Dl.3 idiotype-FITC (clone: ES.2; Fields et al., 1995) (cells gift from R. 
Poljak) 
mouse anti-Dl.3 idiotype-biotin (clone: E5.2) 
mouse CTLA4-human IgG1 fusion protein (Lane et al., 1993) (cells gift from P. 
Lane) 
2.1.6 Miscellaneous chemical and reagents 
Standard chemical and reagents were obtained from BDH, Fischer Scientific, or 
Sigma, unless otherwise indicated. 
Agarose (BioGene Limited) 
Biotin-16-dUTP (Boehringer Mannheim) 
Calf intestinal phosphatase (CIP) (Boehringer Mannheim) 
Concanavalin A (Con A) (Sigma C-5275) 
Fluorescein isothiocyanate (FITC) isomer I (Sigma F5720) 
Foetal calf serum (PCS) (Hyclone Laboratories Inc.) 
Gelase enzyme (Epicentre Technologies) 
Gentamicin (GIBCO BRL) 
G418 sulphate, Geneticin (GIBCO BRL) 
Horse radish peroxidase (HRP), avidin conjugate (Dako) 
Interleukin-2 (IL-2), human (Boehringer Mannheim. 1204 700) 
Interleukin-4 (IL-4), recombinant mouse (Genzyme) 
Lipopolysaccharide (LPS) from E. coli Olll:B4 (Sigma L-4391) 
Mycophenolic acid (GIBCO BRL) 
Phenol, Tris-equilibrated (United States Biochemical) 
Protein A-sepharose (Pharmacia) 
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Protein G-sepharose, pre-packed 1 ml HiTrap columns (Pharmacia) 
Proteinase K (Boehringer Mannheim) 
Restriction endonucleases (New England Biolabs) 
Sephadex (;-25 M, pre-packed PDlO columns (Pharmacia) 
Sucrose (Sigma S-1888) (added to BrdU water) 
Sulfo-NHS-biotin (Pierce) 
Taq polymerase (Promega) 
Terminal deoxynucleotidyl transferase (TdT) (Promega) 
[3H]Thymidine (Amerham) 
T4 DNA ligase (New England Biolabs) 
2.1.7 Buffers and solutions 
Restriction enzyme buffer: 0.1 volume lOX TMN 
1 mM DTT 
lOX TBE: 0.89 M Tris HCl 
0.89 M boric acid 
1 mM spermidine 
25 mM EDTA pH 8.3 
Agarase buffer: lOmM bis Tris-HCl pH 6.5 
1 mM EDTA 
100 mM NaCl 
TB buffer pH 7.5: 50 mM Tris-HCl 
100 mM EDTA pH 8.0 
100 mM NaCl 
1% SDS 
2 X TY medium: · 1.6% tryptone 
1 % yeast extract 
0.5% NaCl pH 7.4 
Phosphate-buffered saline (PBS): for 1 litre: 7.25 g NaCl 
(1 ml lOX TMN: 
150 µl lM Tris pH 7.4 
150 µl MgCb 
750 µl NaCl) 
3.96 g Na2HP04.2H20 
1.31 g NaH2P04.H20 
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RNA lysis buffer: 0.15 M NaCl (for 50 ml: 7.5 ml lM 
0.5 ml lM 
0.25 ml 
FACS buffer: PBS 
10 mM Tris pH 7.4 
0.5 % NP-40 
1 mMMgCb 50 µl lM) 
in dpc H20 (prepared according to (Sambrook et al., 1989)) 
1% FCS 
0.05% azide 
ABTS-peroxide substrate: dissolve 10 mg tablet in: 7.7 ml O.lM trisodium citrate 
9 ml O.lM ctric acid 
add 3.5 µl H202 just before use 
Red blood cell (RBC) lysis buffer: 1 mMNH4HC03 
114 mM NH4Cl 
(for 1 litre: 79 mg) 
(for 1 litre: 6 g) 
1 % paraformaldehyde: for 10 ml: 0.1 g paraformaldehyde 
1.5 ml H20 
DN ase I reaction mix: 
TdT reaction buffer: 
1 drop lM NaOH 
warm tube under hot tap to dissolve 
then 1 ml lOX PBS 
6.9 ml H20 
check pH 6.8-7.0 
150 mM NaCl 
5mM MgC12 
10 µM HCl 
300 µg/ml DNase I (about 500 Kunitz U/ml) 
0.5 M cacodylic acid, sodium salt, pH 6.8 
1 mMCoCb 
0.5 mM DTT 
0.5 ml/ml BSA 
0.15 NaCl 
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2.2 Molecular techniques 
2.2.1 Plasmid construction 
To prepare DNA fragments for cloning, 4-8 µl of plasmid DNA (from mini prep) 
was digested at 37°C for at least 1 h in a total volume of 40 µl containing 2 µl of 
each restriction enzyme and 4 µl of the 10X commercial enzyme buffer, and the 
enzymes were often heat inactivated by incubation for 20 min at 65°C. 
Restriction fragments containing the plasmid vector were 5' dephosphorylated by 
adding 2 µl of calf intestinal phosphatase (CIP) and 5 µl lOX CIP buffer in a total 
volume of 50 µl, incubating for 30 min at 37°C. 
The DNA fragments were separated by agarose gel electrophoresis, depending on 
their size (often 0.7% agarose in lX TBE buffer) and purified by running the band 
into 3MM filter paper backed with dialysis membrane slotted into the lane of the 
gel. The DNA was eluted by microcentrifugation using lX TBE buffer to wash. 
The DNA was ethanol-precipitated by adding 0.1 volumes of 3 M sodium acetate 
pH 5.5, followed by 3 volumes of 95% ethanol and placing on dry ice until frozen. 
After spinning in a microfuge for 5 min, the pellet was aspirated and 
resuspended in an appropriate volume of H20 (often 25 µl). 
DNA ligations were carried out in a total volume of 10 µl containing 1 µl of 
vector fragment to about 3 µl of each insert fragment, 1 µl of T4 DNA ligase and 1 
µl lOX ligase buffer enzyme. Reactions (including controls for vector and inserts 
alone) were left at room temperature (or at l6°C) overnight. 
Competent TGl E. coli for transfection were prepared by the method of 
(Hanahan, 1983) and were prepared freshly prior to use. 
Each ligation reaction was transfected into 200 µl TGl, by leaving on ice for 10-20 
min before heat shocking at 42°C for 2 min and immediately placing back on ice. 
After addition of 400 µl of 2 X TY broth, the cells are allowed to recover for 1 hat 
37°C with shaking before plating out on three 2 X TY + ampicillin (100 µg/ml) 
agar plates and incubating at 37°C overnight inverted. 
If colony numbers suggested the ligations had worked, about ten colonies were · 
picked and minipreps of plasmid DNA were prepared from 5 ml overnight 
cultures of 2 X TY+ ampicillin broth by alkaline lysis using the Promega Wizard 
Miniprep Kit. Larger quantities of plasmid from 100-200 ml cultures were 
prepared using the Promega Wizard Maxiprep Kit and by adding 20 µl DNA to 
380 µl H20, an estimate of mg/ml was equivalent to optical density at 260 nm. 
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For analytical digestion of plasmid DNA, 1 µl of miniprep DNA using 1 µl of 
each restriction enzyme was digested in a total volume of 15 µl restriction 
enzyme buffer for 1 h at 37°C. The fragment bands were resolved by agarose gel 
electrophoresis. 
2.2.2 Preparation of DNA fragments for microinjection 
Choosing restriction sites to remove as much of the vector as possible, the 
plasmids were digested as described for cloning. The fragments were resolved by 
electrophoresis of a 0.7% low melting point agarose gel and the bands were 
removed as gel slices which were equilibrated in 5 ml lX agarase buffer 
overnight at 4°C. The slices were weighed (usually about 200 mg), melted at 70°C 
for 10 min, and pre-incubated at 40°C for 5 min before adding 1 µl of gelase 
enzyme per 100 mg and incubating for 2 h. After digestion, the DNA solution 
was spun in a microfuge for 20 min. The supernatant containing the DNA was 
suitable for microinjection without additional purification and the concentration 
(often used undiluted at about 2-5 ng/µl) was estimated by comparing aliquots 
with known quantities of phage A HindIII digest markers on agarose gels. 
2.2.3 PCR screening of transgenic mice 
Genomic mouse DNA was prepared by digesting 1-2 cm tail biopsies in 750 µl of 
TB buffer supplemented with 450 µg of proteinase K (22.5 µl of 20 mg/ml in H20) 
at 55°C overnight, with occasional mixing. The DNA was purified by successive 
extractions with 750 µl Tris-equilibra ted phenol, 750 µl 
phenol/ chloroform/isoamyl alcohol (25:24:1) and 750 µl chloroform, 
microfuging for 5 min to separate the aqueous and organic phases. The DNA was 
precipitated by adding to 1.3 ml 95% ethanol, drawn out using a disposable 
inoculating loop, and washed in 50 µl of 70% ethanol before the pellet was left to 
dry out. 100 µl H20 was added to the pellet and the DNA was often left to dissolve 
at 4°C overnight. 
PCR reactions were carried out in a total volume of 50 µl containing 1 µl 
genomic DNA from tail, 5 µl lOX Taq buffer, 2 µl 10 mM dNTP, 2.5 µl of each 
oligo diluted to 10 pmol/µl and ~lµl Taq polymerase. One drop of mineral oil 
was added to each tube and the reactions were incubated according to a 
" touchdown" programme (succcessive steps have decreased annealing 
temperatures) with a 5 min polymerase extension time. PCR products were 
analysed by 2.0% agarose gel electrophoresis. 
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2.2.4 Cytoplasmic RNA preparation 
Lymphocytes were pelleted (1,100 rpm, 4°C, 5 min) and washed in cold PBS, 
removing all supernatant. The cells were resuspended in 0.4 ml of cold RNA 
lysis buffer, and were microfuged at 4°C for 5 min. The supernatant lysate was 
transferred into 200 µl phenol + 50 µl 10% SDS, vortexed hard and microfuged 
again. The supernatant was re-extracted with 200 µl phenol, then 40 µl 3M 
sodium acetate pH 5.5 was added with 1 ml RNase-free 95% ethanol to precipitate 
at -20°C overnight. RNA preps were often stored at -20°C or -70°C until further 
analysis. 
2.2.5 RT-PCR analysis (performed by Kerstin Meyer) 
0.1-1.0 µg RNA was reverse transcribed with MMLV reverse transcriptase using 
100 ng (dT)is primer for 1 hat 37°C. Aliquots of the reaction were then used in 
PCR annealed at 60°C for 1 min, extended at 72°C for 1 min and denatured at 
92°C for 1 min for a total of 30 cycles. 
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2.3 Antibody-mediated techniques 
2.3.1 Preparation of non-commercial immunoreagents 
Cells expressing the monoclonal antibody or transfected fusion protein were 
grown to a density of about 5xl05 cells/ml in DMEM/5-10% FCS and were 
transferred (70-100 ml per tube of dialysis membrane) to an OBC ("oscillating 
bubble chamber" - designed by Milstein and Pannell). The OBC was filled with 
about 1.5 L of serumless DMEM which was changed every 2-3 days for 14 days. 
The culture supernatants were harvested for purification. 
The desired protein was purifed by affinity chromatography. Where possible, a 
protein A-sepharose column were used to recover protein of interest: a 1 ml 
column was equilibrated with 100 mM Tris pH 8.0, the antibody supernant 
(equilibrated by adding 0.1 volume of lM Tris pH 8.0) was loaded, washed with 
100 mM Tris, then lOmM Tris, and eluted with 100 mM glycine pH 3.0 in 500 µl 
fraction, neutralising with 50 µl of lM Tris pH 8.0. However, 1 ml pre-packed Hi-
Trap Protein G columns were used for purifying mouse IgG1 monoclonal 
antibodies (FCS did not contribute much to recovered protein) equilibrating 20 
mM sodium phosphate buffer pH 7.0, eluting with 100 mM glycine pH 2.7 and 
neutralising with 0.1 volume 1 M Tris pH 9.0. 
Protein concentration of the recovered material was estimated by optical density 
at 280 nm (where OD 1.0 is approximately equivalent to about 1.4 mg IgG) and 
purity was checked by SDS-PAGE. 
Biotinylation was performed by dialysing the antibody prep (about 1 mg/ml) 
against 50 mM sodium bicarbonate buffer pH 8.5 at 4°C and after addition of the 
sulfo-NHS-biotin, the reaction was incubated with inversion at room 
temperature of 2-3 h, before dialysis against PBS at 4°C. 
For FITC conjugation, the antibody prep (about 1 mg/ml) was dialysed against 
FITC conjugation buffer pH 9.3 at 4°C. FITC (isomer I, Sigma) was dissolved in 
buffer at 1 mg/ml and 0.3 volumes was added to the antibody solution and 
incubated in the dark with inversion at room temperature for 3 h. The free FITC · 
molecules were removed by gel filtration using prepacked PD10 columns 
containing Sephadex G-25 M, equilibrating and eluting with PBS. 
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2.3.2 Immunofluorescent microscopy 
15-well multi-test microscope slides were coated with one drop per well of 1 
mg/ml poly-L-lysine, left at room temperature for 10-15 min, rinsed in distilled 
water and left to dry vertically. 
A cell suspension in PBS was spotted onto the wells and the slides were placed 
into a humid box for 20-60 min at 37°C. .The cells were fixed by placing the slides 
in methanol at -20°C for only 20 min and left to dry at -20°C for 10 min (or stored 
indefinitely). 
To stain, the slides were dipped three times into PBS and not allowed to dry out 
during subsequent steps. Using filter paper, the wells were wiped around and 
after the slide was placed in a humid box, 4 µl of diluted FITC-conjugated 
immunoreagent in PBS/1 % FCS/0.05% azide was pipetted per well and left for 20 
min at room temperature. Rinsing in PBS and staining was repeated for each 
layer of reagent. Finally, the slide was dipped a three times in PBS and wiped, 
before drops of glycerol/PBS/0.05% azide and the coverslip were applied, sealed 
with nail varnish for analysis under the fluorescence microscope. 
2.3.3 Flow cytometry 
For surface staining, 0.5-2xl06 cells per 6 ml round-bottomed tube (Falcon 2058) 
were pelleted (1,lOOrpm, 4°C, 5 min), the medium aspirated, resuspended in 60 µl 
diluted immunoreagent(s) in PBS/1 % FCS/0.05% azide (FACS buffer) and left for 
at least 20 min on ice. After filling the tube with cold FACS buffer to wash, the 
procedure was repeated for each layer of reagent (e.g. subsequent staining with 
streptavidin [SA]-conjugates or secondary antisera). Immediately before filling 
the tube for the final wash, propidium iodide (PI; to indicate viability) was added 
if desired. 
For cytoplasmic staining, cells were washed in cold PBS, pelleted, the medium 
aspirated and fixed in 0.5 ml cold PBS/3.7% formaldehyde for 10 min on ice. 0.5 
ml PBS/0.1 % NP-40 was added to permeabilise, the tube inverted to mix, and left 
on ice for 5 min-. After the cells were pelleted and the medium aspirated, they 
were resuspended in F ACS buffer for staining as above. 
For flow cytometric analysis, the cells were resuspended m 0.5-1.0 ml FACS 
buffer. Becton Dickinson FACScan or FACSCalibur instruments with LYSYS II or 
CELLQuest software were used. In addition to experimental samples, unstained 
and single fluorochrome (FITC, PE, RED670, PI) controls for each reagent were for 
included for setting gains and compensation. Viable cells were gated by forward 
and side scatter and for PI exclusion where possible. 
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To enrich subpopulations, cells were surface stained as above under sterile 
conditions, and the cells were sorted on Becton Dickinson FACStar Plus 
(operated by D. Gilmore and A. Riddell). They were collected for immediate 
cytoplasmic RNA isolation or cultured in DMEM/10% FCS/50 µM 2-Me/50 I 1 
µg/ ml gentamicin. 
2.3.4 ELISA screening of transgenic mice 
96-well flat-bottomed plates were coated with 1 µ1/ml mouse anti-rat K (MRC 
OX12) or 5 µg/ml goat anti-mouse IgM in PBS (50 µl per well) overnight at 4°C or 
for 2 hat 37°C. Plates were blocked by addition of 150 µ1/well of PBS/ 5% FCS/ 
0.05% azide for 30 min at 37° (and could be stored at 4°C for months). 
After washing three times with PBS, 50 µl diluted mouse serum was added to 
each well and incubated for 1.5 hat 37°C. Serum was diluted in PBS/5% FCS and 
for each mouse, usually two dilutions were analysed in duplicate (for rat K in the 
range 1/10 - 1/500; forµ, 1/400 - 1/2,000). After careful washing with PBS three 
times, mouse serum antibodies were detected using 50 µl per well of 1 µg/ml 
mouse anti-rat K-biotin (MRC OX12) or goat anti-mouse IgM-biotin in PBS/5% 
FCS, incubating for 45 min at 37°C. 50 µ1/well avidin-conjugated horse radish 
peroxidase (1:2,000 in PBS/ 5% FCS) was added for 15 min at 37°C after washing 
with PBS three times. The final washes consisted of three with PBS, followed by 
three with distilled water. 50 µ1/well of the ABTS (2,2'-azino-bis(3-ethylbenz-
thiazoline-6-sulphonic acid)-peroxide substrate was added and left to develop for 
a few minutes before the reaction was stopped with 50µ1/well of O.lM citric acid/ 
0.05% axide. If desired the OD at 405 nm was read on a Molecular Devices plate 
reader using Softmax software. 
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2.4 Cellular assays 
2.4.1 Preparation of lymphoid tissues from mice 
Single cell suspensions were prepared from mouse lymphoid tissues. Spleen and 
thymus were dissected, bone marrow was washed from within the femurs, and 
Peyer's patches were pinched off the gut, Tissues were disrupted by gentle teasing 
with forceps and by pushing gently through a cell strainer into PBS or culture 
medium. 
If desired, erythrocytes were depleted by resuspending the cells (after pelleting at 
1,100 rpm at 4°C for 5 min) in 1 ml PBS or medium and adding 4 ml RBC lysis 
buffer. After gentle inversion to mix, the cells were left for 10 min on ice or room 
temperature before washing with PBS or medium. 
2.4.2 Antigen presentation 
In a flat-bottomed 96-well plate, triplicate wells each containing 105 A20 B cells 
and 105 1E5.lll T cell hybridomas were cultured in 200 µl complete medium 
(DMEM/10% FCS/50 µM 2-ME) supplemented with 10-fold serial dilutions of 
antigen hen egg lysozyme (HEL) or turkey egg lysozyme (TEL). After incubation 
for 24 hat 37°C/10% C02, the plates were spun down (1,100 rpm, 4°C, 5 min) and 
the supernatants (50 µl per well) were transferred to a fresh plate and to each well 
was added 2.5xl05 HT2 (IL-2 dependent) T cells in 50 µl complete medium. After 
20-24 h at 37°C/10% C02, each well was pulsed with 10 µl of 5 mg/ml MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) in PBS for 4-6 h, 
then the crystals were dissolved by vigorous pipetting after the addition of 110 µl 
of 5% formic acid in isopropanol. The optical density at end point 570-650 nm 
was measured on Molecular Devices plate reader using Softmax software and 
units of IL-2 produced were calibrated against recombinant IL-2 standards. 
2.4.3 B cell activation 
The production of IL-2 by A20 cells was measured by adapting the antigen 
presentation assay without T cells. lQ5 B cells were incubated with 10-fold serial 
dilutions of HEL or TEL antigen or F(ab')2 goat anti-mouse IgM or anti-IgG 
antiserum and subsequent stages proceed as for the antigen presentation assay. 
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To monitor proliferative responses, splenocytes that had been depleted of 
erythrocytes were cultured in triplicate aliquots (2xl05 in 200 µl) in RPMI/10% 
FCS/10 µM 2-ME in the presence of 1 µg/ml LPS or 10 µg/ml F(ab')2 goat anti-
mouse IgM + IL-4 (100 U per 200 µl). After 48 h, the cells were pulsed with 0.5 µCi 
[3H]thymidine for 15 h before scintillation counting. 
To monitor CTLA4 binding, spleen cells depleted of erythrocytes were cultured 
(106 cells/ml) in medium in the presence or absence of 50 µg/ml LPS, 10 µg/ml 
F(ab'h goat anti-mouse IgM, 1.0 µg / ml HEL or 10 µg/ml monoclonal E5.2 anti-
Dl.3 idiotype antibody for 24 h prior to staining with mCTLA4-Hyl fusion 
protein, goat anti-human IgG-FITC and propidium iodide. 
K L chain expression in LPS-activated B cells was analysed after incubation of 
splenic B cells in medium supplemented with 50 µg/ml LPS for 48 h. Cells were 
harvested, fixed and permeabilised before cytoplasmic staining with mouse anti-
rat K-biotin or rat anti-mouse K-biotin followed by SA-PE. 
2.4.4 T cell activation 
Splenocytes depleted of erythrocytes were cultured (5x105 /ml) in the presence or 
absence of 2 µg/ml concanavalin A for 24 h before staining for the surface 
expression of Thy 1.2 (CD90.2), CD4, CD44, CD25, CD69 and IgM and analysis by 
flow cytometry. 
2.4.5 BrdU uptake 
Mice were given two intraperitoneal injections 4 h apart of 1 mg BrdU (5-bromo-
2-deoxyuridine) in PBS and the drinking water was supplemented with 1 mg/ml 
BrdU and 1 % sucrose for 72 h before analysis of bone marrow and spleen. Cells 
were surface stained with rat anti-B220-PE and either goat anti-IgM-biotin or anti-
Dl.3 idiotype-biotin (both revealed by SA-RED670) prior to fixation. The cells 
were washed (pelleted at 1,1000 rpm, 4°C, 5 min) and resuspended in 200 µl PBS, 
and fixed by injecting into 1 ml ice-cold 70% ethanol to prevent cell clumping. 
After 30 min on ice, the fixed cells were pelleted at 1,500 rpm (and at subsequent 
spins) and resuspended in 500 µl PBS to which was added 500 µl of 2% 
paraformaldehyde/ 0.01 % Tween 20 in PBS, and left overnight at 4°C. After 
washing once in PBS, the cells were resuspended in 1 ml of DNase I reaction mix 
for 10 min at room temperature. The cells were washed once with FACS buffer, 
stained with anti-BrdU-FITC for 20 min at room temperature, then washed and 
resuspended for analysis . 
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2.4.6 TUNEL analysis 
Splenocytes that had been depleted of erythrocytes were cultured (106 per 1 ml) in 
the presence and absence of 10 µg/ml F(ab')2 goat anti-mouse IgM for 0, 4, 8 or 24 
h . Cells were harvested and surface stained with rat anti-B220-PE before fixation 
for TUNEL (terminal dexoynucleotidyl transferase [TdT]-mediated dUTP-biotin 
nick end labelling). After washing in PBS (pelleted at 1,100 rpm, 4°C, 5 min) the 
cells were resuspended in 250 µl PBS and fixed by adding 750 µl of ice-cold 95% 
ethanol dropwise over a period of 5-10 sec while gently vortexing to prevent cell 
clumping. After incubation for 20 min on ice, the cells were washed on ice and 
pelleted at 1,500 rpm (fixation causes shrinkage). The cells were fixed with 1 ml of 
1 % paraformaldehyde in PBS by adding dropwise and gently vortexing, and 
incubated at room temperature for 30 min. Cells were washed in PBS (when they 
could be stored for a few days at 4°C in the dark), followed by TdT reaction buffer 
prior to resuspension of the cells in 50 µl TdT reaction buffer containing SU TdT 
and 10 µM biotin-dUTP. The TdT reaction was incubated for 45 min at 37°C. 
After washing the cells were stained with SA-FITC for analysis by flow cytometry. 
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Chapter 3: Results 
Expression and function of chimeric B cell antigen receptors in cell line 
transfectants 
The Ig-a/lg-P heterodimer plays a critical role in B cell antigen receptor (BCR) 
function, not only for surface transport of membrane IgM (Williams et al., 1990), 
but also because the ITAMs (immunoreceptor tyrosine-based activation motifs) 
(Reth, 1989) present in the cytoplasmic domains of both polypeptides are 
essential for the initiation of transmembrane signalling (Flaswinkel and Reth, 
1994; Papavasiliou et al., 1995; Sanchez et al., 1993; Taddie et al., 1994; Williams et 
al., 1994). Aside from the ITAMs, lg-a and Ig-p differ significantly and are well 
conserved in evolution (Hermanson et al., 1988; Muller et al., 1992; Sakaguchi et 
al., 1988; Yu and Chang, 1992). Thus, it has been disputed whether lg-a and Ig-P 
mediate essentially similar activities or if they perform distinct roles. The 
abilities of the individual cytoplasmic domains have been determined in cell 
lines transfected with chimeric receptors bearing either the lg-a or Ig-P tail alone. 
Some groups found no differences in the signalling activities of either the lg-a or 
Ig-P chimeras compared to wild type BCR (Law et al., 1993; Taddie et al., 1994; 
Williams et al., 1994). Others, however, found that whilst the lg-a chimeras 
could signal, signalling by the Ig-P chimeras was impaired to variable extents, 
depending on the nature of the chimeric constructs and the assay conditions 
(Choquet et al., 1994; Kim et al., 1993; Sanchez et al., 1993). Furthermore, it has 
been suggested that the lg-a and Ig-p cytoplasmic domains bind different sets of 
downstream effectors (Cassard et al., 1996; Clark et al., 1992). 
The conflicting evidence regarding the relative roles of lg-a and Ig-P may be due 
to the use of cell lines. A cell line provides a convenient model system of a 
homogeneous population of cells that is relatively easy to maintain. However, 
different cell lines may express limiting amounts of signalling molecules and 
they are subject to the effects of long-term culture. Thus, they may not accurately 
reflect events in primary cells. 
An alternative approach to cell line transfectants is the introduction of · 
transgenes the germline of mice in order to generate a good source of primary B 
cells expressing antigen-specific receptors. Transgenic mice made it possible to 
extend the study of lg-a and Ig-P in BCR signalling to primary cells. In 
preparation for the transgenic experiments, it was first necessary to prepare and 
check the transgene constructs. This chapter describes the BCR transgenes and 
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their expression and function in cell line transfectants. Additional findings to 
result from these studies were that the cytoplasmic tails of lg-a or lg-~ could 
independently mediate antigen-induced signals in this cell line system, but that 
mutation of the lg-~ ITAM tyrosines abrogated signalling. 
3.1 Anti-HEL receptor transgene constructs contain genomic regulatory elements. 
In order to discriminate between the independent functions of lg-a and lg-~, a set 
of plasmids was constructed encoding BCRs of µ H chains and K L chains bearing 
the VH and V1 regions of the Dl.3 monoclonal antibody (Amit et al., 1985) that 
specifically binds the antigen hen egg lysozyme (HEL) (Fig. 3.1). 
The wild type µ construct derived from pSV-Vµl (Neuberger, 1983) (which 
includes the appropriate genomic elements of the VH promoter and lgH 
enhancer [Eµ] for efficient tissue-specific expression in mice), but with the VNP 
VH replaced by the Dl.3 VH (Fig. 3.lA). For the µ chimeras, Apal fragments 
extending from Cµ4 into the pSV2gpt plasmid vector were exchanged to encode 
for the extracellular µ domains fused via a hydrophobic transmembrane region 
to the cytoplasmic domains of lg-a alone (lgM/ a) (Aluvihare et al., 1997) or lg-~ 
(lgM/~) or mutant lg-~ with the ITAM tyrosines substituted by leucine (lgM/~Y-
>L) (Patel and Neuberger, 1993) (Fig. 3.lA and B). The transmembrane segment 
(which derives from the H2-Kh gene) confers surface transport without detectable 
association with the lg-a/lg-~ heterodimer (Patel and Neuberger, 1993; Williams 
et al., 1993). 
The K L chain construct (Aluvihare et al., 1997) bore a rat CK reg10n for 
discrimination from endogenous K in mice or in mouse B cell lines (Fig. 3.lA). It 
also contained the required regulatory elements of VK promoter, intron 
enhancer (Ei) and 3' enhancer (E3'). 
3.2 The transgenfo receptors are expressed on the surface of A20. 
A20 is a mouse B cell lymphoma that expresses endogenous BCRs composed of 
lgG2a and K. The set of µ H chain plasmids was transfected into an A20 
transfectant that already expressed the anti-HEL rat K L chain as a means for 
checking that the DNA constructs were functional and could be expressed 
properly. 
After initial screening by immunofluorescent microscopy, clones of each 
transfection were selected for analysis by flow cytometry (Fig. 3.2). All of the 
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transfected receptor constructs were detected by staining for IgM and rat K, 
indicating that the plasmids could indeed encode the H and L chains for 
functional expression as surface receptors on B cells. Although each transfectant 
clone varied in expression level and homogeneity, the positive populations were 
enriched by cell sorting if necessary. 
3.3 The anti-HEL V region mediates specific antigen presentation. 
Having shown that the transfected Hand L chain C regions were detectable with 
µ- and rat K-specific antisera, it remained to be shown that the Dl.3 V region was 
also expressed correctly and could bind antigen specifically. 
One of the functions of the BCR is to internalise and target antigen 
intracellularly for processing and presentation to specific T cells. Antigen 
presentation by B cell lines can be monitored by the levels of IL-2 secreted by the 
antigen-specific helper T cell hybridoma in a colorimetric assay. The antigen 
presentation assay provided a convenient system not only for verifying antigen 
binding, but also for assessing receptor function. Indeed, it has been shown that 
an IgM/ ~ chimeric receptor could mediate antigen presentation with similar 
efficiency to the wild type IgM receptor (Patel and Neuberger, 1993). 
For the BEL-specific antigen presentation assay, the A20 transfectants expressing 
the Dl.3 receptors were incubated with HEL, and the presentation of antigen was 
detected by the lES.111 T cell hybridoma which recognises HEL peptide amino 
acids 108-116 in the context of I-Ed (Adorini et al., 1993). The sequence of this 
peptide is identical in HEL and the related turkey egg lysoyme (TEL) (Canfield, 
1963; LaRue and Speck, 1970), thus HEL and TEL share the same epitope 
recognised by lES.111. However, the epitope recognised by Dl.3 is specific to HEL 
and not TEL (Harper et al., 1987). Therefore, the specific internalisation and 
presentation HEL via the Dl.3 receptors could be monitored using the uptake 
and presentation of TEL as a control for non-specific fluid phase-mediated 
internalisation. 
The receptor constructs all contained the Dl.3 V region since they shared the 
same L chain and the H chains had been derived by "tail swapping" of the same 
H chain plasmid clone bearing the Dl.3 VH. A representative JgM/~ transfectant 
(clone-14) was assessed for its ability to present HEL but not TEL, alongside a wild 
type IgM transfectant (AK1158-7) which has already been shown to mediate 
specific HEL presentation (Aluvihare et al., 1997). From the levels of IL-2 secreted 
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by the T cell hybridoma, it is clear that both lgM and lgM/ p receptors mediated 
the specific presentation of HEL (Fig. 3.3B). HEL presentation was evident from 
0.01 µg/ml, at 100-fold lower concentrations than that of the non-specific 
presentation of TEL which was detectable from 1.0 µg/ml (Fig. 3.3B). Thus the 
expression of the Dl.3 V region was intact and functional, also confirming that 
the lg-P cytoplasmic tail alone can mediate antigen presentation. 
Surprisingly, IL-2 was detected in the "no T" control containing B cells and 
antigen, but no T cells. Only the antigen-induced T cell hybridoma was expected 
to secrete IL-2. Since the "no T" cultures contained A20 transfectant cells 
incubated with 0.1 µg/ml HEL, the IL-2 production indicated that A20, as well as 
IES.111 could be induced to secrete IL-2. 
The A20 transfectants were made available to others in the group who have 
continued the analysis of antigen presentation by comparing the presenting 
activities of lgM/a versus lgM/P (Aluvihare et al., 1997). Both chimeric receptors 
mediated the efficient presentation of HEL, suggesting that the cytoplasmic 
domains of either lg-a or lg-P are sufficient to drive intracellular targetting of 
antigen for presentation and revealing no major differences in their contribution 
to this BCR function. 
3.4 HEL stimulates greater IL-2 production in A20 transfectants than anti-lg. 
Antibodies are routinely used to mimic antigen crosslinking of BCRs m 
biochemical signalling assays. For example, after ligation with anti-lgM, lgM/P 
chimeras have been shown to mediate downstream tyrosine phosphorylation 
within five minutes (Law et al., 1993; Williams et al. , 1994). The finding that A20 
can be stimulated to secrete IL-2 suggested that IL-2 production could be exploited 
as a signalling assay in response to anti-lg. Since cytokine secretion occurs further 
downstream than tyrosine phosphorylation events, it might provide a more 
sensitive readout -for signalling. 
When the lgM/P transfectant was incubated with ,increasing concentrations of 
anti-lgM, IL-2 secretion was induced from 1.0 µg/ml anti-lgM (Fig. 3.4A). Anti-
lgM did not induce untransfected A20 to signal, but IL-2 production was 
detectable when the endogenous BCRs were crosslinked by 100 µg/ml anti-IgG. 
These results confirmed that the cytoplasmic tail of lg-P alone is sufficient to 
mediate signalling in response to anti-lgM. However, the levels of IL-2 were 
rather low, making detection difficult and limiting the sensitivity range of the 
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assay. 
Recalling the signal clearly apparent in the antigen presentation assay (Fig. 3.3B), 
a greater response might be conferred using the natural antigen HEL, rather than 
anti-lg. Indeed, IgM/~ did produce higher levels of IL-2 in response to HEL 
compared to anti-IgM (Fig. 3.4B). IL-2 production in IgM/~ was triggered from 0.1 
µg/ml HEL, but untransfected A20 did not respond to HEL. Thus, the signalling 
ability of the lg-~ cytoplasmic tail was further demonstrated in mediating the 
response to the receptor's natural antigen. Furthermore, monitoring IL-2 
production in A20 transfectants seemed to be a promising signalling assay in 
terms of using antigen, rather than anti-lg, and sensitivity. 
The evidence that 0.1 µg/ml HEL induced the IgM/~ transfectant to secrete IL-2 
does not invalidate the earlier conclusions that IgM and IgM/~ can mediate 
specific antigen presentation since IL-2 production (by the T cell hybridoma) was 
clearly evident after incubation with 0.01 µg/ml HEL. 
3.5 BCR signalling in A20 may be induced by multivalent forms of HEL. 
It is curious that HEL should induce the BCR to signal, since HEL is a 
monovalent antigen and effective signal transduction requires receptor 
aggregation. One explanation might be that HEL exists in a higher valency form 
than a monomer. For example, HEL may form dimers on an opposite face from 
the Dl.3 epitope that facilitates crosslinking of the receptors. 
In order to test whether multimeric forms of HEL existed, a 1 mg/ml solution of 
HEL in PBS was analysed by HPLC (high-performance liquid chromatography) at 
4°C (Fig. 3.5) . Although the large majority of the protein was present in the 
monomer peak, two other peaks were detected and they may correspond to HEL 
dimers and trimers. Thus it may be possible that HEL aggregates crosslink the 
Dl.3 receptors and induce BCR signalling, even if present in such small 
quantities. 
3.6 HEL-induced signalling is specific over a range of concentrations. 
The IL-2 assay system was further characterised by determining the concentration 
range for which signalling in response to HEL was specific. The dose response of 
IgM/~ to HEL shows that IgM/~ secreted IL-2 when incubated with 0.1 to 100 
µg/rhl HEL (Fig. 3.6). Untransfected A20 was not induced by HEL and IgM/~ did 
not respond to TEL, indicating that the BEL-induced response was specific to the 
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presence of Dl.3 receptors as well as the recognition of HEL by Dl.3. Interestingly, 
higher concentrations of HEL seemed to inhibit the IL-2 signal. 
3.7 IgM/a and IgM/13 but not IgM/l3Y->L can signal in A20. 
The development of an antigen-dependent signalling assay facilitated the 
comparison of the different receptors by monitoring their abilities to induce IL-2 
secretion in response to HEL. 
The IgM/ 13 transfectant has already been shown to secrete IL-2 after incubation 
with HEL, therefore it was not surprising that the wild-type IgM receptor 
mediated signalling (Fig. 3.7 A). Additionally, IgM/ a was induced to produce IL-
2. Thus the IgM/ a and IgM/ 13 chimeras, as well as the wild type IgM receptor 
mediated responses to antigen, indicating that the individual cytoplasmic 
domains of lg-a or Ig-13 are sufficient for signalling in A20. The differences in the 
levels of IL-2 secreted by IgM, IgM/a and IgM/13 may simply reflect the expression 
levels of the A20 transfectants (Fig. 3.7B). 
In contrast to the response of IgM/13, the IgM/l3Y-L transfectant did not secrete IL-
2 (Fig. 3.7 A). Mutation of the tyrosine residues prevented signalling, revealing 
that the ITAM tyrosines are essential for the ability of the Ig-13 cytoplasmic 
domain to signal. 
3.8 Discussion 
Resulting from the original intention to examine the roles of lg-a and Ig-13 in 
transgenic mice, plasmids encoding wild type and chimeric BCRs were 
constructed to confer anti-HEL specificity and to include genomic regulatory 
elements for their appropriate expression in mice. In order to check the receptor 
constructs for expression and function, they were transfected into the A20 cell 
line. The results in this chapter have not only shown that they were correctly 
expressed and assembled as anti-HEL receptors on the cell surface, but that a 
transfected BCR could also mediate the functions of antigen presentation and 
antigen-induced transmembrane signalling. Thus, the constructs proved 
satisfactory for generating transgenic mice. 
In addition, the cell line experiments resulted in the development of an antigen-
induced signalling assay. The production of IL-2 was detected as a readout for the 
response of the anti,..HEL A20 transfectants to the natural antigen HEL, extending 
experiments that have used antibodies to crosslink and induce A20 to secrete IL-2 
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(Beaufils et al., 1993; Justement et al., 1989). 
It was intriguing that HEL induced BCR signalling since it was expected to 
behave as a monovalent antigen. HPLC analysis suggested that small quantities 
of HEL may be present in dimeric or trimer forms which could mediate 
crosslinking of the receptors. Indeed, it has been possible in ELISAs to capture 
HEL with the same anti-HEL mAb as used to subsequently detect HEL (G. 
Williams, unpublished observations). The observation that the same epitope of 
HEL can be recognised on two faces of the protein is consistent with the presence 
of the antigen as a dimer. Whilst it remains to be shown whether these results 
can be extrapolated to other assay conditions, the dimerisation of HEL offers an 
explanation that could be pursued. 
The basis of the possible dimerisation of HEL is unclear. If a distinct surface of 
HEL mediates association, then only BCRs that recognise epitopes on the outer 
faces of the dimer could be crosslinked. However, B cells expressing receptors 
bearing HyHELlO V regions also undergo BEL-induced activation (Cooke et al., 
1994), even though HyHELlO binds to an epitope on a different face of the 
antigen from Dl.3 (Davies et al., 1990). 
It could be argued that the crosslinking of anti-HEL receptors resulted from the 
aggregation of HEL with serum proteins over the 24 h-culture period in the IL-2 
assay. However, anti-HEL receptors have been shown to mediate increases in 
intracellular calcium levels within 1 min of the addition of HEL, and tyrosine 
phosphorylated substrates were detected after 5 min incubation with HEL in 
serum-free medium (Cooke et al., 1994). 
Other mechanisms to explain the triggering of the BCR by HEL may be that HEL 
mediates co-crosslinking of the BCR with other receptors, or that HEL does bind 
as a monovalent antigen, but effects a conformational change in the BCR 
resulting in transmembrane signalling. 
IL-2 production was stimulated over the range of 0.1 to 100 µg/ml HEL, but was · 
inhibited at higher concentrations. It is possible that the BCRs become saturated 
at high HEL concentrations and are ligated separately, preventing agregation and 
signalling. Alternatively, at high concentrations HEL may bind to other 
receptors, such as Fe receptors, that negatively regulate BCR signalling, or the 
presence of excess HEL may result in receptor downmodulation over the 24 h-
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assay period without generating detectable IL-2 levels. 
Anti-lg is standardly used for activation at 1-20 µg/ml, both in biochemical assays 
over a few minutes and physiological assays over days. In the IL-2 assays shown 
here, F(ab')2 fragments were used instead of whole lg to eliminate inhibitory 
effects resulting from Fe receptor coligation. It was thus surprising when anti-lg 
stimulation of A20 did not induce much IL-2 production. Perhaps, anti-lg over-
crosslinked the BCRs. Membrane IgM that is highly crosslinked by anti-lg patches 
and caps by association with the cytoskeleton (Williams et al., 1994), and IgM has 
been shown to be partitioned in the detergent-insoluble phase after cell lysis 
(Braun et al., 1982). Thus the receptors may be rendered inaccessible to 
downstream signalling molecules by association with the cytoskeleton. It will be 
interesting to see whether HEL, like anti-lg, causes BCRs to patch and cap. 
Application of the IL-2 assay to discriminate between the functions of lg-a and lg-
~' indicated that whereas the lg-~ ITAM tyrosines are essential, the lg-a and lg-~ 
cytoplasmic domains can independently mediate signalling, with no significant 
differences in their abilities. The results are in agreement with previous findings 
in cell lines (Law et al., 1993; Sanchez et al., 1993; Taddie et al., 1994; Williams et 
al., 1994), although in conflict with others (Choquet et al., 1994; Kim et al., 1993; 
Sanchez et al., 1993) . The limitations of cell line systems discussed at the 
beginning of this chapter and the original decision to generate transgenic mice 
were thus reinforced. 
Nevertheless, HEL-induced IL-2 production by A20 provides a convenient 
signalling assay, and opens up the possibilities of testing further mutant chimeric 
receptors to assess the roles of BCR components. Other parameters important to 
signalling such as affinity for antigen could also be monitored. 
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Figure 3.1 Chimeric receptor transgenes 
(A) Schematic representation of the DNA constructs. Coding regions are shown in rectangles 
with regulatory regions indicated in italics.The µ constructs contained the anti-hen egg 
lysozyme (HEL) Dl.3 VH region inserted as a Pstl-BstEII fragment. The 3' exons of µ were 
exchanged for Apal fragments extending from within Cµ4 and bearing the chimeric exons of a 
transmembrane region (TM) derived from H2-Kb fused to the cytoplasmic domains of lg-a or 
lg-~. The K construct contained the Dl.3 VK region inserted as a Sacl-Xhol fragment. Vector-free 
fragments were generated for microinjection: wild type µ (Clal-Xhol), µ chimeras (Clal-Kpnl), 
K (EcoRI). (R, Ecorl; C, Clal; P, Pstl; Bs, BstEII; A, Apal; K, Kpnl; S, Sacl; X, Xhol) 
(B) Predicted structures of the chimeric receptors. The extracellular lgM (µ and K) domains were 
fused via a hydrophobic transmembrane region (TM) to the cytoplasmic tail of lg-a, lg-~ or a 
mutated lg-~ with the ITAM tyrosines mutated to leucine (lg-~Y->L). 
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Figure 3.2 Expression of A20 transfectants 
The transfected receptors were identified from the endogenous IgG2a, K of A20 by staining with 
goat anti-IgM.~biotin (revealed by SA-PE) and goat anti-rat Ig-FITC (for rat CK). Figures after 
transfectant denote clone number. 
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Figure 3.3 Antigen presentation assay 
(A) Expression levels of the A20 transfectants used in the assay. Flow cytometric analysis of IgM 
(AK1158 clone-7) and IgM/~ (clone-14) after staining with goat anti-IgM-FITC (unstained controls 
depicted by shaded histograms). 
(B) IgM//3, as well as IgM, mediates specific antigen presentation of HEL, but not TEL. Levels ofIL-2 
(expressed as OD units) produced after antigen presentation of hen egg lysozyme (HEL; open circles) 
or turkey egg lysozyme (TEL; crossed circles) by A20 to T cell hybridoma 1E5.111 for 24 h. The "no T" 
control (filled cross) value resulted from culture of A20 and 0.1 µg/ml HEL in the absence of T cells. 
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Figure 3.4 Activation of A20 by HEL versus anti-lg 
(A) Anti-IgM triggers IgM//3 but the signal is weak. IL-2 production after 24 h incubation of 
lgM/13 (clone-14) transfectant (open symbols) and untransfected A20 (filled symbols) with goat 
anti-IgM F(ab')z (triangles) or goat anti-IgG F(ab')z (diamonds). 
(B) HEL induces a greater IL-2 response than anti-lg. Levels of IL-2 secreted after incubation of 
untransfected (A20; filled circles) and transfected (IgM/13, open circles) A20 for 24 h with HEL. 
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Figure 3.5 HPLC analysis of HEL 
<...I 
,--
I I 
A solution of 1 mg/ml HEL (Sigma L-6876) in PBS was analysed by HPLC (high-performance liquid chromatography) at 4°C and the OD at 280nm was detected at high and low sensitivity, 
revealing possible dimer and trimer forms in addition to the predominant monomer peak. 
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Figure 3.6 Dose response cmve for HEL-specific signalling 
IL-2 was measured after 24 h culture of IgM/~ (clone-14) transfectant with HEL (open circles) or 
TEL (crossed circles) and untransfected A20 with HEL (filled circles). 
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Figure 3.7 IgM/a or IgM!p, but not IgMfpY->L, can signal in A20. 
(A) Signalling by the A20 transfectants in response to HEL. Levels of IL-2 produced after 
culturing IgM (clone-6) (squares), IgM/a (-9) (triangles), IgM/P (-14) (circles) and IgM/pY->L 
(-5) (diamonds) transfectants with HEL for 24 h. 
(B) Expression of the transfectants used in the assay. For flow cytometric analysis, cells were 
stained with goat anti-IgM-FITC (shaded histograms denote unlabelled controls). 
Chapter 3: Results Chimeric BCRs in transfectants 70 
Results 
B cell antigen receptor signalling 
in transgenic mice 
Chapter 4 
71 
Results 
B cell antigen receptor signalling 
in transgenic mice 
Chapter 4 
71 
Chapter 4: Results 
B cell antigen receptor signalling in transgenic mice 
It has not been clear whether the lg-a and lg-~ polypeptides perform similar or 
different activities within the context of the BCR complex. In the previous 
chapter, both IgM/a and IgM/~ chimeric receptors mediated signalling, 
suggesting that the cytoplasmic domains of lg-a and lg-~ are functionally 
redundant. These results are consistent with some previous findings, but 
disagree with others. Thus, persevering with chimeric receptors in cell lines 
seemed unlikely to clarify the situation. 
Primary B cells might provide a more sensitive and physiological assay system, 
so transgenic mice were generated expressing the anti-HEL BCRs. An additional 
advantage of the transgenic system is that the effect of the transgenes could be 
monitored at different stages in B cell development. Indeed, the BCR plays a 
critical role in developmental processes that occur independent of antigen, as 
well as in B cell activation and other antigen-induced differentiation events. 
4.1 The transgenes are expressed in splenic B cells. 
Once the anti-HEL BCR transgene constructs had been checked for correct 
expression and function (see Chapter 3), vector-free DNA fragments were 
prepared for microinjection into (CBA/Ca x C57Bl/6) Fl zygotes. Each H chain 
fragment of the wild type IgM (Clal-Xhol) or the chimeric IgM/a, IgM/~ or 
IgM/ ~Y->L (Clal-Kpnl) constructs was co-injected with the K L chain EcoRI 
fragment bearing a rat CK region (see Fig. 3.lB). 
Putative founder mice were screened by ELISA for the expression of transgenic 
(rat) K and genomic integration of the H chain transgenes was detected by PCR. 
Mutiple founders were identified carrying either the H or L chain transgenes, 
however, only one founder for each chimeric receptor was found to have 
cointegrated both Hand L chain constructs. Two founders (lines A and B) for the 
wild type IgM receptor had cointegrated the H and _L chains. Depending on the 
experiment, mice were bred with (CBA/Ca x C57Bl/6) Fl, C57Bl/6 or µM.T B-cell 
deficient mice (Kitamura et al., 1991). Analyses were performed on multiple 
individuals from each transgenic line, although only line B of the IgM transgenic 
mice was crossed into a µMT background. 
With the generation of founder lines that had integrated the transgenes into the 
Chapter 4: Results BCR signalling in transgenic mice 72 
genome, the expression of the transgenic receptors was analysed by flow 
cytometry (Fig. 4.1). Transgenic K could be discriminated from the endogenous K 
since the L chain transgene bore a rat CK region. The expression of secretory 
transgenic K had already been detected by ELISA in the serum of the mice during 
screening (not shown), and staining for rat K revealed that the transgenic K 
chains were expressed on the cell surface in spleen (Fig. 4.lA). 
The detection of transgenic µ H chain was not as straightforward as that of 
transgenic K. The antigen binding site of the BCRs is formed by both VH and VL 
regions, thus specific binding of the antigen HEL would give an indication of the 
expression of both H and L chain transgenes. Attempts to obtain good staining 
with HEL conjugates (to biotin or FITC) proved unsuccessful. However, since 
numerous anti-HEL monoclonal antibodies have been generated and 
characterised, it was possible to visualise HEL binding using a second anti-HEL 
antibody, HyHELlO (Smith Gill et al., 1984). HyHELlO recognises a 
complementary epitope to Dl.3 and binds to a different face of HEL (Davies et al., 
1990). When the splenic B cells were identified by the B cell marker B220 
(CD45R), HEL binding revealed that both H and L chain transgenes were 
expressed as receptors on the B cell surface (Fig. 4.lB). 
Binding of the Dl.3 idiotype to HEL has been characterised and compared to the 
binding of Dl.3 to an anti-Dl.3 idiotype, E5.2 (Fields et al., 1995). The monoclonal 
antibody E5.2 mimics the binding of HEL by forming similar structural contacts 
within the antigen binding site of Dl.3. Thus, the transgenic receptors could also 
be identified by staining for Dl.3 with the anti-Dl.3 idiotype. The pattern of B cell 
staining with the E5.2 antibody seemed similar to that of HEL itself, and it is 
evident that all the transgenic lines do express their transgenes (Fig. 4.lC), 
although the levels of expression and proportion of transgenic B cells (B220+D1.3 
idiotype+) varied (Table 4.1), with IgM/ a least efficiently expressed. 
These results demonstrate that splenic B cells of all the transgenic mice express 
their H and L chain transgenes, forming a functional Dl.3 idiotype that binds its 
antigen, HEL. 
Unexpectedly, it is apparent that the Dl.3 transgenes were also expressed on a 
proportion B220- cells in the spleens of mice bearing the chimeric transgenes 
(Fig. 4.lC). 
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Table 4.1 B cell populations in transgenic mice. 
Cells from spleen and bone marrow of non-transgenic (Non-tg) and transgenic mice were analysed 
by flow cytometry as in Fig. 4.lC. Mean values are shown with standard deviations in brackets 
for n individuals. 
Spleen Bone marrow 
Total number %8220+ %8220+ Total number %8220+ %B220+ 
of cells 01.3+ of cells 01.3+ 
Non-tg 9.4 X 107 57 2 1.7x107 23 0 
(2.4x107) n=18 (7.7) n=18 (0.9) n=11 (8.6x106) n=7 (3.7) n=7 (0.0) n=2 
lgMA 4.2 X 107 15 9 1.9x107 13 6 
(1.5x107) n=6 (5.2) n=6 (5.8) n=6 (8.5x106) n=2 n=1 n=1 
lgMB 5.2 X 107 26 20 2.2 X 107 
(2.5x1 o?) n=2 (1.4) n=2 (0.7) n=2 n=1 
lgM/a 5.1x107 18 4 1.9x 107 15 6 
(2.1x107) n=9 (7.4) n=9 (1.5) n=9 (7.0x106) n=3 (0.0) n=2 (0.0) n=2 
lgM/~ 2.6 X 107 21 12 1.1x107 14 8 
(8.9x106) n=4 (1.5) n=3 (2.1) n=3 (3.7x106) n=2 n=1 n=1 
lgM/~Y->L 1.8 X 108 46 38 1.4x107 9 8 
(1.1x108) n=5 (10) n=5 (7.9) n=5 (7.1 x1 os) n=2 n=1 n=1 
4.2 Splenic T cells also express the chimeric transgenes. 
Expression of the chimeric transgenes was most obvious in the spleens of IgM/ ~ 
and IgM/ ~Y->L mice (Fig. 4.lC). In order to identify the cells that aberrantly 
expressed the transgenic receptors, IgM/~Y->L mice were analysed further, since 
transgene expression might be least perturbed by any signalling ability. 
When IgM/~Y->L splenocytes were stained for different cell lineage markers, IgM 
was detected on the surface of cells stained for Thyl.2 (CD90.2) (Fig. 4.2A), but not 
Mac-1 or Gr-1 (not shown), indicating that the B22Q- cells expressing surface IgM 
were a subset of T cells. 
The splenic T cells from IgM/~Y->L mice that expressed surface IgM seemed to 
reflect the activity of the IgH enhancer (Eµ) in the T cell lineage (Cook et al., 
1995), and µ transgenic mice often express µ intracellulatly in thymus and 
peripheral T cells (Lamers et al., 1989; Storb et al., 1986). When IgM/~Y->L 
thymus was analysed, cytoplasmic µ (IgM) was indeed expressed in most 
thymocytes, although it was not transported to the surface (Fig. 4.2B). 
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The inability of the IgM/pY->L receptor to be detected on the surface of the 
thymocytes suggested that the receptor complex may be incomplete . The 
chimeric µ chains contain a hydrophobic transmembrane region deriving from 
H2-Kb which facilitates surface transport of the chimeras in the absence of lg-a 
and Ig-P (Williams et al., 1993). Thus, unlike wild type µ, the chimeric receptors 
do not require association with the Ig-a/Ig-P heterodimer for surface transport, 
and indeed no such complex has been detected (Patel and Neuberger, 1993). 
However, L chain association is still required. The surface expression of 
transgenic K was detected in a proportion of IgM/pY->L splenic T cells similar to 
the subpopulation that expressed surface IgM (Fig. 4.2A). Furthermore, the intact 
transgenic Dl.3 idiotype formed by both VH and VK regions can be identified on 
CD4 + and CDS+ subsets of splenic T cells. However, the K transgene was not 
detected in thymus (not shown). Thus, the pattern of transgenic K expression 
suggests that the K transgene acts as the limiting factor for surface transport of the 
chimeric µ H chain. 
The expression of transgenic K in peripheral T cells may be regulated by binding 
of the transcription factor NFKB to the K intron enhancer (Staudt and Lenardo, 
1991). Following activation of the T cell, NFKB activity increases (Baeuerle and 
Henkel, 1994) and may induce transcription of the rearrranged K transgene. 
Association of the transgenic K chain with the chimeric µ chain renders the 
chimeric receptor competent for surface expression. To test this hypothesis, 
splenic T cells were assessed for increases in surface expression of the IgM/pY->L 
receptors after activation for 24 h. Splenocytes from IgM/pY-> L mice were 
cultured in the presence and absence of the lectin concanavalin A (Con A), 
which crosslinks CD3 receptors, inducing T cell activation. After 24 h, the surface 
expression of activation markers CD44, CD25 and CD69 was upregulated on the 
splenic T cells (gated Thyl.2+ or CD4+) (Fig. 4.2 C), indicating that the cells were in 
an activated state. However, the expression of IgM/pY->L did not increase and in 
fact, incubation of- the splenic T cells reduced the number of IgM+ cells detected. 
Thus, the conditions of the 24 h Con A culture were not sufficient to induce 
further expression, but it is possible that in viva activation of the T cells had 
been induced by other mechanisms. 
Nevertheless, it is clear that the non-B22Q+ cells expressing the chimeric 
transgenes are peripheral T cells of both CD4+ and CDS+ subpopulations. 
Chapter 4: Results BCR signalling in transgenic mice 7 5 
4.3 IgM/a and IgM/P, but not IgM/pY->L, generate a peripheral B cell pool. 
BCR expression and signalling is essential for differentiation of the B cell lineage, 
as illustrated by the µMT mouse which bears a germline disruption in the 
merr.brane exons of the µ H chain (Kitamura et al., 1991). Inability to express 
membrane µ prevents assembly of the pre-BCR and results in a block at the pro-B 
cell stage (fraction C, according to (Hardy et al., 1991)) (Ehlich et al., 1993). Thus, 
no B22Q+ IgM + cells could be detected in the bone marrow or the spleen of µMT 
mice, in contrast to non-transgenic wild type mice (Fig. 4.3). 
Introduction of all the anti-HEL transgenes into a µMT background resulted in 
the detection of B22Q+JgM+ bone marrow cells (Fig. 4.3 and Table 4.2). In non-
transgenic mice, the expression of surface IgM can be used as a differentiation 
marker for immature and mature B cells. However, in transgenic mice bearing 
rearranged IgM transgenes, the expression of surface IgM may be misleading 
since the H and L chain transgenes do not need to undergo V region 
rearrangement. By-passing the rearrangement stages in differentiation may cause 
premature expression of transgenic IgM and apparent acceleration of the B cell 
precursor through early development. 
One indication of a functional BCR is its ability to drive the generation of 
B22Q+JgM+ cells in the peripheral B cell pool. When cells from the peripheral 
lymphoid organ, spleen, were analysed, it was clear that the IgM transgene 
overcame the defect in the µMT mouse (Fig. 4.3 and Table 4.2), indicating that 
the wild type anti-HEL receptor can mediate B cell development. In addition, 
both . IgM / a and IgM/ p chimeras effected reconstitution of a splenic B cell 
population in µMT mice. 
In contrast, the IgM/pY->L transgene did not rescue the µMT phenotype (Fig. 4.3 
and Table 4.2) . No B22Q+JgM+ cells were identified in the spleen, although they 
were detected in the bone marrow. These results indicated that although IgM/pY-
>L could be expressed on the surface of B cell precursors in the bone marrow, it 
proved inadequate to reconstitute a peripheral B Cf'.ll pool. The only IgM+ cells 
detected in the spleen were the aberrant T cells previously identified (see Fig. 4.2). 
The results from the µMT reconstitution assay indicate that the Ig-P ITAM 
tyrosines are essential for signalling, but suggest that the cytoplasmic domains of 
either lg-a or Ig-P are sufficient mediate the generation of peripheral B cells in 
µMT B cell-deficient mice. 
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Table4.2 B cell populations in transgenc mice crossed into a µMT background. 
Spleen and bone marrow cells from transgenic mice in a µM.T background or non-transgenic (Non-tg) 
controls were analysed by flow cytometry as in Fig. 4.3. Numbers indicate mean values with 
standard deviations in brackets for n individuals. 
Spleen Bone Marrow 
Total number %8220+ Total number %8220+ %8220+ 
Transgene Background of cells lgM+ of cells lgM+ 
Non-tg Wild type 9.4 X 107 57 1.7x107 23 9 
(2.4x107) n=18 (6.4) n=B (8.6x106) n=7 (3.7) n=7 (2.3) n=6 
Non-tg µMT 6.4 X 107 0 2.2 X 107 6 0 
(2.5x107) n=4 (0.5) n=4 (1.1 x107) n=3 (0.6) n=3 (0.0) n=3 
lgMB µMT 5.6 X 107 26 2.0 X 107 15 7 
(2.3x107) n=4 (19) n=4 (9.0x106) n=4 (10) n=4 (5.7) n=4 
lgM/a µMT 4.6 X 107 15 1.9x107 10 6 
(2.4x107) n=B (6.6) n=B (6.4x106) n=6 (3.5) n=6 (1.9) n=6 
lgM/ ~ µMT 3.9 X 107 15 2.1x107 7 5 
(1.0x107) n=5 (6.0) n=5 (7.4x106) n=4 (3.4) n=4 (2.0) n=4 
lgM/~Y->L µMT 3.3 X 107 1 1.3x107 4 3 
(1 .8x107 ) n=2 (0.7) n=2 n=1 n=1 n=1 
4.4 The transgenic B cells turnover more rapidly in viva. 
The splenic B cell populations generated by the IgM, IgM/a and IgM/~ 
transgenes in µMT mice was reduced compared to that of non-transgenic wild 
type mice (Fig. 4.3 and Table 4.2). Fewer B cells seemed to be generated in the 
bone marrow. However, an alternative explanation for the reduced B cell 
numbers could be an increased turnover or shorter lifespan of the B cells in 
viva. 
Cell turnover can be measured by the uptake of BrdU (5-bromo-2-deoxyuridine) 
in proliferating cells. BrdU is an analogue of thymidine that can be incorporated 
during DNA replication and can be detected using a specific anti-BrdU antibody. 
For the in viva production of cells in mice, BrdU can be administered as an 
injection or added to the drinking water. Depending on the period of BrdU 
uptake, the proportions of cells that are labelled with BrdU indicate the relative 
lifespans of different cell populations. 
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After 72 h of BrdU incorporation, most of the B220+ bone marrow cells of the 
non-transgenic mice had taken up BrdU (Fig. 4.4), but the majority did not 
express surface IgM, indicating that most of the newly-generated B220+ cells in 
the bone marrow are early B cell progenitors that have yet to express a functional 
BCR. 
BrdU uptake was also detected in most of the B220+ cells in the bone marrow of 
the transgenic mice (Fig. 4.4). However, the effects of the transgenes on the bone 
marrow cells were difficult to determine. Although transgenic receptors (stained 
for Dl.3 idiotype) were expressed on a large proportion of the transgenic 
B220 +Brd U + cells, the transgenes are not reliable markers of differentiation 
status. Nevertheless, these results indicate that in the bone marrow, B cell 
turnover is rapid in all the transgenic mice as well as in the non-transgenic mice. 
B cells in the periphery are long-lived compared to those with a rapid turnover 
in the bone marrow. Thus, in non-transgenic mice, a small proportion of splenic 
B220+ cells had incorporated BrdU (Fig. 4.4). By comparison, BrdU uptake by the 
transgenic (Dl.3+) B cells was significantly increased in the spleens of IgM and 
IgM/P, but not IgM/pY->L mice. The relative proportions of BrdU+ cells suggest 
that the splenic B cells are shorter-lived in the transgenic mice than in non-
transgenic mice. Since the expression of a functional transgenic receptor, 
whether wild type or chimeric IgM, increased B cell turnover, it is possible that 
the shorter lifespan of the transgenic B cells is due to the Dl .3 V region 
specificity. 
The IgM/ a transgene was expressed at consistently lower levels in the spleen 
(Fig. 4.4; also Fig. 4.1 and 4.3), making identification of the IgM/ a transgenic B 
cells less straightforward than for the other transgenic mice. Therefore the results 
for BrdU uptake by the IgM/ a splenic B cells were difficult to interpret. 
However, despite its poor expression in the spleen, IgM/ a was clearly detected in 
the bone marrow (Fig. 4.4) . Indeed, BCR expression was lower on the BrdU-B220+ 
cells compared to the BrdU+B220+ cells in the IgM, IgM/a and IgM/P transgenic 
mice, but not in the non-transgenic controls. The reduced levels of transgene 
expression in both the longer-lived BrdU- B cells and the more mature splenic B 
cells may indicate that exp ression of the anti-HEL receptor transgenes is 
downregulated over the lifetime and maturation of the transgenic B cells 
(possibly another effect of the Dl.3 specificity). 
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These results suggest that the Dl.3 idiotype confers a common effect of increased 
turnover of the transgenic B cells. Thus, the reduced splenic B cell pools 
reconstituted in µMT mice may be explained by the shorter lifespan of peripheral 
B cells as well as the decreased generation of B cell precursors in the bone 
marrow of the transgenic mice. 
4.5 The reconstituted B cells reveal altered expression of mature B cell markers. 
The IgM, IgM/ a and IgM/P transgenes rescued the development of B cells in 
µMT B cell-deficient mice. Such transgenic µMT mice and their B cells will be 
referred to as reconstituted mice and reconstituted B cells for the remainder of 
this chapter since transgenic may be ambiguous since it also describes the 
IgM/pY->L transgene which does not effect µMT reconstitution. The 
reconstituted mice provided a source of transgenic B cells in the absence of 
contaminating B cells that expressed endogenous BCRs. For example, the 
reconstituted splenic B cell population could be analysed without enriching for 
transgenic B cells or anti-IgM could be used for detecting or stimulating the 
transgenic B cells, since the only IgM expressed on the surface was transgenic IgM 
and not endogenous membrane IgM. 
In order to determine any differences in the extent of maturation effected by the 
chimeric IgM/ a and IgM/ P receptors compared to the wild type IgM BCR, the 
reconstituted B cells were characterised by the expression of cell surface markers 
(Fig. 4.5). 
B-1 cells constitute a separate B cell lineage in the peritoneum that can be 
discriminated from conventional mature B cells by the expression of the cell 
surface marker, CD43. B-1 cells are self-renewing (not bone marrow-derived), but 
have a low turnover rate. The anti-HEL transgenes seemed to increase the 
turnover of transgenic B cells and therefore may reduce the size of the long-lived 
B-1 pool. Indeed, -the IgM, IgM/ a and IgM/ p mice in a µMT background had 
fewer peritoneal B cells (Fig. 4.5A). However, the reconstituted mice contained 
reduced numbers of total B22Q+, and as a proportion of the total peritoneal B 
cells, the CD43+B220 + B-1 cell pools were of similar size to those in non-
transgenic wild type mice. 
During the development of conventional B cells in the bone marrow of adult 
mice, CD43 is expressed on pro-B cells before the expression of the BCR. Indeed, 
surface IgM is not yet expressed on the CD43+ pro-B cells in the non-transgenic 
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bone marrow (Fig. 4.5B). However, IgM/a and IgM/P chimeras, but not the wild 
type IgM transgene, are detected on CD43+ pro-B cells, suggesting that the 
chimeric transgenes are expressed prematurely. 
At later stages in B cell development, peripheral B cells express the mature B cell 
markers CD22, CD21/35 (complement receptors 2 and 1) and CD23 (Fe receptor for 
IgE), as observed in the splenic B cells from non-transgenic mice (Fig. 4.SC). CD22 
expression appeared relatively unaffected in the IgM, IgM/ a and IgM/P splenic B 
cells, although a few IgM+CD22- B cells were detected in the IgM/a and IgM/P 
spleens . 
The splenic B cell populations from IgM/a and IgM/P exhibited a shift to lower 
expression of CD21/35 and CD23, compared to non-transgenic mice (Fig. 4.SC). 
The reduced proportions of B cells expressing high levels of CD21/35 and CD23 
suggest that the chimeric transgenes do not effect the same degree of maturation 
as for non-transgenic peripheral B cells. However, analysis of these mature B cell 
markers on splenic B cells from wild type IgM transgenic mice also revealed 
CD21/35 and CD23 expression altered from the non-transgenic controls. 
Characterisation of the different B cell populations by cell surface markers 
suggests that although total peripheral B cell numbers are reduced, the B-1 pool 
seems unaffected. However, the IgM/a and IgM/P chimeric transgenes appear to 
be expressed prematurely in pro-B cells in the bone marrow. Furthermore, the 
phenotype conferred by the IgM, IgM/ a and IgM/ P transgenes in spleen suggests 
that the anti-HEL receptors do not drive the same distribution of maturational 
development of peripheral B cells as that observed in non-transgenic mice. 
4.6 The transgenic B cells proliferate poorly in vitro. 
In chapter 3, A20 transfectants expressing the IgM/a and IgM/P receptors 
transfected mediated signalling in response to the antigen HEL, but it remains to 
be shown that the chimeras can mediate antigen-dependent activation in 
primary cells. 
The proliferation of cells following stimulation can be judged by the 
incorporation of [3H]thymidine during DNA replication. After incubation with 
anti-IgM + IL-4 for three days, splenic B cells from non-transgenic mice showed a 
strong proliferative response (Fig. 4.6A) . In contrast, when reconstituted B cells 
from the IgM/ a and IgM/ p chimeras crossed into a µMT background were 
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cultured with anti-IgM + IL-4, they accumulated few counts over the IL-4 alone 
controls. Surprisingly, even the wild type IgM transgenic B cells proliferated 
poorly. 
The poor proliferative response of the transgenic B cells to anti-IgM + IL-4 might 
be due to defective BCR-mediated signalling. Alternatively, the reconstituted B 
cells might exhibit an inability to undergo proliferation to any stimulant. In 
order to discriminate between the two possibilities, the B cells were incubated 
with lipopolysaccharide (LPS) which induces B cell proliferation by a different 
mechanism from that mediated by the BCR. When incubated with LPS, the 
proliferation of the IgM, IgM/a and IgM/P reconstituted B cells was again greatly 
diminished compared to the non-transgenic controls (Fig. 4.6B). 
The poor proliferation of the IgM, IgM/a and IgM/P splenic B cells in response to 
both anti-IgM + IL-4 and LPS therefore seemed to reflect an intrinsic defect of the 
reconstituted B cells expressing anti-BEL transgenes, regardless of the wild type 
or chimeric nature of receptors. 
4.7 The transgenic B cells die more quickly in vitro. 
The reduced proliferative response of the transgenic B cells revealed an inability 
to induce proliferation, possibly due to a defect required for the proliferative 
process. Another explanation, in view of their increased turnover in viva (Fig. 
4.4), might be that the transgenic B cells die more quickly than non-transgenic B 
cells when cultured in vitro . 
Preliminary experiments, using propidium iodide to stain dead cells as a crude 
estimate of B cell viability, showed an overall trend. The IgM, IgM/a and IgM/P 
reconstituted B cells all revealed a decrease in viability compared to B cells from 
non-transgenic mice after 24 h. For example, cultures of B cells with anti-IgM 
resulted in only 20-30% viability of the transgenic B cells versus 65% of the non-
transgenic controls. The reduced viability of the IgM, IgM/a and IgM/P B cells 
suggests that they may behave like immature B cells, which are susceptible to 
deletion and are induced to die by apoptosis following BCR crosslinking. 
Dying cells may be identified by the characteristic feature of DNA fragmentation 
which occurs during the early stages of apoptosis. Biotin-conjugated dUTP can be 
added to the broken ends of the double-stranded DNA using the enzyme 
terminal deoxynucleotidyl transferase (TdT). The cells thus labelled can be 
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visualised by flow cytometry. Such TUNEL (TdT-mediated dUTP-biotin nick 
end-labelling) analysis revealed that almost all the splenic B cells from transgenic 
and non-transgenic mice had been labelled by 24 h incubation in the presence of 
anti-IgM (Fig. 4.7). However, a large proportion of the IgM/a and IgM/~ B cells 
were dUTP+ after incubation for only 4 h. By 8 h, the majority of B cells 
expressing the wild type IgM transgene, as well as the IgM/ a and IgM/ ~ chimeras 
had incorporated dUTP. These results suggest that the B cells expressing the 
chimeric receptors were already dying from as early as 4 h, with almost all the 
reconstituted B cells induced to die within 8 h. The increased rate of dUTP 
labelling in the transgenic versus non-transgenic B cells suggests that the B cells 
expressing the anti-HEL receptors are more susceptible to cell death. 
Little difference was observed in the rate of dUTP incorporation between B cells 
cultured in the presence, and absence, of anti-IgM (Fig. 4.7), suggesting that the 
cell death detected was not induced by BCR crosslinking. Thus, it is possible that 
the B cells are undergoing spontaneous apoptosis. Cell death is a dynamic 
process, however, and TUNEL may also detect necrotic cells, if analysis is 
performed at later stages. 
The phenotypic analysis of the transgenic B cells included faster cell turnover in 
viva (Fig. 4.4), lower expression of mature B cell markers (Fig. 4.5), poor 
proliferation (Fig. 4.6) and increased cell death (Fig, 4.7). Taken together, these 
results suggest that the Dl.3 V region specificity may confer a (possibly more 
immature) phenotype that is common to all the anti-HEL transgenic receptors 
and is not due to their specific cytoplasmic domains. 
4.8 IgM/a and IgM/~ can signal to upregulate B7. 
BCR-mediated signalling results in the upregulation of B7 costimulatory 
molecules on the B cell surface, which can be detected by the binding of its 
natural ligand, CTLA4. An increase in binding of a CTLA4 fusion protein was 
detected within a few hours and was clearly evident after 24 h stimulation (Fig. 
4.8A). 
Although the reconstituted transgenic B cells exhibited increased cell death, it 
was still possible to monitor the B7 response of those cells that remained viable 
over the 24 h period. Indeed, CTLA4 binding increased on reconstituted splenic B 
cells from the wild type IgM transgenic in a µMT background in response to anti-
IgM (Fig. 4.8B). Similarly, B7 upregulation was also mediated by crosslinking the 
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IgM/a and IgM/~ chimeras. 
The upregulation of B7 was also monitored in B cells from the transgenic mice 
in a wild type background. The antigen HEL and anti-Dl.3-idiotype antibody 
induced B7 upregulation in the IgM, IgM/a and IgM/~ transgenics, but not in the 
non-transgenic controls (Fig. 4.8C). The variations in levels of CTLA4 binding 
may be due to the presence of contaminating non-transgenic B cells from the 
non-µMT wild type background, since the cells were gated by expression of B220. 
These experiments also facilitated the analysis of IgM/~Y->L, which did not 
mediate B7 upregulation in response to HEL or anti-idiotype. 
Thus, IgM/ a and IgM/~, but not IgM/~Y->L receptor, were able to signal B cell 
activation, indicating that the cytoplasmic tails of both lg-a and lg-~ can 
independently mediate a response to antigen in primary cells, but that the lg-~ 
ITAM tyrosines are essential. 
4.9 IgM/a and IgM/~ mediate allelic exclusion although less efficiently than IgM. 
The B cell pool recognises diverse antigens, but it is essential that each B cell 
expresses antibodies of a monoclonal specificity. Early in B cell development, a 
functionally-rearranged lg chain is expressed as a (pre-)BCR, which mediates 
allelic exclusion by signalling to inhibit rearrangement and prevent expression of 
the other allele. 
In order to analyse the abilities of the transgenes to mediate allelic exclusion, it 
was necessary to discriminate transgenic from endogenous lg. One approach was 
to exploit H chain isotype expression, since the IgD expressed in a transgenic 
mouse would derive only from the endogenous alleles. Whilst the transgenes 
encode only the IgM class, normal (non-transgenic) mature B cells can co-express 
both IgM and IgD . classes. In a non-transgenic mouse, most of the splenic B cells 
expressed high levels of IgD, but not the transgenic Dl.3 idiotype (Fig. 4.9A). In 
striking contrast, the wild type IgM transgene suppressed endogenous IgD 
expression and the B cells expressed only the transge~e. In addition, both IgM/ a 
and IgM/~ were also able to mediate allelic exclusion. However, some IgD-
expressing B cells leaked through, suggesting that the chimeras were less efficient 
than the wild type IgM transgene. Nevertheless they were more effective than 
the IgM/~Y->L receptor, which could not exclude co-expression of the transgene 
and IgD on most cells. 
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An alternative way of discriminating the transgenes from the endogenous alleles 
was to take advantage of the different mouse strain allotypes, since the 
transgenes encoded the lgMa allotype. The transgenic receptors (identified by 
Dl.3 or lgMa) were bred into a background that expressed only the lgHb allotype. 
Thus, the expression of transgenic versus endogenous lg could be stained for 
either Dl.3 versus lgMb, or lgMa versus IgMb (Fig. 4.9B). The lgMa versus lgMb 
staining also facilitated the detection of allelic exclusion exhibited by a non-
transgenic (lgHa x lgHb) Fl mouse. The patterns of allelic exclusion seen for each 
mouse with either set of reagents are consistent with the above results, although 
the combination of weaker staining by the anti-lgMa reagent and consistently 
lower expression of the transgene makes exclusion less obvious in lgM/ a. 
The patterns of expression of transgenic versus endogenous lg show that lgM 
efficiently excludes, lgM/a and lgM/~ effect less complete exclusion, and lgM/~Y-
>L does not inhibit endogenous lg expression. Although an intact lTAM is 
necessary, both lg-a and lg-~ seem able, yet inefficient, to mediate allelic 
exclusion, suggesting that they have broadly similar signalling abilities. 
4.10 The combination of IgM/a and IgM/~ enhances allelic exclusion. 
Since the BCR complex contains both lg-a and lg-~ polypeptides, the lgM/ a 
transgenic was crossed with lgM/ ~ in order to determine whether the expression 
of both lgM/a and lgM/~ together might enhance the ability of the individual 
chimeras to effect complete allelic exclusion. 
Characterisation of the (lgM/ a)x(lgM/ ~) double transgenic showed that the 
transgenic receptors were expressed at equivalent levels to those of the lgM/ ~ 
parent in the spleen (Fig. 4.10A). The single IgM/a and lgM/~ chimeras have 
been shown to mediate antigen-induced activation, therefore it was not 
surprising that splenic B cells expressing both chimeras were also able to 
upregulate B7 in response to HEL and anti-idiotype (Fig. 4.lOB). In contrast to the 
IgM/a or IgM/~ parents, however, (IgM/a)x(lgM/~) did exhibit more efficient 
allelic exclusion, inhibiting endogenous lgD expressic:m similarly to the wild type 
lgM transgene (Fig. 4.lOC). 
The experiments comparing the activities of wild type IgM with those of 
chimeric IgM/a or lgM/~, or both together, suggest that whilst the cytoplasmic 
domains of either lg-a or lg-~ are largely able to mediate the signalling activites 
of the BCR, the cooperation of both polypeptides appears to be required for 
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optimal function. 
4.11 Discussion 
The generation of transgenic mice expressing chimeric BCRs has facilitated the 
study of the roles of lg-a and lg-~ in B cell development and activation in 
primary cells. Although the lg-~ lTAM tyrosines are necessary for signalling, the 
cytoplasmic domains of either lg-a or lg-~ alone can broadly perform the 
functions of an intact BCR in the antigen-induced upregulation of B7, and in B 
cell maturation and allelic exclusion during development. These results do not 
highlight any major differences between the roles of lg-a and lg-~, yet do suggest 
that the combination of the two polypeptides may be necessary for optimal 
signalling potential of the BCR. 
The abilities of lgM/ a and lgM/ ~ to mediate events in antigen-independent B 
cell development are consistent with reports published during the course of this 
work. Using transgenic mice expressing analogous lgM chimeras, the individual 
cytoplasmic domains of lg-a and lg-~ were shown to have sufficient and 
equivalent functions in two checkpoints: pro- to pre-B cell transition and alleic 
exclusion (Papavasiliou et al., 1995; Papavasiliou et al., 1995). The 
progression of pro- to pre-B cells (judged by the loss of CD43 expression) was 
effected by the chimeric receptors in the bone marrow of RAG-1 -I- mice that are 
rendered both B and T cell-deficient by germline disruption of a gene essential 
for V region recombination. The chimeras also inhibited endogenous VH 
rearrangement, detected by PCR, in a wild type background. However, lg-~ lTAM 
signalling activity was abolished by mutation of the essential tyrosine residues to 
phenylalanine. The experiments in this chapter not only confirm these 
conclusions but extend the study to later stages of B cell differentiation: the 
generation of peripheral B cells in µMT mice and antigen-dependent activation 
of the reconstituted mature B cells. 
Allelic exclusion was also exhibited by mice expressing compromised BCRs due 
to gene-targetting of the mb-1 gene, resulting in truncation of the lg-a 
cytoplasmic domain. Bone marrow analysis of such mb-1 Ml M mice suggests that 
early B cell development proceeds relatively normally in the absence of signals 
from lg-a, presumably via lg-~ alone (Torres et al., 1996). However, B cell 
maturation is severely impaired and the long-lived peripheral B cell pool was 
reduced to 1 % of controls, possibly due to a signalling defect in a selection or 
survival checkpoint which is required for maturation and migration from the 
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bone marrow into the periphery. In view of the striking mb-1 Ml M phenotype, 
there was surprisingly little difference between the effects of the wild type IgM 
transgene and the IgM/a and IgM/~ chimeras (Table 4.2). Indeed, compared to 
normal mice, all three anti-HEL transgenes generated reduced splenic B cell 
numbers in the reconstitution of µMT B cell-deficient mice. The apparent 
conflict in peripheral B cell numbers may be attributable to differences in the 
receptor complexes. It is possible that truncation of endogenous lg-a confers a 
defect in surface transport of the BCR (and therefore in BCR function), although 
the few peripheral B cells that were detected in mb-1 toe/ Lie mice did not show 
decreased surface IgM expression. In contrast, the chimeric IgM transgenes can be 
transported to the cell surface in the absence of an attendant lg-a/ lg-~ 
heterodimer due to the hydrophobic H2-Kh transmembrane segment (Williams 
et al., 1990), yet do not show detectable association with endogenous lg-a or lg-~ 
(Patel and Neuberger, 1993). 
A possible indication of lg-a and lg-~ function in selection of immature B cells to 
the long-lived mature B cell pool, is that expression of IgM/a (and to a less 
obvious extent IgM/~) seemed to be downregulated during cell lifespan or 
maturation. The newly-generated B cells in bone marrow expressed high levels 
of transgenic BCRs, and yet the longer-lived BrdU- cells (Fig. 4.4), or the mature 
splenic B cells, expressed fewer receptors (Fig. 4.3). The apparent decrease in 
transgene expression may be due to elimination of the high expressers or 
selection and exit from the bone marrow of the low expressers. Although highly 
speculative, if transgenic BCR is used as a (rather unreliable) indicator of B cell 
maturity, then perhaps signalling via lg-a alone advances the differentiation of 
the B cell, causing a shift from IgMhi to IgM1° expresssion as exhibited by B cells 
from gene-targetted CD22-deficient mice (O'Keefe et al., 1996; Otipoby et al., 1996; 
Sato et al., 1996). Indeed, whilst the transgenes bearing Dl.3 specificity exhibited a 
common phenotype, IgM/ a often deviated less from normal mice, whereas 
IgM / ~ w as m ore extreme, in displaying the altered phenotype of increased cell 
turnover in viva and cell death in vitro, and lower expression of mature B cell 
markers. 
Caution must be exercised when deriving conclusions from the small differences 
between IgM, IgM/ a and IgM/ ~ because founder effects cannot be excluded and 
the site of transgene integration m ay influence its function . Regrettably, 
although other founder lines were produced, they either did not express both the 
H and L chain transgenes or subsequent breeding proved difficult to establish . It 
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was difficult to detect whether the lgM/a or lgM/P chimeras revealed 
compromised signalling abilities because of the predominant phenotype 
common to the anti-HEL transgenes. Although a difference is seen between the 
wild type lgM and chimeric receptors in the µMT reconstitution assay, its 
significance is doubtful in the absence of multiple founder lines. The fact that 
even the wild type lgM BCR drives B cell maturation altered from normal 
suggests that the transgene specificity is not neutral and illustrates the 
limitations of monoclonal transgenic mice. Whilst some rearranged µ 
transgenes behave as hoped and can mediate allelic exclusion (Nussenzweig et 
al., 1987), others are selected against (Forni, 1990; Grandien et al., 1990) and even 
prove to be deleterious to B cells (Herzenberg et al., 1987; Muller et al., 1989) 
without known auto-antibody specificity. It appears that specificity may be 
important in determining the signalling potential of the transgene as a BCR 
since µ transgenes that strongly inhibit Vtt rearrangment also allow B cell 
precursor development (Chang et al., 1995). Nevertheless, it is clear in this 
chapter that the cytoplasmic domains of lg-a and lg-P are independently 
sufficient to generate a peripheral B cell pool. 
Despite lgM/ a and lgM/P behaving similarly to the lgM transgene in B cell 
maturation and activation, allelic exclusion of endogenous lgH was the only 
readout to show a significant difference in the signalling abilities of the chimeric 
versus wild type BCRs. lgM/ a and lgM/P bore rearranged V regions and thus 
could be expressed to inhibit the endogenous Vtt regions before they start to 
rearrange, but their signalling was inefficient and some endogenous alleles 
escaped exclusion. However, expressing both lgM/ a and lgM/P together 
exhibited an enhanced activity and rescued the deficiency. Although the synergy 
demonstrated by (lgM/a)x(lgM/P) seems to indicate that the chimeras form a 
heterodimeric structure, the biochemical basis has yet to be proven (by, for 
example, immunoprecipitation). Nevertheless, these results are consistent with 
reconstitution studies revealing cooperativity between the two polypeptides 
(Luisiri et al., 1996). Chimeras composed of the extracellular domains of the 
PDGF receptor fused to the lg-a or lg-P cytoplasmic t!1ils were expressed in cell 
line transfectants. Although the chimeric homodimers could transmit signals, 
only the chimeric heterodimer (generated by specific ligand-induced 
dimerisation) could mediate downstream tyrosine phosphorylation similar in 
range and intensity to the endogenous BCR. Furthermore, lg-P seemed to lower 
the stimulation threshold and enhance the activity of lg-a by transferring its 
signalling potential since its own phosphorylation was quenched when 
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complexed with lg-a. Therefore the assumption that the roles of lg-a and lg-~ 
within an intact BCR could be elucidated by discerning their independent 
functions may be misleading and it seems more appropriate to examine how 
they co-operate. The cytoplasmic domains of lg-a and lg-~ need to recruit 
downstream effectors such as protein tyrosine kinase Syk and the Src family 
kinases. It thus seems reasonable that the structure for binding these signalling 
molecules is optimal only in the context of the heterodimer. Indeed "cross-talk" 
between lg-a and lg-~ and co-modulation of the each other's activities may occur 
within the intact BCR. 
No major differences were observed between the signalling activities of IgM/ a 
and IgM/~. However, B cell maturation and activation are complex, involving 
several discrete stages throughout differentiation: progression through 
development in the bone marrow, allelic exclusion of both H and L chains, 
selection or deletion, migration into the periphery, activation, clonal expansion, 
antibody secretion, memory generation, affinity maturation. The roles of lg-a 
and lg-~ may vary in their contribution to BCR function at these stages, either by 
by mediating qualitatively different signals, or by signalling in different cellular 
contexts as the expression of possible downstream molecules for recruitment 
changes. It will be interesting to discover the biochemical mechanisms involved 
in each of these developmental checkpoints. 
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Figure 4.1 Transgene expression in spleen 
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(A) Expression of transgenic K. Histograms depict splenocytes stained with mouse anti-rat-K-biotin (revealed by SA-FITC) for flow cytometry 
and gated by scatter and PI exclusion. 
(B) Transgenic receptors identified by binding of HEL. Splenocytes were stained with rat anti-B220-PE and HEL (0.1 µg/ml) together with 
mouse anti-HEL (mAb HyHELlO), visualised by secondary goat anti-IgGl-FITC. Histograms were gated by scatter, PI exclusion and for B220+ 
cells. Shaded histograms denote secondary antiserum controls (since a few splenic B cells express endogenous IgGl BCRs). (C) Transgenic receptors identified by Dl .3 idiotype. Splenocytes from non-transgenic (Non-tg) and transgenic mice were stained with rat 
anti-B220-PE and mouse anti-Dl.3 idiotype-FITC, and were gated by scatter and PI exclusion. Plots are representative (see Table 4.1) and 
numbers denote percentage of splenocytes in each quadrant. 
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Figure 4.2 Transgene expression in T cells 
(A) Surface transgene expression on splenic T cells . Cells from 
non-transgenic (Non-tg) or IgM/~Y->L spleens were stained using a 
combination of rat anti-Thyl.2-biotin (revealed by SA-PE), goat 
anti-IgM-FITC, mouse anti-Thyl.2-FITC, mouse anti-rat K-biotin 
(with SA-PE), rat anti-CD4-PE, rat anti-CD8-FITC, and mouse 
anti-Dl.3 idiotype-biotin (SA-FITC or SA-PE) . Histograms were 
gated by scatter, PI exclusion and as indicated in the figure. 
(B) Cytoplasmic µ expression in thymocytes. Cells from IgM/~Y->L 
thymus were stained directly (surface), or after fixation and 
permeabilisation (cytoplasmic) with rat anti-Thyl.2-biotin 
(revealed by SA-PE) and goat anti-mouse IgM-FITC. 
(C) Expression is not increased after T cell activation with Con A. 
Splenocytes were stained freshly or after incubation of 24 h in the 
absence (- Con A) or presence ( + Con A) of concanavalin A. Those 
stained with rat anti-Thyl.2-biotin (revealed by SA-RED670), rat 
anti-CD44-PE and rat anti-CD25-FITC were gated by scatter and 
Thy1.2+, whereas those stained with rat anti-CD4-PE, hamster 
anti-CD69-FITC, and goat anti-IgM-biotin (SA-RED670) were gated 
by scatter and CD4+ (numbers denote percentage within region) . 
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Figure 4.4 More rapid turnover of transgenic B cells in vivo 
Mice were administered BrdU for 72 h before cells from bone marrow and spleen were surface stained with rat anti-B220-PE and either mouse 
anti-Dl.3 id iotype or goat anti-IgM-biotin (revealed by SA-RED670). Cells were fixed and permeabilised prior to DNaseI digestion and staining 
with mouse anti-BrdU-FITC. Flow cytometric profiles were gated by scatter and 8220+. Whereas 50% of bone marrow IgM+ and 15% of splenic 
IgM+ B cells from the non-transgenic (Non-tg) controls had incorporated BrdU, the proportions increased to 60-90% and 30-50% in bone marrow and 
spleen respectively of Dl.3+ B cells from the transgenic mice (except IgM/~Y->L splenic B cells which behaved similarly to non-transgenic). 
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Figure 4.5 Expression of cell differentiation markers on reconstituted B cells 
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(A) Peritoneal B-1 population. Cells washed from the peritoneal cavity of non-transgenic (Non-tg) 
controls or transgenic mice crossed into a µMT background were ~tained with rat anti-B220-PE and 
rat anti-CD43-biotin (revealed by SA-RED670) and gated by scatter. The CD43+B220+ cells 
represented 20% of the total B220+ cells for all mice. 
(B) Pro- and pre-B cell pools in bone marrow. Bone marrow cells from mice as above were stained 
with rat anti-B220-PE,rat anti-CD43-biotin (revealed by SA-RED670) and goat anti-IgM-FITC. 
Dot plots were gated by scatter and B220+. 
(C) Expression of mature B cell markers CD22, CD21/35 and CD23 on splenic B cells. Splenocytes 
from mice as above were analysed: for CD22 expression by staining with rat anti-B220-PE, mouse 
anti-CD22-biotin (visualised with SA-RED670) and goat anti-IgM-FITC, gating by scatter and 
B220+; for CD21/35 expression by staining with rat-anti-B220-PE, goat anti-IgM-FITC and 
CD21/35-biotin (with SA-RED670), gating by scatter andB22o+rgM+; for CD23 expression by 
staining with rat anti-B220-FITC and rat anti-CD23-PE, gating by scatter and B220+. Shaded 
histograms represent expression on non-transgenic B cells. 
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Figure 4.6 Reduced proliferation of transgenic B cells 
(A) Response to anti-IgM and IL-4. Mean triplicate values of radioactive counts (cpm, counts per 
minute) were plotted on a logarithmic scale for splenocytes from non-transgenic (Non-tg) 
controls of transgenic mice in a µMT background that were cultured with 10 µg/ml goat anti-IgM 
F(ab')z + 100 U/well IL-4 or IL-4 alone. (n==l in the results shown, however, they are typical of 
other experiments.) 
(B) Response to LPS. Mean triplicate values for splenocytes from mice as above cultured in 
medium alone or supplemented with 1.0 µg/ml LPS. 
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Figure 4.7 Increased cell death of reconstituted B cells in vitro 
Splenocytes from non-transgenic (Non-tg) controls or transgenic mice crossed into a µMT 
background were cultured in the absence and presence of 10 µg/ml goat anti-IgM F(ab'h for 
indicated times before staining with rat anti-B220-PE and fixation for TUNEL (TdT-mediated 
dUTP nick end labelling) with dUTP-biotin (revealed by SA-FITC). Dot plots show cells gated 
as B220+. 
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Figure 4.8 Upregulation of B7 mediated by IgM/a and IgM/~, but not IgMf~Y->L 
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(A) Timecourse in response to LPS. Splenocytes from non-transgenic mice were cultured for a total of 24 h with the addition of 50 µg/ml LPS for incubation periods of 0, 6, 12 and 24 h, followed by staining for flow cytometric analysis with rat anti-B220-PE and mCTLA4-Hyl (revealed by goat 
anti-human IgG-FITC). Histograms were gated by scatter, PI exclusion and B220+. (B) IgM/a and IgM!/3 upregulate B7 in response to anti-IgM. Splenocytes from non-transgenic (Non-tg) controls or transgenic mice crossed into a µMT background were cultured in the presence of 10 µg / ml goat anti-mouse IgM F(ab'h for 24 h. Flow cytometric analysis was performed as above and 
shaded histograms indicate medium alone controls. 
(C) B7 response to HEL and anti-idiotype. Cells from mice in a wild type (i.e. non-µMT) background were analysed as in (B) after incubation with 1.0 µg/ml HEL or 1.0 µg / ml anti-Dl.3 idiotype, mAb ES.2. 
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Figure 4.9 Allelic exclusion of endogenous IgH 
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(A) Exclusion of IgD. Splenocytes from transgenic or non-transgenic (Non-tg) mice were stained with rat anti-B220-FITC, 
mouse anti-Dl.3 idiotype-biotin (revealed by SA-RED670) and rat anti-IgD-PE, and flow cytometry plots were gated by 
scatter and B220+. Numbers denote percentage of splenic B cells within each quadrant. 
(B) Allotype exclusion. Splenocytes from non-transgenic (IgHaxigHb) Fl mice or transgenic mice crossed into an IgHb 
background were stained with rat anti-B220-PE, either 01.3-idiotype-biotin or mouse anti-IgMa-biotin (visualised with 
SA-RED670) and mouse anti-IgMb-FITC, gating as above. 
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(A) Exclusion of IgD. Splenocytes from transgenic or non-transgenic (Non-tg) mice were stained with rat anti-B220-FITC, 
mouse anti-Dl.3 idiotype-biotin (revealed by SA-RED670) and rat anti-IgD-PE, and flow cytometry plots were gated by 
scatter and B220+. Numbers denote percentage of splenic B cells within each quadrant. 
(B) Allotype exclusion. Splenocytes from non-transgenic (IgH3 xlgHb) Fl mice or transgenic mice crossed into an IgHb 
background were stained with rat anti-B220-PE, either Dl.3-idiotype-biotin or mouse anti-IgM3-biotin (visualised with 
SA-RED670) and mouse anti-IgMb-FITC, gating as above. 
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Figure 4.10 The (IgM/a)x(IgM/~) double transgenic mouse 
(A) (IgM/a)x(IgM!/3) expresses similar levels of transgenic receptors as the IgM//3 parent. Cells 
were treated as in Fig. 4.lC, gating by scatter and PI exclusion. Numbers denote percentage of 
splenocytes in each quadrant. 
(B) Upregulation of B7 in response to HEL and anti-Id by splenic ,B cells. Cells were cultured as 
in Fig. 4.SC with 1.0 µg/ml HEL or 10 µg/ml anti-Dl.3 idotype, mAb ES.2, and analysed for 
binding of mCTLA4-Hyl fusion protein. Histograms are gated for B220+ and shaded histograms 
depict medium alone controls. 
(C) (IgM/a)x(IgM//3) exhibits efficient exclusion of endogenous IgH. Cells were stained as in 
. Fig. 4.9A and were gated as B220+. Numbers indicate splenic B cells present in quadrants. 
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Chapter 5: Results 
Developmental effects of a µ transgene driven by the K enhancers 
In the previous chapter, the chimeric IgM/ a and IgM/~ transgenes did not 
inhibit endogenous IgH expression to the same extent as the wild type IgM 
transgene, suggesting that the compromised BCRs mediated less efficient 
signalling in allelic exclusion. Thus, the quality of BCR signal appears to be a 
major factor in fully effective allelic exclusion. However, if allelic exclusion is 
regarded as a race for productive rearrangement, it is evident that the timing of 
BCR expression is also an important determinant. Transgenes bearing rearranged 
V H regions ought to be expressed as receptors before endogenous VH 
rearrangement, resulting in efficient inhibition of endogenous IgH expression. 
Indeed, transgenes bearing VH region miniloci seem less effective at mediating 
allelic exclusion (Briiggemann et al., 1989). Miniloci transgenes, as well as the 
endogenous IgH, need to undergo V region rearrangement before their 
expression as receptors in order to inhibit the competing alleles. 
In contrast, both rearranged µ transgenes and those bearing V region miniloci 
can rescue B cell development in a µMT B cell-deficient mice blocked at the pro-
B cell stage (chapter 4, (Kitamura et al., 1991; Wagner et al., 1994)). The 
differentation checkpoints of allelic exclusion and pro- to pre-B cell transition 
both result from pre-BCR signalling, occuring at similar stages in early 
development. However, the timing of receptor expression may need to be more 
critical for allelic exclusion than for the pro- to pre-B cell transition. Under the 
threat of competition from the other allele, transcription of . a rearranged µ must 
occur before the other in order to ensure exclusion. The generation of pre-B cells 
in µMT mice may have more flexible timing restrictions since the pro-B cell may 
be able to "wait", providing a functionally rearranged µ chain is expressed within 
the time window before the pro-B cell dies . 
In order to test the timing hypothesis, the expression of a rearranged µ transgene 
was postponed by placing it under the transcriptional regulation of the two 
enhancers from the K L chain gene. Thus, the effect of delayed µ expression on 
early B cell development could be assessed from allelic exclusion and 
reconstitution of the peripheral B cell pool in µMT B cell-deficient . mice. 
Chapter 5: Results µ transgene driven by K enhancers 100 
I 
11 I 
, 'I 
5.1 VNpCµ[Ei,E3']K does not mediate allelic exclusion. 
Transgenic founder lines, that were originally generated for somatic 
hypermutation experiments (N. Klix et al., in preparation), carry a 
VNpCµ[Ei,E3']K transgene (Fig. 5.lA) based on pSV-Vµl (a genomic clone of µ 
with a rearranged Vtt region bearing anti-NP specificity) (Neuberger, 1983). The 
IgH enhancer (Eµ) was replaced by the K intron enhancer/matrix attachment 
region (Ei/MAR), and the K 3' enhancer (E3') was placed downstream of the 
coding regions. K L chain expression appears not to be required until after µ H 
chain expression in B cell development, therefore regulation by the K enhancers 
might delay the expression a µ transgene. The availability of the VNpCµ[Ei,E3']K 
transgenic mice made it possible to address the importance of timing of pre-BCR 
expression in allelic exclusion and B cell maturation, and also gave an indication 
of the activation of the K enhancers during early B cell development. 
The ability of the VNpCµ[Ei,E3']K transgene to mediate allelic exclusion was 
assayed as in chapter 4. In the absence of specific L chain, the VNrCµ[Ei,E3']K 
transgenic µ chain could not be identified by an anti-idiotype (unlike the anti-
HEL transgenic mice). However, the transgenic µ (of the IgHa allotype) could be 
discriminated from endogenous IgM by breeding VNrCµ[Ei,E3']K into an IgHb 
background. Non-transgenic (IgHa x IgHb) Fl mice exhibited efficient allotype 
exclusion in that the splenic B cells expressed either IgMa or IgMb, but not both 
allotypes (Fig. 5.lB). In contrast, the VNpCµ[Ei,E3']K transgene (IgMa) was 
ineffective at inhibiting the expression of endogenous IgMb and most of the B 
cells that expressed the transgene co-expressed the endogenous allotype. 
The B cells that expressed endogenous IgH were also be detected by their 
expression of IgD. Most of the VNpCµ[Ei,E3']K splenic B cells expressed IgD in a 
profile similar to the non-transgenic Fl (Fig. 5.lB) and this lack of suppression of 
IgD expression is consistent with the lack of allotype exclusion. 
The effect of the VNrCµ[Ei,E3']K transgene on allelic exclusion is in contrast to 
that of the IgM transgene in the previous chapter (see Fig. 4.9A). Thus, 
VNpCµ[Ei,E3']K appears not to be expressed early enough in B cell development 
to prevent the expression of endogenous IgH. 
5.2 VNpCµ[Ei,E3']K does rescue B cell development in a µMT background. 
Although the lack of allelic exclusion may be attributable to the timing of 
VNpCµ[Ei,E3']K expression, it was not clear that the K enhancers were even 
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sufficient to activate transcription of the µ transgene at the late pro-/pre-B cell 
stage for its expression in a pre-BCR. Some VK rearrangement has been observed 
in µMT mice (which bear a germline disruption of the membrane exons of µ) 
(Ehlich et al., 1993; Kitamura et al., 1991), suggesting that the K regulatory 
elements can still initiate rearrangement despite the block in pro-/pre-B cell 
development and in the absence of a pre-BCR. However, the VK rearrangment 
was detected at low frequency, and it has been suggested that pre-BCR signals 
induce the further activation of the K locus (Iglesias et al., 1991; Reth et al., 1987; 
Tsubata and Reth, 1990). 
In order to determine whether the K enhancers were activated early enough to 
drive the transcription of the rearranged µ transgene for pre-BCR signalling, the 
mice were crossed into a µMT background. Non-transgenic µMT mice, which 
cannot express surface IgM, had no IgM+B22Q+ cells in the bone marrow (Fig. 5.2). 
In contrast, the VNpCµ[Ei,E3']K transgene was able to reconstitute a B22Q+IgM+ 
population in the bone marrow. Indeed, it is clear from the B22Q+IgM+ cells also 
present in the VNpCµ[Ei,E3']K spleen (Fig. 5.2) that the transgene rescues the µMT 
phenotype and can effect the maturation of a peripheral B cell pool. 
These results indicate that the K enhancers are active at the late pro-/pre-B cell 
stage and are able to drive expression of a rearranged µ transgene. In the absence 
of endogenous competition, VNpCµ[Ei,E3']K can indeed function as a pre-BCR, 
suggesting that once a functional µ chain is expressed (even if later than usual), 
the B cells can continue to mature and migrate into the periphery. 
5.3 Discussion 
Placing a rearranged µ transgene under the regulatory control of the K Ei/MAR 
and E3' resulted in its expression in B cells, but seemed to modify its timing and 
therefore its effect on developmental processes. VNpCµ[Ei,E3']K did not mediate 
allelic exclusion, but did rescue the µMT phenotype, suggesting that the K 
enhancers mediated transcription of the rearranged µ transgene at a stage 
between allelic exclusion and pro- to pre-B cell progression in B cell 
differentiation. 
VNpCµ[Ei,E3']K was unable to cause exclusion of the endogenous IgH loci. This 
was not due to a defect in the ability of the transgenic µ to function as a pre-BCR, 
since in the absence of competing membrane µ, it could rescue B cell 
development in a µMT background . Rather, its inability to mediate allelic 
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exclusion can be explained by the differential timing of endogenous µ expression 
( driven by Eµ) compared to the transcriptional activity of the K enhancers. These 
results reveal that the K enhancers do not seem to become active until after Vtt 
rearrrangement, but appeared to be active (presumbly earlier than necessary for K 
rearrangement) before the µMT block in B cell development (fraction C; Ehlich et 
al., 1993; Hardy et al., 1991). These indications of K enhancer activity are in 
aggreement with the detection of endogenous VK rearrangement in µMT mice 
(Ehlich et al., 1993), and with reports of sterile K transcription in late pro-/pre-B 
cell subpopulations (Grawunder et al., 1995). 
The timing in expression of VNpCµ[Ei,E3']K is later than that of µ transgenes 
driven by Eµ. The delay in transcription appears to be regulated by the K 
enhancers, although it was not possible to discriminate the relative contributions 
of Ei/MAR and E3' . One could only speculate on their roles in transcription of 
VNpCµ[Ei,E3']K. From experiments in cell lines, Ei has been thought to play a 
predominant role in early developmental events such as demethylation and VK 
rearrangement in pre-B cells (Chen et al., 1994; Klug et al., 1994; 
Lichtenstein et al., 1994). Since the VNpCµ[Ei,E3']K transgene already has a 
rearranged V region, its expression gave an indication of the activities of the K 
enhancers in locus accessibility and transcriptional regulation. It would be 
necessary to monitor the activities of Ei/MAR and E3' independently in order to 
determine whether transcription of the K locus is indeed controlled only by 
Ei/MAR. Alternatively, if Ei/MAR was essential only for demethylation and VK 
' rearrangement, but not transcription, E3' may be sufficient drive the I ' 
transcription of a rearranged K transgene. 
The K Ei/MAR and E3' together are sufficient to drive the expression of a 
rearrangedµ transgene at a late pro-/pre-B cell stage just after Vtt rearrangement, 
resulting in the rescue of B cell development in µMT mice. Their independent 
contributions to transcriptional regulation in early B cell development should be 
determined and one approach for discriminating their roles could be to analyse 
the effects of deleting Ei/MAR or E3' from a rearranged K transgene. 
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(A) VNpCµ[Ei,E3']/( transgene construct based on pSV-Vµl. The IgH ,enhancer (Eµ) in the J-C 
intron of pSV-Vµl was exchanged for the K intron enhancer (Ei), and the K 3' enhancer (E3') was 
inserted 3' of theµ coding regions. 
(B) V NPCµ[Ei,E3 'JI( does not inhibit endogenous IgH expression. Splenocytes from (IgH3xlgHb) 
Fl mice or VNPCµ[Ei,E3']K mice were stained with rat anti-B220-PE, and either mouse 
anti-IgM3 -biotin (revealed by SA-RED670) with mouse anti-IgMb-FITC, or sheep anti-mouse 
IgD-FITC. Dot plots and histograms were gated by scatter and B220+. 
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Cells from bone marrow and spleen of non-transgenic (Non-tg) wild type or µMT controls or 
V NPCµ[Ei,E3' ]K crossed into a µMT background were stained with rat anti-B220-PE and goat 
anti-IgM-FITC for flow cytometric analysis, gating by scatter and PI exclusion. Numbers denote 
percentage of cells in quadrant or region. 
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Chapter 6: Results 
Transcriptional regulation by the K enhancers during B cell 
development 
The previous chapter showed that the two enhancers from the immunoglobulin 
K light chain gene were able to drive the expression of a rearranged µ transgene 
(VNpCµ[Ei,E3']K), leading to reconstitution of peripheral B cells in a µMT 
background, but not allelic exclusion of endogenous IgH alleles. These findings 
suggested that the K enhancers become activated at a precise time in pro- /pre-B 
cell development after Vtt rearrangment. However, it was not clear what the 
relative contributions of the two K enhancers were to the transcriptional activity 
at that differentiation stage. The K intron enhancer (Ei), located in the JK-CK 
intron (Picard and Schaffner, 1984), and the K 3' enhancer (E3'), situated 9 kb 
downstream of CK (Meyer and Neuberger, 1989), bind different sets of 
transcription factors (Pongubala and Atchison, 1991; Staudt and Lenardo, 1991). 
Thus, the two enhancers presumbly play distinct roles in controlling different 
events at the K gene locus thoughout B cell development. 
Prior to commencement of this study, the literature might have suggested that 
the transcriptional regulation,at the pre-B cell stage was mostly attributable to Ei, 
since Ei seemed to be involved primarily in processes early in B cell 
development. Cell line transfection experiments suggested that Ei is essential not 
only for transcription, but for demethylation, germline K expression (sterile 
transcription), and VK rearrangement (Chen et al., 1994; Klug et al., 1994; 
Lichtenstein et al., 1994). Indeed gene-targetted disruption of Ei by insertion of a 
neo gene in rri.ice abolished VK rearrangement (Takeda et al., 1993). In contrast, 
E3' has been assumed not to become important until later stages in B cell 
development. E3' activated reporter gene expression only weakly in a mature B 
cell line, yet greatly enhanced expression in plasmacytomas (Fulton and Van 
Ness, 1993; Meyer et al., 1990). Furthermore, E3' has been shown to be neccessary 
for high levels of expression in transgenic mice (Betz et al., 1994; Meyer et al., 
1990). 
In this chapter, the relative roles of Ei and E3' in the transcriptional regulation of 
rearranged K could be addressed in mice expressing of K transg~nes containing 
either Ei/MAR or E3' . The results described here indicate that E3' seems to be the 
more important of the two enhancers for transcription, becoming active at the 
pre-B cell stage when the locus is accessible for sterile transcription prior to VK 
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rearrangement. 
6.1 The K enhancers have been shown to be important for somatic 
hypermutation in transgenic mice and expression in hybridomas. 
Transgenic mice, established previously for somatic hypermutation experiments, 
were used in this study to investigate the relative importance of the two K 
enhancers in regulating transcription and expression during B cell development. 
The different transgene constructs were derived from L K, composed of a 
rearranged mouse VKOx exon linked to a rat CK exon (to facilitate discrimination 
from endogenous mouse K)and regulated by Ei and the adjacent matrix 
attachment region (Ei/MAR) and E3' (Fig. 6.1) (Meyer et al., 1990). Ei/MAR and 
E3' were deleted independently to form LKL'.i[Ei/MAR] and LKL'.i[E3'] respectively 
(Betz et al., 1994). 
Founder lines differing in transgene copy number (denoted in superscript) have 
been analysed in a previous report (Betz et al., 1994) (notation in different reports 
is clarified in Materials and Methods). Lines LK3 and LK6, LKL'.i[Ei/MAR]4 and 
LKLi[Ei/MAR]7, and LKL'.i[E3']2 are also presented in this study. The second 
L KLi[E3']5 founder was lost, but a third LKL'.i[E3']6 founder was analysed here 
instead. The founder lines bearing the LK and LKLi[Ei/MAR] transgenes gave 
consistent results. Interestingly, although LK~[E3']5 has previously been shown to 
behave similarly to LKL'.i[E3']2, LKLi[E3']6 differed in this chapter, and this line-to-
line variation will be discussed. 
It has been shown that these transgenes differ in their abilities to undergo 
somatic hypermutation and the conclusions are summarised in Fig. 6.1 (Betz et 
al., 1994). Although LK contained sufficient information to hypermutate, 
deletion of either Ei/MAR or E3' abrogated mutation, suggesting that both 
enhancers are necessary for targetting the hypermutation process. 
If high levels of expression are required to drive the hypermutation machinery, 
loss of mutation could merely be due to reduced transcriptional activity. 
Therefore hybridomas generated from the transgenic m'ice were analysed for 
transcription of the transgenes. The levels of transgenic mRNA from the 
LK~[E3'] hybridomas were greatly reduced indicating that E3' is necessary for high 
level K expression. In contrast, transgene expression of LK~[Ei/MAR] was similar 
to LK, suggesting that deletion of Ei/MAR had little effect on transcription, 
unlike hypermutation, at the terminal stage in differentiation. 
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The obvious importance of Ei/MAR to the somatic hypermutation process is 
under investigation by others, however, these findings also suggest that E3' is 
both essential and sufficient (in the absence of Ei/MAR) for transcription in 
hybridomas. Since hybridomas are only a model for the terminal antibody-
secreting plasma cell stage in B cell differentiation, it was obviously interesting to 
determine whether E3' also plays a critical role in K expression earlier in B cell 
development. 
6.2 K transgene expression in germinal centre cells from Peyer's patches 
In the previous studies of the K transgenic mice, hybridomas were established in 
order to correlate transcription of the transgenes with their ability to 
hypermutate. However, hybridomas are believed to represent terminally-
differentiated plasma cells and may not accurately reflect processes that occur in 
the mature B cells undergoing somatic hypermutation within the germinal 
centre (GC). 
Peyer's patches, lymphoid tissue in the gut containing a large proportion of 
somatically hypermutating B cells, were dissected, and the GC B cells were 
identified by binding high levels of the lectin peanut agglutinin (PNA). All the 
transgenic mice revealed good expression of their transgenes in the PNAhi cells 
(Fig. 6.2), although the levels might differ slightly. The few cells that expressed 
endogenous K also expressed it to high levels. It was most noticeable, however, 
that different lines varied in the proportions of cells expressing transgenic versus 
endogenous K. In LK mice, almost all the PNAhi cells expressed transgenic K, but 
very few expressed endogenous K. Most of the PNAhi cells in mice from both 
L K~[Ei/MAR] founder lines also expressed the transgene, indicating that 
Ei/MAR is not necessary for good expression in GC B cells. 
The LK~[E3'] mice gave conflicting results (Fig. 6.2). LK~[E3']6 behaved like LK6, 
whereas L~[E3']2 had almost reversed ratios of transgene+ : endogenous K+ cells. 
These findings suggest that E3' may be required for efficient expression of K, but 
that integration effects may compensate for its absence. 
6.3 LK and LKMEi/MAR] exclude endogenous K expression on splenic B cells. 
Although GC B cells are at a mature B cell stage in development, they are 
specialised cells that have been activated by antigen and have migrated into the 
GC to hypermutate. They may have undergone proliferation, class-switching or 
differentiation into memory B cells, and thus are a population selected by 
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antigen. Since most B cells in the periphery are waiting to interact with antigen, 
spleens from the transgenic mice were analysed to determine the activity of E3' 
on K expression in resting mature B cells. 
Splenic B cells (identified by IgM) from both LK founder lines expressed high 
levels of transgenic K, but very few expressed endogenous K (Fig. 6.3). Similarly, 
the absence of Ei/MAR had little effect on the expression levels of transgenic K, 
although a few more cells expressed endogenous K with only slight variation 
between the two founders. Furthermore, double-staining for both transgenic and 
endogenous K revealed that the LK and LKLi[Ei/MAR] cells exhibited allelic 
exclusion, suggesting that expression of the endogenous K genes was inhibited by 
L K and also by LKLi[Ei/MAR], to a slightly lesser extent. The good expression 
(similar to LK) of the LKLi[Ei/MAR] transgene containing E3' in the absence of 
Ei/MAR, indicates that Ei/MAR is not required, but that the presence of just E3' 
alone seems sufficient for high levels of transcription of a rearranged K 
transgene. Additionally, E3' appears to be active early in B cell development, 
driving expression to cause allelic exclusion. 
In contrast to these findings, the deletion of E3' dramatically affected the levels of 
expression of the transgene in LKLi[E3']2 and also its ability to inhibit expression 
of the endogenous alleles (Fig. 6.3). Thus, transgenic K expression suggests that in 
the LKLi[E3']2 founder line, E3' is essential for both transcription and allelic 
exclusion. However, the LKLi[E3']6 founder behaved more similarly to LK6 than 
even LK3. 
(Although three out of six profiles in Fig. 6.3 were obtained with flow cytometry 
settings differing from the other three, additional experiments have 
demonstrated that the flourescence intensities of LK3 and LK6 [positive controls 
for the other transgenes] are equivalent.) 
6.4 K expression in LPS-activated B cell blasts 
Having observed the effect of the K transgenes in mature splenic B cells, the 
transgenes were analysed in splenic B cell populations that had differentiated 
into antibody-secreting blasts in order to monitor any changes in expression 
pattern mediated by the K enhancers following cellular activation . . 
After culturing splenocytes with LPS to induce terminal differentation, 
cytoplasmic expression of the transgenes did not reveal any significantly altered 
Chapter 6: Results Transcriptional regulation of 1C 110 
I , 
ii I 
111 
I 
1 I 
I 
distribution (Fig. 6.4), reinforcing the observation that the ratio of transgene- to 
endogenous K-expressing cells seems to reflect the ability of the transgenes to 
inhibit expression of the endogenous K alleles. 
Transgene expression was high in cells from all transgenic lines, except LK[E3']2 
(Fig. 6.4). It was not possible, however, to dis.criminate whether deletion of E3' in 
L K[E3']2 affected the proportion of cells that expressed transgenic K in a 
heterogeneous population, or affected the levels of expression within each cell. 
Indeed, analysis of cloned hybridomas from these mice suggested that E3' is 
necessary for high levels expression at this terminal stage in differentiation (Betz 
et al., 1994). 
In each transgenic line, the expression pattern of that particular transgene was 
consistent in GC, spleen and LPS-activated spleen from that line. The major 
differences observed between the different transgenes seemed to be their abilities 
to inhibit endogenous K expression, that is, to mediate allelic exclusion. Since the 
LK~[Ei/MAR] transgene behaved almost as efficiently as LK, Ei/MAR does not 
appear to be necessary for expression of a rearranged K transgene and in fact, 
despite suggestions that E3' is important only later in B cell development, E3' 
seems to be active early enough for driving transcription at sufficient levels to 
effect the exclusion of endogenous K. 
Further characterisation of the transcriptional activity of E3' proceeded as a 
collaboration with Kerstin Meyer: I prepared the lymphoid tissues for F ACS, 
whilst she performed the RT-PCR analysis. 
6.5 E3' drives the lymphoid-specific transcription of a heterologous reporter gene. 
It is clear that Ei/MAR is not necessary for either the efficient expression of a 
rearranged K transgene or the inhibition of endogenous K expression, suggesting 
that the activity of E3' (in the absence of Ei/MAR) is sufficient. In order to further 
analyse the role of E3' in transcription, a transgene bearing a heterologous 
human p-globin reporter gene with E3' placed downstream of the coding 
sequences (PG[E3']) (Fig. 6.5A) was introduced into mice. This approach facilitated 
the characterisation of E3' activity in isolation of any other K sequence that may 
contribute to transcriptional regulation or mRNA stability. Thus, E3' could be 
tested for tissue-specificity, and the stage at which it is activated could be 
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determined. 
The initial analysis of tissues from ~G[E3'] mice by RT-PCR (reverse transcriptase-
polymerase chain reaction) analysis, using HPRT (hypoxanthine phosphoribosyl 
transferase) transcripts as an internal controls, revealed that, although the 
transgene was expressed in spleen and bone.marrow, ~G[E3'] transcripts were not 
detected in liver (Fig. 6.5B). Thus, E3' was able to drive the lymphoid-specific 
expression of the reporter gene in viva. 
6.6 The transcriptional activity of E3' is B cell-specific. 
Although E3' was able to drive expression in lymphocytes, it was necessary to 
establish that its activity was restricted to the B cell lineage. Although IgH is 
normally expressed only in a B cell-specific manner, Eµ can drive the expression 
of transgenes in the T cell lineage (see Fig. 4.2; Cook et al., 1995). Indeed, there 
have been suggestions that E3' exhibits activity in thymocytes (Hiramatsu et al., 
1995) and that K transgenes are expressed in the thymus (Storb et al., 1996; Lamers 
et al., 1989; Xu et al., 1981). 
When ~G[E3'] splenocytes were fractionated by FACS (fluorescence-activated cell 
sorting) into B22Q+ and Thyl.2+ populations (Fig.6.6A), transgenic transcripts 
were expressed in the splenic B cells but not in the T cells (Fig. 6.6B) . 
Additionally, transgene expression was not detected in newborn thymus, 
although newborn spleen contained transcripts (Fig. 6.6C). (Newborns were 
analysed to minimise the risk of contamination of the thymus by lymph node B 
cells at that age.) Therefore E3' does not seem to drive transcription in the T cell 
lineage, but is transcriptionally active only in B cells. 
6.7 E3' is transcriptionally active in pre-B cells. 
The inhibition of endogenous K expression evident in LKL1[Ei/MAR] mice, as 
well as LK mice, indicated that expression of a rearranged K transgene driven by 
E3' was effective enough to mediate allelic exclusion. E3' seemed to be not only 
sufficient for good expression, but more importantly, to become activated before 
most endogenous VK rearrangement, rather than only in the later stages of B cell 
development. In order to determine the differentiation stage at which E3' 
becomes active, bone marrow B cell precursors were sorted by F ACS. 
BP-1 is a cell differentiation molecule whose surface expression at a discrete stage 
in B cell development, fractions C and D (Hardy et al., 1991), defines the late pro-
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1t which is lost on progression to the 
~ marrow from ~G[E3'] mice were 
based on the levels of BP-1 expression 
xpected to contain ~G[E3'] transcripts 
2nt, as well as pro-B cells (Fig. 6.7B). 
ed in the B22Q+BP-1 + pre-B cell 
~ transcription at the pre-B cell stage. 
-- · .... .1rve transcription in pro-B cells. 
E3' appears to be active in pre-B cells at a time when the K locus is preparing for 
V K rearrangement. At the earlier pro-B cell stages, though, only Vtt 
rearrangement is necessary. Nevertheless, it is possible that E3' becomes active 
earlier, since the LKL1[Ei/MAR] seemed to be expressed before rearrangement of 
the endogenous VK alleles. 
CD43 is another cell surface marker that has been used in the fractionation of B 
cell subpopulations in the bone marrow, allowing discrimination of the CD43+ 
pro-B cells (fractions A to C; Hardy et al., 1991) from the later stages of B cell 
differentiation that have lost CD43 expression (fraction D onwards), the only 
exception being the expression of CD43 on the B-1 cells in the peritoneum. The 
analysis of ~G[E3'] bone marrow that was enriched for the presence or absence of 
CD43 on B subpopulations (Fig. 6.8A) revealed that although transcription of the 
transgene was detected on B22Q+CD43- pre-B and B cells, ~G[E3'] was not 
transcribed in the pro-B cells that were B22Q+CD43+ (Fig. 6.8B). Thus, E3' appears 
to become transcriptionally active around the pro- to pre-B transition before VK 
rearrangement occurs, but at a time when the cells no longer express CD43 (see 
Fig. 1.3 in Introduction). 
6.9 Discussion 
The expression of rearranged K transgenes and the inhibition of endogenous K in 
the mature B cells of LK, LKL1[Ei/MAR] and LKL1[E3'] mice suggested that E3' was 
sufficient to direct high levels of transgene expression causing allelic exclusion 
early in B cell development. Further characterisatio·n of the transcriptional 
activity of E3' linked to a ~-globin reporter gene indicated that E3' does indeed 
become active in pre-B cells at the stage when sterile K transcripts are detected 
and when RAG expression is upregulated (Grawunder et al., 1995), suggesting a 
role in regulating locus accessibility prior to VK rearrangement. 
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and pre-B cells in the bone marrow, but which is lost on progression to the 
1mmature B cell stage. Therefore, bone marrow from PG[E3'] mice were 
fractionated into B lineage subpopulations based on the levels of BP-1 expression 
(Fig. 6.7 A). The B22Q+BP-1- fraction was expected to contain PG[E3'] transcripts 
since immature/mature B cells were present, as well as pro-B cells (Fig. 6.7B). 
Trans gene expression was also detected in the B22Q+ B P -1 + pre-B cell 
compartment, indicating that E3' can induce transcription at the pre-B cell stage. 
6.8 E3' does not drive transcription in pro-B cells. 
E3' appears to be active in pre-B cells at a time when the K locus is preparing for 
V K rearrangement. At the earlier pro-B cell stages, though, only Vtt 
rearrangement is necessary. Nevertheless, it is possible that E3' becomes active 
earlier, since the LK~[Ei/MAR] seemed to be expressed before rearrangement of 
the endogenous VK alleles. 
CD43 is another cell surface marker that has been used in the fractionation of B 
cell subpopulations in the bone marrow, allowing discrimination of the CD43+ 
pro-B cells (fractions A to C; Hardy et al., 1991) from the later stages of B cell 
differentiation that have lost CD43 expression (fraction D onwards), the only 
exception being the expression of CD43 on the B-1 cells in the peritoneum. The 
analysis of PG[E3'] bone marrow that was enriched for the presence or absence of 
CD43 on B subpopulations (Fig. 6.8A) revealed that although transcription of the 
transgene was detected on B22Q+CD43- pre-B and B cells, PG[E3'] was not 
transcribed in the pro-B cells that were B22Q+CD43+ (Fig. 6.8B). Thus, E3' appears 
to become transcriptionally active around the pro- to pre-B transition before VK 
rearrangement occurs, but at a time when the cells no longer express CD43 (see 
Fig. 1.3 in Introduction). 
6.9 Discussion J I 
The expression of rearranged K transgenes and the inhibiti~n of endogenous K in 
the mature B cells of LK, LKMEi/MAR] and LK~[E3'] mice suggested that E3' w as 
sufficient to d irect high levels of transgene exp ression causing allelic exclusion 
early in B cell development. Further characterisation of the transcriptional 
activity of E3' linked to a P-globin reporter gene indicated that E3' does indeed 
become active in pre-B cells at the stage when sterile K transcripts are detected 
and when RAG expression is upregulated (Grawunder et al., 1995), suggesting a 
role in regulating locus accessibility prior to VK rearrangement. 
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The expression of the LK~[Ei/MAR] and LK~[E3'] transgenes parallels 
experiments using gene-targetted mice where the K enhancers were deleted by 
replacement with a recombined LoxP site. LKMEi/MAR] was expressed almost as 
well as LK and similarly, there was no apparent change in the level of basal K 
expression in E KND mice which lacked the genomic region containing Ei and its 
associated MAR (Xu et al., 1996). However; germline deletion of E3' in 3'EKD 
mice resulted in a two- to three-fold decrease in expression levels in resting B 
cells (Gorman et al., 1996), consistent with the requirement for E3' activity as 
shown by low level expression in LK~[E3']2 mice (and LK~[E3']5 in Betz et al., 
1994) and may possibly suggest that E3' behaves analogously to a locus control 
region (LCR) as described originally for the human ~-globin gene (Grosveld et al., 
1987). LCRs direct high-level and tissue-specific expression of transgenes, 
independent of their site of integration, perhaps by establishing an open 
chromatin structure (Dillon and Grosveld, 1993). Thus, a K transgene lacking the 
putative E3' LCR, would essentially be poorly expressed. However, position 
effects at the integration site may compensate for absence of an LCR, providing a 
possible explanation for the behaviour of the other LK~[E3']6 founder whose 
transgene expression was very similar to that of the intact LK construct. 
Consistent with the detection of different proportions of B cells that express 
transgene versus endogenous K, the E KND and 3'E K:0 mice exhibited altered 
ratios of K- to A-expressing B cells (of 1:1 and 2:1 respectively instead of 20:1 in 
non-transgenic mice), indicating impaired VK rearrangement and suggesting that 
Ei/MAR is more important than E3' for this event. Although the results 
described in this chapter compare the roles of Ei/MAR and E3' in the distinct 
processes of transcription of rearranged transgenes and rearrangment of 
endogenous VK, taken together, they shown that both K enhancers are involved 
in the activation of the K locus at this pre-B cell stage in development. 
Activation for sterile- transcription and VK rearrangement correlate with recently 
characterised molecular events at the K locus, and at E3' in particular. Although 
the interaction of the NFKB transcription factor with Ei seemed to be an 
attractive mechanism for regulation in early B cell development, in viva 
footprinting of primary cells revealed that the NFKB binding site of Ei was 
occupied at both pro- and pre-B stages (Shaffer et al., 1997). In contrast, at E3', an 
early type of chromatin structure was detected in pro- and pre-B cell lines, that 
persisted until the mature B cell stage (Roque et al., 1996). These results agreed 
with the genomic footprints of transcription factors already shown to bind E3', 
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such as CREM/ ATF-1 (Pogubala and Atchison, 1995) and PU.l/NF-EM5 (Pip-1) 
(Eisenbeis et al., 1995; Pongubala et al., 1992), and additionally showed the 
association of BSAP (Pax-5) (Busslinger and Urbanek, 1995). Changes in binding 
at E3' across the pro- to pre-B cell transition were further dissected in primary 
cells and suggested that although NFKB binding may be neccesary, activation of 
the K locus is regulated by factors that associate with E3' (Shaffer et al., 1997). 
Moreover, nuclear extracts from primary cells analysed by gel mobility shift 
revealed that BSAP and PU.l compete for binding. This led to the speculation 
that bound BSAP might inhibit PU.l binding in pro-B cells until the 
differentiative signal (via the pre-BCR) for progression to the pre-B cell stage 
when BSAP binding decreases and allows PU.l binding to increase. 
The chromatin structure and genomic footprinting of E3' in cells lines has also 
revealed a change on the transition from mature B cells to plasma cells (Roque et 
al., 1996). These findings are consistent with indications that E3' might be 
responsible for the increased expression in plasma cells that are necessary for 
antibody secretion (Blasquez et al., 1989; Meyer and Neuberger, 1989), and with 
our findings (not included in this chapter) that the activity of E3' in regulating 
the ~G[E3'] transgene is enhanced on LPS activation (Meyer et al., 1996). In 
contrast, a surprising result to arise from the germline deletion of E3' in 3'EKND 
mice, was that although expression was reduced in resting B cells, it was normal 
in LPS-activated B cells from these mice (Gorman et al., 1996). Whilst Ei/MAR 
may be partially compensating for the loss of E3' activity in 3'EKND, these results 
could point to the existence of an additional endogenous element, absent from 
transgenic constructs, that drives high level endogenous K expression (and 
cooperates with Ei/MAR) in the absence of E3'. 
There have also been indications that E3', although originally identified as a 
transcriptional enhancer, acts as a negative regulator in determining both T /B 
specificity and pro-B/pre-B specificity of VK rearrangment in transgenic mice 
(Hiramatsu et al., 1995). When E3' was deleted, the transgene containing 
germline VK and JK segments was observed to undergo rearrangement in splenic 
T cells. Premature VK rearrangement of the transgene was also observed in early 
pro-B cells, not only by the detection of rearranged VK substrates, but also by the 
presence of non-germline (N) nucleotides at recombination junctions which are 
only normally incorporated in Vtt rearrangement since TdT activity is absent in 
pro-B cells. However, no indications of E3' activity in pro-B cells or T cells were 
observed in this chapter. Whilst any negative regulation of the transcriptional 
Chapter 6: Results Transcriptional regulation of 1C 115 
readout would have gone undetected, it is possible that differenc
es in the precise 
nature of the transcription factors involved in these proc
esses, or their 
recruitment by the transgene substrates, result in alternative outc
omes. 
In conclusion, it is clear that the activities of E3' are sufficient to
 direct the high 
level transcription of a rearranged K at a time in B cell developm
ent when it can 
effect allelic exclusion. Although E3' seems to be domin
ant in driving 
transcriptional activity in this study, the gene-targetted deletions
 in E KND and 
3'EKD mice suggest that Ei/MAR and E3' may have overlapping
 functions, with 
their relative contributions varying in different processes (Gorman et al., 1996
; 
Xu et al., 1996). Whilst Ei may primarily influence rearrangement, E3' seems to
 
be important both in rearrangement and expression. However, 
neither element 
appears to be necessary for the expression of K in the gene-targ
etted mice and 
additional elements regulating the K locus remain to be identified
. 
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Figure 6.2 K expression in germinal centre B cells 
Cells from Peyer's patches of transgenic mice were stained with either mouse anti-rat K-biotin (transgenic K) or rat anti-mouse K-biotin (endogenous K) (both revealed by SA-PE) and peanut 
agglutinin (PNA)-FITC. Dot plots were gated by scatter and PI exclusion. 
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Figure 6.3 K expression and allelic exclusion in splenic B cells 
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Splenocytes from transgenic mice were stained with either mouse anti-rat K-biotin (transgenic K) or rat anti-m
ouse 
K biotin (endogenous K) (both revealed by SA-PE) and goat anti-IgM-FITC. For double-staining of K, goat an
ti-rat 
Ig-FITC was used to detect transgenic K. The plots (gated by scatter and PI exclusion) shown were analysed o
n two 
two different settings for flow cytometric analysis (LK~[Ei/MAR]4, LK~[Ei/MAR]7 and LK3; 
LK6, 
LK~[E3']2,LK~[Ei/MAR]6) but are representative of multiple individuals and other experiments have sh
own LK to 
be expressed to the same levels in both founders . 
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Figure 6.4 K expression in LPS-activated spleen 
After incubation of splenocytes from transgenic mice for 48 h in the presence of 50 µg/ml LPS, the cells were fixed 
and permeabilised prior to staining with either mouse anti-rat K-biotin (transgenic K) or rat anti-mouse K-biotin (endogenous K) detected by SA-PE. Gates for histograms were set for activated lymphocyte scatter and shaded 
histograms indicate SA-PE alone controls . 
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Figure 6.5 Lymphoid-specific transcription of the ~G[E3'] transgene 
0.5 kb 
I I 
(A) Schematic representation of f}:;[E3 '] transgene. The human ~globin reporter gene (coding 
regions shown as rectangles) is regulated by the lgK 3' enhancer (E3') placed downstream. 
(B) Transcription of f}:;[E3 '] in lymphoid tissues. cDNA prepared from liver (Li), spleen (Sp) 
and bone marrow (BM) of ~G[E3'] mice were analysed by RT-PCR detecting ~globin (~G) 
transcripts or HPRT as an internal control. (M, molecular weight markers) 
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Figure 6.6 Transcription of ~G[E3'] is B cell-specific. 
(A) Splenic B220+ B cell and Thy1.2+ T cell populations fractionated by FACS. Splenocytes 
from ~G[E3'] transgenic mice were stained with rat anti-B220-PE and mouse anti-Thyl.2-FITC 
and sorted by viable lymphocyte scatter and gated regions as indicated. 
(B) Expression of f{;[E3 '] in splenic B cells but not T cells. !3-globin (~G) transcripts were detected 
by RT-PCR analysis of serial dilutions of cDNA derived from the above FACS populations 
using HPRT as an internal control. (M, molecular weight markers) 
(C) f{;[E3'] is not expressed in thymus . Spleen (Sp) and thymus (Th) from newborn (day 0) 
~G[E3'] transgenic (Tg) mice or non-trangenic (Non-tg) littermates were analysed for !3-globin 
transcripts as in (B). 
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Figure 6.7 PG[E3'] is transcribed in pre-B cells. 
(A) Enrichment of BP-1 + pre-B cells by FACS. Bone marrow cells from PG[E3') mice were stained 
with rat anti-B220-FITC and mouse anti-BP-1-biotin (revealed by SA-PE) and sorted by viable 
lymphocyte scatter and by gates as indicated. 
(B) JX;[E3 '] is detected in both B220+BP-1+ and B220+BP-1- subpopulations. Serial dilutions of 
cDNA prepared from the above bone marrow sorts were analysed by RT-PCR for the presence of 
!3-globlin (PG) transcripts or HPRT as an internal control. 
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Figure 6.8 ~G[E3'] is not transcribed in pro-B cells. 
(A) Enrichment of CD43+ pro-B cells by FACS. Bone marrow cells from ~G[E3'] mic
e were 
stained with rat anti-B220-PE and rat anti-CD43-biotin (revealed by SA-FITC) an
d gates were 
set for viable lymphocytes by scatter and regions as indicated. 
(B) jX;[E3 '] is only detected in the B220+co43- subpopulation. RT-PCR analysis for the 
presence 
of !3--glolin (~G) transcripts in serial dilutions of cDNA prepared from the above
 bone marrow 
sorts using HPRT as an internal control. (M, molecular weight markers) 
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Chapter 7: Conclusion and Prospect 
The immune system can generate and regulate the production of functional 
antibodies bearing diverse specificities for antigen, but not self-antigen. This 
remarkable process centres on the BCR which is fundamental to the B cell's 
existence. As a pre-BCR complex of surfaceµ and surrogate light chain associated 
with the lg-a/lg-~ heterodimer, it mediates antigen-independent events in the 
bone marrow (such as allelic exclusion) necessary for B cell development. 
Following maturation and migration of the B cell into the periphery, the BCR 
can mediate antigen-dependent activation by transmembrane signalling and 
intracellular targetting for antigen presentation. 
Using a transgenic approach, some of these checkpoints in B cell differentiation 
were addressed, from the expression of lg to subsequent signalling events 
mediated by BCR. The cytoplasmic domains of lg-a and lg-~, but not an lg-~ with 
a mutant lTAM, could independently mediate B cell activation in vitro, and 
effect the maturation of peripheral B cells in viva. However, the allelic exclusion 
assay revealed that the individual tails were not adequate on their own to fully 
inhibit endogenous lgH expression, and allelic exclusion was optimal only when 
both were expressed together, suggesting that the lg-a/lg-~ heterodimeric 
structure exhibits cooperativity and bears additional features not present in the 
homodimers. The findings that the signal requirements for efficient allelic 
exclusion differed from those driving B cell maturation in the anti-HEL 
transgenic mice were also observed in mice expressing VNpCµ[Ei,E3']K, a 
rearranged µ transgene regulated by the K enhancers. Whilst the µ transgene 
rescued B cell development in µMT B cell-deficient mice, the delay in its 
expression led to defective lgH exclusion, indicating that the timing of expression 
can be critical, as well as the quality of signal (via lg-a and lg-~), for pre-BCR 
function. Although both Ei/MAR and E3' were present in the VNpCµ[Ei,E3']K 
transgene construct, the -transcriptional activity at the pre-B cell stage seemed 
largely attributable to regulation by E3' since further characterisation suggested 
that E3' may regulate locus accessibility and sterile transc~iption leading to VK 
rearrangement in the absence of Ei/MAR. 
These studies have highlighted the complexity of B cell differentiation, 
suggesting several discrete · processes in development. For example, one 
interesting checkpoint is that of selection into the periphery since the bone 
marrow produces many more B cells than those that mature and exit . mb-1 Ml M 
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mice, bearing germline truncation of the lg-a cytoplasmic domain, have greatly 
reduced peripheral B cell numbers, and 3'EKD mice lacking E3' due to targetted 
deletion have decreased numbers of K+ splenic B cells. These observations 
cannot be accounted for solely by the reduction in B cell generation exhibited in 
the bone marrow of these mice. Selection may depend on the strength of signal 
generated via the BCR, however, additional mechanisms are likely to influence 
B cell maturation, and certainly the selection mechanism for the discrimination 
between self and non-self is a major question in immunology that endures. 
The presence of an anti-HEL transgene bearing the Dl.3 V region conferred a 
phenotype, possibly arising from selection against the specificity. Although 
transgenic mice were used to generate primary B cells expressing the same BCRs 
and to gain insight into B cell events in viva, there are dangers in generating a 
monoclonal population of B cells. An essential feature of the antibody response 
is its diversity, and mechansims may operate that act against monoclonality. One 
solution may be to use transgenes bearing miniloci and thus, events such as 
rearrangement, selection on the basis of specificity or affinity, or class switching 
could be analysed. 
However, the transgenic system has its limitations in general. Much remains to 
be learnt about the regulation of the genome and major concerns in the analysis 
of transgenic mice are not only artefacts such as specificity or abberrant tissue 
expression (as observed for the anti-HEL chimeric receptors), but founder effects 
due to integration site (LKLi[E3'] transgenic mice). Transgene constructs may lack 
some important, but as yet unidentified, regulatory elements such as those 
suggested by the gene-targetted EKND and 3'EKD mice in which neither Ei nor E3' 
is an absolute requirement for K expression. 
An alternative approach for addressing development and selection of a diverse, 
yet non-self repertoire of B cells into the periphery, would be to target the gene 
directly, eliminating transgene integration effects. Although any experimental 
system is subject to artefacts, gene-targetting technology i~ gradually becoming 
m ore versatile, facilitating the dissection, deletion, reconstitution and tissue-
specific regulation of genomic factors. 
Differentiation processes occurring in viva need to be correlated with stud ies of 
the biochemical mechanisms operating from sites proximal to the BCR, such as 
the recruitment of effectors to lg-a and lg-~, to the occupancy of genomic 
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regulatory sites by transcription factors. Whilst these expe
riments are an 
immense undertaking, and as yet most easily pursued in ho
mogeneous cell 
lines, the means for enriching primary B cell subpopulations 
are continually 
improving, combining physical sorting techniques with the explo
itation of gene-
targetted and transgenic mice. 
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Abstract 
lgK gene expression is controlled by two enhancers, one located within the major intron (Ei) and 
the other located downstream of CK (E3'). Whereas loss of E3' has previously been shown to 
diminish K expression, we show here that a rearranged K transgene lacking Ei is well expressed, 
even at the pre-8 cell stage. This suggests that E3' alone might be sufficient to give properly 
regulated transcription throughout B cell development. Indeed, we show that a transgene 
composed of a p-globin reporter linked to E3' is expressed in a B cell-specific manner, becoming 
activated at the late pro-8 to pre-8 cell stage but with dramatically enhanced activity on B cell 
activation. Thus, E3' becomes active as a transcription enhancer at the stage when VcJK 
rearrangement is being initiated and is sufficient to yield an expression pattern in a linked reporter 
gene similar to that of fully rearranged K genes. 
Introduction 
lg genes have been widely studied in order to further our 
understanding of the developmental regulation of gene 
expression. The productive rearrangement and transcription 
of both lg heavy and light chain genes occurs early in B cell 
development leading to the production of a repertoire of 
B lymphocytes displaying membrane lg on their surface. 
Encounter with antigen can lead to terminal differentiation of 
a B lymphocyte into an antibody-secreting plasma cell and 
is accompanied by a large increase in the steady-state levels 
of lg mRNA. 
Three major regulatory regions have been identified that 
control the expression of rearranged lgK genes: the V K 
promoter at the 5' -end of the gene, the intron-enhancer/matrix 
attachment region (Ei/MAR) located in the major JK-CK intron 
and the 3' -enhancer (E3') located downstream of the constant 
region. All three regions exhibit B cell-specific activity as 
judged by transfection assays (reviewed in 1 ). However, their 
different roles in regu lating light chain gene expression during 
B cell development remain unclear. 
Here, we find that a rearranged K transgene containing E3' 
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but not Ei/MAR is nevertheless well expressed during B 
cell development. The transgene effects allelic exclusion of 
endogenous K expression suggesting that Ei/MAR is not 
required even for transgene expression at the pre-B cell 
stage; E3' appears sufficient. We therefore sought to confirm 
this by charting the expression of E3' during lymphoid devel-
opment, analysing the expression pattern of an E3' -linked P-
globin reporter gene. The results indicate that E3' is activated 
early in B cell development but its activity is substantially 
enhanced on B cell activation . 
Methods 
Transgenes and transgenic mice 
Mice carrying the LK, LKL'>[ Ei/MAR] and LKL'>[E3 ' ] transgenes 
(Fig. 1A) have been described previously (2). 
The PG[E3'] transgene (Fig. 4A) was assembled by inserting 
a 1 kb Xba l- Sacl fragment including the mouse K E3' (3) into 
a Bluescript derivative in wh ich a human p-globin gene had 
been inserted between the Kpnl and Xbal sites. The Kpnl-
Received 18 May 1996, accepted 9 July 1996 
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Fig. 1. Flow cytometry analysis of transgenic and endogenous mouse x: e · 
lines. (A) The transgenes. (B) Two"-dimensional FACS plots. Spleen cells from ;~ress1on on the surface of spleen cells of _various x:-transgenic 
(revealed by phycoerythrin- streptavidin) specific for the transgenic (rat) or end to 12-week-old mice wer_e stained with _b1ot1nylated monoclonals 
anti-mouse lgM antiserum. Double staining for transgenic and end ogenous (mouse) x: chains together with FITC-conjugated goat 
ant_1serum and biotinylated anti-mouse x:. The data are representativ~gitouf/1 chains was performed using _FITC-conjugated goat anti-rat lg 
staining on LKti[E3'] mice seen here was not always observed. mu ip e experiments although the slightly reduced brightness of lgM 
Xbal P~globin fragment was generated by PCR from human 
genomic DNA using oligonucleotides priming 105 nucleotides 
5 ' of the transcription start site (introducing a 5' Kpnl site) and 
3~0 nucleotides 3' of the polyadenylation signal (introducing a 
3 Xbal site) The amplified p-globin gene (which extends 
from 5' of the promoter to 3' of the polyadenylation site) was 
assembled from two subfragments; the strategy involved 
creating a Spel site in the second p-globin intron, 460 
nucleotides downstream of the splice donor site. 
. The VNPCµ[Ei , E3'JK ·trar.isgene was obtained from a derivat-
ive of plasmid pSV-Vµ 1 (4) in which the region of DNA located 
between the most 5' and 3' Xbal sites in the JwCµ intron 
was replaced by a 2.1 kb section of the mouse J -C intron 
spanning KEi/MAR obtained by PCR using oligonKucl;otides 
GGACTAGTGATAGGAACAGAGCCACT and GCTCTAGACA-
GAGATTCAGACCAGTTTA. The Xbal-Sacl 802 bp fragment 
containing the K E3' was then introduced into the unique Xhol 
site located_ just_ 3' of the CµM exons of pSV-Vµ 1. 
Transgenic mice were created by injecting vector-free DNA 
fragments into the nuclei of (C57BL/6XCBA/Ca)F1 zygotes 
and founder animals were bred further against F1s. The 
number of transgene copies was estimated from Southern 
blots (not shown) and, for K transgenic lines, is denoted by 
a superscript following the transgene designation Offspring 
transgenic for LK-derived transgenes were screened by ELISA 
detecting rat K determinants. Mice transgenic for pG[E3'] 
were screened by PCR of tail DNA 
lmmunofluorescence analysis 
Following removal of erythrocytes, samples comprising single 
cell suspensions were stained with various combinations of 
FITC-conjugated goat anti-mouse lgM or goat anti-rat lg 
antisera (Southern Biotechnology, Birmingham, AL), FITC-
conjugated peanut agglutinin (Sigma, Dorset, UK), FITC-
conjugated anti -Thy-1.2 (CD90) (TS; Sigma), FITC-conjugated 
anti-lgMb [MB86 (5)] mAb, biotinylated anti-rat K [RG-7/9.1 
(6)], anti-mouse K [187.1 (7)], anti-BP-1 (8), anti-Thy-1.2 
(CD90) (53-2.1; PharMingen), anti-CD43 (S7; PharMingen) 
and anti-lg Ma (DS-1; PharMingen) mAb, and phycoerythrin-
conjugated anti-CD45R(B220) antibody (RA3-6B2; Gibco). 
The biotin conjugates were revealed using FITC-streptavidin 
(Amersham, Buckinghamshire, UK) , phycoerythrin- streptavi-
din (Jackson , Baltimore, PA) or Red670-streptavidin (Gibco). 
Flow cytometric analysis and cell sorting were performed on 
a Becton Dickinson (San Jose, CA) FACScan and FACStar 
Plus respectively, using Lysys II and CELLQuest software; 
viable lymphocytes were gated by forward/side scatter and 
by exclusion of propidium iodide. 
Preparation of RNA and analysis of gene expression 
RNA was extracted by the guanidine isothiocyanate method 
(9) and transgene expression analysed by ribonuclease pro-
tection using rat K or human p-globin probes with a heat 
shock cognate gene probe acting as internal reference as 
previously described (10). Densitometry tracing was per-
formed on Molecular Devices Computing Densitometer Model 
300A using lmageQuant software. For RT-PCR analysis , 0.1-
1 µg RNA was reverse transcribed with MMLV reverse tran-
scriptase (Gibco/BRL, Gaithersburg, MD) using 100 ng (dT) 15 
primer for 1 h at 37°C. Aliquots of the reaction were then 
used in PCR. The p-globin forward and reverse primers 
(CCTGAGGAGAAGTCTGCC and AGCACACAGACCAGC-
ACG) yield a 328 bp product; the HPRT forward and reverse 
primers used as internal control (TGCCGACCCGCAGTCCCA-
GCGTCG and GCTGTAC-TGCTTAACCAGGGAAAG) amplify 
a 461 bp product. PCR were annealed at 60°C for 1 min , 
extended at 72°C for 1 min and denatured at 92°C for 1 min 
for a total of 30 cycles. 
Results 
lg,c gene expression in splenic B cells in the absence of 
Ei/MAR 
We have used transgenic mice in order to address. the relative 
importance of the two lgK enhancers (Ei and E3') in regulating 
K gene expression at the different stages of B cell develop-
ment. The lgK transgenes are derived from LK (Fig. 1A). LK is 
composed of a mouse V KOx-1 segment rearranged to JK5 
and linked to CK. The entire construct is of mouse origin 
except for a 470 nucleotide stretch extending from the Hpal 
site in the CK exon to a Bg/11 site 3' of CK, this region having 
been replaced by the corresponding portion of rat CK. This 
means that the transgenic light chains can be serologically 
distinguished from endogenous mouse K. The LK11[Ei/MARJ 
and LKl1[E3'] transgenes differ from LK by deletion of Ei/MAR 
or E3' respectively. 
Spleen cells from the transgenic mice were stained for 
transgenic Kor endogenous K together with lgM ; they were 
also double-stained for both transgenic and endogenous K 
chains (Fig. 1 B). In two different LK lines (LK3 and LK6 , with 
the superscript denoting copy number), the transgene stains 
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brightly on the surface of most lgM+ B cells, apparently 
inhibiting expression of the endogenous alleles since few 
cells express endogenous K chains. The pattern of K chain 
expression in mice carrying the LKL',[Ei/MAR] transgene is 
essentially similar although the degree of inhibition of endo-
genous light chain expression is somewhat less than that 
observed with the LK mice. This is particularly true in the case 
of the LKL',[Ei/MAR]7 line. Nevertheless , it is evident that, even 
in the absence of Ei/MAR, the light chain transgene is 
expressed at a good level on sp lenic B cells and can mediate 
allelic exclusion. 
In contrast to these findings, the transgene in LKL',[E3'] 2 
mice is relatively poorly expressed on splenic B cells. It is 
also co-expressed with endogenous light chain, there being 
little evidence of an inhibition of endogenous K rearrangement/ 
expression. Interestingly, LKL',[E3'] mice exhibit significant 
line-to-line variation in expression levels that is not simply 
attributable to transgene copy number (2). We have not so 
far observed this with LK or LKt>[Ei/MARJ transgenic lines. 
Thus, of three LKL',[E3'] lines examined , two (containing two 
and six transgene copies) expressed badly whereas a third 
line (harbouring six copies) expressed well (data not shown). 
This suggests that E3' behaves analogously to a locus control 
region as originally described for the human p-globin gene 
(11 ). Thus, in the absence of E3', the K transgene is essential ly 
poorly expressed although, in some mouse lines, position 
effects at the integration site can compensate for its absence. 
/g,c gene expression in germinal centre cells in the absence 
of Ei/MAR 
We have previously noted (2) that removal of Ei/MAR resulted 
in a substantial drop in the accumulation of somatic mutations 
in lgK transgenes. The mechanism of hypermutation is 
unknown but one possible explanation of this finding is that 
the mutation rate drops as a consequence of decreased 
transgene expression. To test the feasibility of this explanation , 
we compared the expression of the LK and LKL',[Ei/MARJ in 
the germinal centre cells of Peyer's patches (identified as 
staining brightly with peanut agglutinin). The results (Fig. 2) 
show that, as in the sp lenic cells, the transgene is expressed 
well in the LKL',[Ei/MAR] mice although neither of the lines 
studied manifests as high a degree of exclusion of endogen-
ous K expression as is observed in LK mice. Furthermore , 
transgene express ion in the LKL',[Ei/MAR]7 line is slightly higher 
than in the LKL',[Ei/MARJ4 line. It is nevertheless clear that 
despite removal of Ei/MAR, transgene expression in these 
cells is good. 
/g,c gene expression in pre-8 cells in the absence of Ei/MAR 
The fact that the presence of the LKL',[Ei/MAR] transgene 
leads to diminished expression of endogenous mouse K 
chains suggests that, even in the absence of Ei/MAR, the 
transgene is activated early enough in B cell ontogeny for it 
to inhibit rearrangement of the endogenous mouse K locus. 
Furthermore, removal of Ei/MAR does not affect the expression 
of the K transgene in bone marrow as judged by ribonuclease 
protection assays (Fig . 3A). As expected the K transgene is 
also expressed in spleen. A much weaker signal is seen in 
both kidney and thymus. However, both cytoplasmic immuno-
fluorescence (not shown) and FACS analysis (Fig. 3C) have 
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Fig. 2. Flow cytometry analysis of transgenic and endogenous K 
staining of Peyer's patch cel ls from LK and LK6[Ei/MARJ mice. Cells 
from 11- to 14-week-old mice were stained with biotinylated anti-K 
antibodies (as in Fig. 1) together with FITC-conjugated peanut 
agg lutin in (PNA). 
confirmed that the Thy-1 + population in thymus is in fact 
negative for rat K polypeptide. The weak CK RNA signal 
detected in thymus may be due to contaminating plasma 
ce lls (Fig. 3C). 
To confirm that LKLi[Ei/MARJ is we ll expressed in pre-B 
cells we crossed the LKLi [Ei/MAR] transgene into a µMT/µMT 
background. The µMT/µMT mice (12) carry a targeted neo 
insertion into the CµM1 exon and are blocked in B cell 
development since they cannot make membrane lgM. The 
bone marrow B lineage cells in these mice therefore al l belong 
to the pro-B fractions A-C (in the classification of Hardy et al.) 
or pro-B/pre-B-1 fractions (classification of Rolink et al.) (13-
15). The almost complete absence of transgene expression 
in spleen confirms that B cell development in LKLi[Ei/MARJ 
µMT/µMT mice is blocked before the mature B cell stage. 
The abundance of transgene RNA in the bone marrows of LK 
µMT/µMT (not shown) and LKLi [Ei/MARJ µMT/µMT mice (Fig. 
3B) strongly supports the proposal that, even in the absence 
of Ei/MAR, the K transgene is we ll expressed in the early 
stages of B cell development. 
E3' activates expression of a heterologous reporter transgene 
in pre-8 cells 
The studies on the LK, LKLi[Ei/MAR] and LKLi [E3 '] mice not 
only demonstrate that Ei/MAR is not essential for the activation 
of rearranged K gene expression early in B cell differentiation 
but also point to an important role for E3' throughout B cell 
development, since it is sufficient to drive expression in the 
absence of Ei/MAR. We therefore linked E3' to the human ~-
globin gene (to create ~G[E3'], Fig. 4A) to test whether E3 ' 
wou ld be sufficient to confer lymphoid-specific expression 
in viva and , if so, to determine the stage at wh ich E3' is 
activated. From ribonuclease protection assays, it is clear 
that E3' conferred lymphoid specificity of expression in that 
~-globin mRNA was detected in spleen and bone marrow but 
not in kidney or liver (Fig. 48). 
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Fig. 3. Ribonuclease protection assays of transgene expression in 
LK6[Ei/MAR] and LK mice. (A) RNA (10 µg) from kidney (Ki), spleen 
(Sp) , bone marrow (BM) and thymus (Th) from two lines of LK6[Ei/ 
MAR] and two lines of LK mice were mapped with a K transgene-
specific probe as well as a probe for an hsp70 heat shock cognate 
(Hsp) as an internal reference. (B) RNA (10 µg) from bone marrow, 
liver (Li) and spleen from an LK6[Ei/MAR]4 mouse and from an LK6[Ei/ 
MAR]4 mouse that had been backcrossed into a homozygous µ·MT/ 
µMT background were mapped as in (A). The mobilities of the 
undigested C" and Hsp cognate probes are illustrated. M, DNA size 
markers. (C) Flow cytometry analysis of transgenic (Tg) K expression 
in permeabil ized spleen (Spl) and thymus (Thy) samples from an L< 
mouse as well as from a non-transgenic (n-Tg) control. The spleen 
cells have been gated for Thy-1.2- whereas the thymus samples are 
gated for Thy-1.2+. 
We then used RT-PCR assays to assess expression of 
the ~G[E3'] transgene wi thi n the lymphoid sub-compart-
ments. For these assays, we used HPRT transcripts as 
internal control , initially confirming that the assay gave the 
same results as the ribonuclease protection experiments 
wi th respect to transgene expression in liver, spleen and 
bone marrow [Fig. 5A( i)] . Fractionation of splenocytes into 
CD45R(B220)+ and Thy-1 + subpopulations reveals that 
transgene expression is restricted to B as opposed to T 
cel ls [Fig. 5A( ii )] and indeed transcripts are detected in 
newborn spleen but not newborn thymus [Fig. 5A(iii)] With 
regard to expression in bone marrow, expression is found 
in the 8P-1 + CD45R(8220j+ fraction (indicating that the 
transgene is already activated at the late pro-8/pre-8 cell 
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Fig. 4. Lymphoid-specific expression of the KE3'-linked human ~ 
globin transgene. (A) Structure of the ~G[E3'] transgene. (B) 
Ribonuclease protection mapping of RNA (10 µg) from liver (Li), 
kidney (Ki) , spleen (Sp) and bone marrow (BM) from two lines of 
~G[E3' ] mice and a non-transgenic littermate. The ~G[E3' ]A line 
contains 10-20 transgene copies whereas ~G[E3' ]8 harbours five to 
1 O cop ies . 'Hsp' denotes bands derived from the hsp70 cognate 
internal reference probe; RNA from kidney, as opposed to that from 
many other tissues, usually gives a full length, readthrough protected 
fragment (Hsp-RT) with this probe. 
stage) as well as in the 8P-1- CD45R(8220)+ fraction 
(which includes early pro-B as we ll as mature and 
recirculating 8 cells) (Fig. 58). [8P-1 (8) is an aminopeptid-
ase whose expression with.in the B lineage is restricted to 
the pre-8 cell stage.] However, enriching the bone marrow 
8-lineage cells for co43+ and c o43- subtractions suggests 
that the transgene is not fully active at the early pro-8 
cel l stage. 
Timing of activation of an lgH transgene linked to KEi/E3' 
The results regard ing expression of the ~G[E3'] transgene 
in B cell precursors as well as that of LK-derived transgenes 
in µMT/µMT bone marrow suggest that reporter genes linked 
to the lgK enhancers become transcriptionally activated at 
a stage late in pro-B cell development when CD43 
expression levels are decreasing , but prior to the major 
expansion at the pre-B ce ll stage [fraction C' of Hardy 
et al. (13)] which is absent in µMT/µMT mice (15). Th is 
predicts that a lgµ transgene driven by the lgK enhancers 
will be expressed prior to the block in µMT/µMT mice (and 
will therefore be able to rescue B cell development in these 
animals) but subsequent to V- DJ rearrangement at the lgH 
locus (and will therefore not mediate lgH chain al lelic 
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Fig. 5. Expression of the KE3'-linked human ~ globin transgene in 
lymphoid subsets of ~G[E3']A mice. The presence of transgene-
derived human ~-g lobin transcripts was analysed by RT-PCR using 
HPRT as an internal control. (A) Expression is largely restricted to 
the B lineage. Comparison of ~-globin expression levels in: (i) Liver, 
sp leen and bone marrow; (ii) Serial di lutions of cDNA derived from 
sorted splenic CD45(B220)+ and Thy-1.2+ cells; (ii i) Spleen and 
thymus of newborn (day 0) mice (Tg, transgenic , n-Tg, non-transgenic 
litter mate). (B) Transgene expression within the B lineage. Bone 
marrow from ~G[E3']A mice (8- 11 weeks old) was sorted into: (i) 
CD45R(B220)+ /BP-1 + and CD45R(B220)+ /BP-1 - subpopulations ; (ii) 
CD45R(B220j+/CD43+ and CD45R(B220)+;co43- subpopulations. 
M, molecular weight markers. 
exclusion). We tested this prediction by examining the 
expression of a transgene, VNpCµ[Ei , E3']K (Fig . 6A), 
containing a mouse lgµ chai n gene but in which (i) the 
lgH intron-enhancer has been replaced by KEi/MAR 
enhancer and (ii ) KE3 ' has been placed 3' of the 
transcription unit. The results are entirely consistent with 
our pred ictions. The VNPCµ[Ei, E3' ]K transgene effectively 
rescues 8 cell development in µMT/µMT mice and is well 
expressed on the surface of the splenic 8 cel ls (Fig . 68). 
However, despite this good expression, the same transgene 
(which is of lgM8 allotype) does not inhibit endogenous µ 
expression in a wi ld-type lgHb background; the splenic 8 
cells that express the transgene (lgM8 ) also express 
endogenous (lgM b) alleles, in comparisoh to allelic exclusion 
demonstrated by (CBA/CaxC57BL/6)F1 mice (Fig. 6C) or 
other µ transgenes driven by lgH enhancers. 
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Fig. 6. An lgµ transgene linked to K[Ei/MAR, E3'] rescues B cell 
development in µMT/µMT mice but does not mediate lgH allelic 
exclusion. (A) The VNpCµ[Ei , E3' JK construct. (B) The abundance of 
splenic B cells. in 7-9 week old µMT/µMT, VNpCµ[Ei, E3 'JK µMT/µMT 
and wild-type litter mate mice was assessed by double staining with 
phycoerythnn-conJugated anti-CD45R(B220) and FITC-conjugated 
goat anti-mouse lgM antiserum. Viable lymphocytes were gated as 
Judged by forward and side scatter and exclusion of propidium 
1od1de, the figures denoting the percentage in each quadrant. (C) 
Al lelic exclusion of lgH expression was assessed by staining spleen 
cells from 8- to 9-week-old mice with phbcoerythrin-conjugated anti-
CD45R(B220) , FITC-conJugated anti-lgM and biotinylated anti-lgMa, 
revealed by Red6.70-streptavidin, and gating on CD45R(B220j+ 
lymphocytes (as Judged by scatter). The mice analysed were 
VNpCµ[Ei, E3'JK transgenics crossed into an lgHb background with 
(CBA/CaxC57BL/6) F1 mice (lgHa/lgHb) staining as a control. 
KE3' activity increases dramatically on lipopolysaccharide 
(LPS) activation 
lg mRNA levels increase cons iderably on activation of mature 
B cel ls. In the case of the lgH locus, this has been shown to 
be attributable in part to increased stability of lgH mRNA 
( 16, 17) and in part-in both lgH and K light chain loci-to 
increased transcription (18, 19). In order to test whether KE3' 
might contribute to effecting the increased K mRNA abund-
ance in plasma cells, splenic B cells from pG[E3'] mice were 
cultured in the presence-of 50 µg/ml bacterial LPS and RNA 
extracted at various times. A dramatic up-regulation of p-
globin mRNA levels is obtained as judged by ribonuclease 
protection assays (Fig . 7). Densitometry tracing control led by 
the heat shock cognate internal reference reveals that the 
LPS treatment lead to a 10- to 20-fold increase in p-globin 
mRNA levels after 48 h. 
~G[E3'] ~G[E3'] 
M 10 23451 ~ daysatterLPS 
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Fig. 1: KE3' is activated on LPS stimulation. Ribonuclease protection 
mapping of transgenic ~-globin transcripts in RNA (5 µg) from total 
spleen cells (left hand panel) or T cell-depleted spleen cells (right 
hand panel) from two 12 week old ~G[E3 'JA mice that had been 
cultured in the presence of bacterial LPS (50 µg/ml) for up to 5 days. 
Discussion 
The results presented here indicate that, assayed as a 
transcription enhancer, E3 ' is a B cell-specific element that 
is activated at the late pro-8/pre-B cel l stage of differentiation 
but with its activity being significantly enhanced on B cell 
activation. This pattern of enhancer activity nicely parallels 
the differentiation-specific changes in chromatin structure 
around the K 3'-enhancer that have very recently been noted 
by Roque et al. (20). The early activation of the enhancer 
correlates with the stage at which sterile K transcripts are 
detected and the cells up-regulate RAG expression for VcJK 
rearrangement (21 ). It is tempting therefore to speculate that 
E3' may activate VcJK rearrangement at the pre-B cell stage. 
Recent experiments by Hiramatsu et al. (22) using trans-
genic K rearranging substrates have revealed that the pres-
ence of E3 ' suppresses VcJ,c rearrangement in developing 
thymocytes. There is an apparent contrast between these 
observations and our own findings that the E3' -linked p-globin 
transgene is not detectably expressed in T cells. The resolution 
of the paradox probably lies in the fact that suppression of 
V K-JK rearrangement and potentiation of p-globin transcription 
depend on distinct constellations of E3'-binding factors. 
Indeed, like a locus activating region , E3' might serve as a 
focus to alter local chromatin structure early in lymphoid 
ontogeny (possibly before BIT lineage separation). The pre-
cise constellation of DNA-binding factors subsequently 
recruited wou ld then depend on the differentiation stage of 
the host cell, leading to an inhibition of VcJK rearrangement 
1n T cells but an activation of transcription and rearrangement 
in late pro-/pre-B cel ls. Later, the activity of E3' increases 
on B cell activation to contribute to the increase in lgK 
mRNA levels. 
That E3' plays a role in lgK gene expression at the later 
stages of B cell development is entirely consistent with 
previous work which has revealed a dependence of transgenic 
K expression on sequences 3' of C,c (2, 10) as well as from 
transfection assays revealing E3 ' to be a potent enhancer in 
myeloma cells (3,23). Its role at earlier stages of B cel l 
development is less clearly anticipated. Thus , E3' was found 
to be very weak in activating a reporter gene in the A20 B 
cell lymphoma unless acting synergistically with Ei (24). 
Furthermore, some E3'-linked reporter genes transfected 
into AMLV-immortalized pre-B cell lines were only activated · 
following LPS induction (10,25) leading to the suggestion that 
E3 ' on ly becomes activated at the pre-B to B cell transition . 
Our results here indicate that this is not the case, rather that 
E3' is activated at earlier stages in B cel l development. The 
apparent discrepancy may well result from the effects of 
AM LV immortalization Indeed, in the case of Ei , it has been 
shown that its activity in AM LV-immortalized cells is inhibited 
by the v-ab/ gene product, an inhibition which is relieved by 
LPS treatment (26). 
How can the cell-type specificity of E3' activity be under-
stood in terms of the cell -type specificity of its known cognate 
binding factors? While the KE3' was initially defined as an 
808 bp fragment (3), subsequent analysis has mapped most 
of its activity to a 132 bp core region (10,25) which is already 
active in pre-B cells (25). Although, rabbit, human and mouse 
E3' are highly conserved even outside the core (27,28) wi th 
functionally important sites being apparently located within 
the flanking reg ions (29) , the cell-type specificity of PG[E3'] 
expression is ful ly consistent with what we know of the 
transcription factors recognizing the core. Thus, three func-
tional nuclear factor binding sites have been identified in the 
core. One is a cAMP response element that is bound by the 
widely expressed CREM/ATF-1 transcription factors (30). The 
other two are binding sites for E2A and PU.1/NF-EM5(Pip-
1) (31,32) , sites which are recognized by B cell-specific 
complexes. Equivalent sites have also been identified in the 
human E3 ' (33). Whilst PU .1 is expressed in both B and 
myeloid cells (34) , Pip-1 (which is thought to encode NF-
EM5) is lymphoid specific, being well expressed in pre-B and 
B cells and present at increased levels in plasma cells but 
only weakly detectable in T cells (32). Thus , the complex which 
forms between phosphorylated PU.1 and Pip is restricted to 
the B-lineage. In fact, the transcriptional activation of the E3'-
linked p-globin reporter at the pro-pre-B cel l stage with no 
detectable activity in T cells correlates well not only with cell-
type specificity of the PU 1 /Pip-1 complex but also wi th that 
of the E1 2/E47 dimer whose levels rise at the pro- to a pre-8 
cell transition (35,36). However, the suppressive effect of E3' 
on V,c-J,c rearrangement in T cells is less easily rationalized 
in terms of known E3'-binding factors. The effect depends 
on the PU.1 binding site present in E3 ' but cannot reflect an 
involvement of PU .1 in the repression (since PU.1 is unlikely 
to be present at this stage) but has rather been interpreted 
in terms of an as yet unidentified rearrangement repressor 
that binds the same site as PU.1 and is displaced when PU.1 
becomes available (22). 
With regard to the activity of E3' at later stages in B cell 
development, it is notable that mutating any of the three 
identified sites in the mouse core enhancer diminishes tran-
Activation by the lg/( 3' -enhancer 1567 
scriptional activity in pre-B as we ll as in plasma cell lines 
(30). This suggests that these factors play a role throughout 
the pre-B , B and plasma cell stage. It is unclear which of the 
nuclear factors mediate the up-regulation seen on B cell 
activation. Thus, PU.1 can be phosphorylated by casein 
kinase II , JNK and as yet unidentified kinases (37) which 
may affect its transcriptional activity. It also interacts with 
retinoblastoma protein in vitro (38) suggesting that its tran-
scriptional activity might be repressed in resting cells. Sim-
ilarly, CREM has been shown to be inducible by cross-linking 
of surface lg in a B cell line (39). 
Finally we come to the issue whether Ei and E3' fulfil distinct 
roles. Considered as transcription enhancers, it is notable 
that although Ei/MAR affects K gene transcription (since the 
L,ci'.i[Ei/MAR] transgene is not as consistently well expressed 
as L,c; see also Xu et al. (40)), E3' nevertheless appears the 
more important of the two enhancers since its removal clearly 
has a more severe effect on transgene expression at all 
stages of B cell differentiation than does deletion of Ei/MAR. 
Very recent confirmation that Ei/MAR is also not needed for 
good expression of rearranged K genes in the context of the 
endogenous locus has come from gene targeting experiments 
( 41 ). Thus, both Ei and E3' are likely to contribute to K gene 
expression with the E3' being the more potent and necessary 
transcriptional activator. However, both enhancers are 
involved in the regulation of somatic hypermutation (2) and 
V K-JK rearrangement (22,41,42) and it will be interesting to 
ascertain the relative importance of the two enhancers in 
these two processes. 
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